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ABSTRACT 
 
FOLATE RECEPTOR-TARGETED DELIVERY OF SMALL INTERFERING  
RNA TO CANCER CELLS 
by Yilin Zhang 
December 2010 
The vitamin folic acid (folate, FA) has been extensively explored as a targeting 
ligand to deliver a variety of diagnostic/prognostic/therapeutic agents into various tumors 
through the assistance of its receptor – the folate receptor (FR). FR is over-expressed in 
many types of human cancer and can mediate internalization of FA-conjugates through 
an endocytic pathway.  The discovery of small interfering RNA (siRNA), which is cable 
of inducing potent gene silencing in a sequence-specific manner, provides an excellent 
molecular tool to suppress aberrant gene expression in malignancies, and therefore 
siRNA has the potential to revolutionize cancer therapeutics. Towards the goal of 
developing an efficient and cancer-specific siRNA strategy, three types of FA-conjugated 
molecules have been synthesized to investigate targeted siRNA delivery to cancer cells in 
vitro.  
 In the first section, FA-linked siRNA was synthesized through our one-step in 
vitro transcription using FA-HAD-AMP as a transcriptional initiator. FR-dependent 
cellular uptake and moderate specific gene down-regulation (50%) were observed in a 
stable cell line (Gluc-KB), which was established in this work by integrating Gaussia 
luciferase (Gluc) gene to the genome of KB cells (human nasopharyngeal carcinoma). 
Gluc-KB provides a platform to better evaluate gene expression changes upon siRNA 
treatment. 
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In the second section, a FA-functionalized, multivalent copolymer (FAPol13) was 
introduced to: (i) complex with siRNA to form a FAPol13/siRNA complex, (ii) protect 
siRNAs from enzymatic degradation, (iii) enhance cellular uptake by conjugating several 
FA molecules to copolymer, and (iv) increase RNAi efficacy eventually. A typical 
FAPol13 compound has three functional groups: cationic, hydrophilic, and FA moieties 
for providing siRNA packaging site, water solubility, and cell-selectivity, respectively. 
This nontoxic polymer successfully delivered siRNAs against Gluc, survivin (Sur), 
Caspase 8 associated protein 2 (Casp8ap2) genes in KB cells and efficiently reduced 
their expression (i.e., 62% and 68% downregulation from siSv and siGLuc treatments, 
respectively). Strikingly, treatment of KB cells with FAPol13/siCasp8ap2 significantly 
repressed cell growth and induced cells into apoptosis (24.5%, p = 0.01). Furthermore, a 
real-time imaging system, employing fluorescence approaches (time-lapse, z-stacking, 
and colocalization analysis), has been developed to evaluate siRNA binding, cellular 
uptake, and escape from compartments, respectively. In particular, Pearson’s correlation 
coefficient (PCC) was employed to quantify siRNA endosomal escape, one of the crucial 
steps of siRNA intracellular trafficking. This method was further applied to the analysis 
of siRNA delivery in HeLa (human cervical carcinoma) and SKOV3 (human ovary 
carcinoma).  
In the third section, a gold nanoparticle (AuNP) capable of packaging and 
protecting siRNAs was utilized to transport siRNA to cancer cells. Cytotoxicity assay, 
cellular uptake, and gene down-regulation studies of the AuNP-siRNA system indicate 
that AuNP can be an efficient siRNA platform.  
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In the fourth section, a correlation between FR expression level and the delivering 
effectiveness of FA-conjugates was established by comparing cellular absorption, cellular 
uptake, and RNAi efficiency among KB, HeLa, SKOV3 and A549 (human lung 
carcinoma) cells.  
Collectively, we have demonstrated effective FR-mediated and cancer cell-
specific siRNA delivery by several approaches. Further studies may lead to the 
development of therapeutic siRNA delivery systems.
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CHAPTER I 
LITERATURE REVIEW 
Cancer and Cancer Treatment 
Cancer is a class of diverse diseases associated with uncontrolled growth of 
abnormal cells where a series of genetic alterations leads to either activated oncogenes 
(gain of function) or inactivated cancer suppressor genes (loss of function).1 Currently, 
cancer is the second leading cause for human death with more than 10 million new cases 
every year.2 
After decades of persistent effort, cancer research has achieved rapid progress and 
generated a large body of knowledge, revealing that malignant cells are transformed from 
normal cells after a succession of genetic changes that confer cell growth advantages.1 
Through progressive conversion, cancerous cells gain the capabilities to proliferate 
aberrantly (anti-apoptosis, growth signal autonomy), to stimulate the formation of blood 
vessels (angiogenesis), and to travel to adjacent tissues (invasion, metastasis).3  
Characteristics of Cancer 
Cancer cells are transformed from normal cells that have defects in regulation on 
cell proliferation and homeostasis. 4A large and diverse collection of cancer-associated 
genes is involved in this conversion, resulting in the observed complexity and 
heterogeneity of cancer 1. However, most tumors share well-defined characteristics, such 
as unrestrained cell growth, deregulated cell cycle control, anti-apoptosis (immortality), 
invasion, metastasis, and angiogenesis (formation new vessels from the old ones to 
supply oxygen and nutrients through blood stream).  
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Proliferation of normal cells is under a strict homeostatic control of growth 
signals and anti-growth signals, while in malignant cells, this balance is broken due to 
genetic alterations.5 As a result, tumor cells obtain the capability to produce growth 
signals, thereby reducing their dependence on stimulation from the normal tissues nearby, 
and simultaneously becoming insensitive to anti-growth signals. This process is 
designated growth factor autonomy — cells responding to the signals produced by 
themselves. To achieve growth factor autonomy, cancer cells either overexpress receptor, 
such as epidermal growth factor receptor (EGFR), vascular endothelial growth factor 
receptor (VEGFR), fibroblast growth factor receptor, (FGFR),6 folate receptor (FR),7 or 
alter transcellular/intracellular signal transducers (e.g., mitogen-activated protein kinase, 
MAPK pathway).8  
Normal cells are under strict regulation associated with the homeostatic balance 
between pro- and anti-apoptotic signaling molecules. Cancerous cells, however, acquire 
abilities from genetic alternations to destruct the pro-apoptotic regulators (e.g., p53) and 
induce anti-apoptotic regulators (e.g., inhibitor of apoptosis proteins, IAPs). Apoptosis ― 
a process of programmed cell death ― causes a series of cellular/molecular changes in 
organisms, including cell blebbing, cell shrinkage, chromatin condensation, and nuclear 
fragmentation. Apoptosis is conducted by a class of intercellular proteases termed 
caspases.9 Caspases harbor a critical cysteine residue at the active site and hydrolyze 
target proteins on the carboxyl-terminal side of specific asparagine residues. Under 
apoptosis, cells were triggered to release cytochrome C (a potent catalyst of apoptosis) 
from mitochondria, destroy subcellular structures, organelles, and genome 
(defragmentation).10 Numerous data have revealed that many apoptotic genes (e.g., 
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caspase 8 and caspase 9) are suppressed and anti-apoptotic genes (e.g., survivin, and 
livin) are activated in various types of tumors.11 For example, survivin (an apoptosis 
inhibitor), which expresses at low to undetectable levels in most normal tissues, is found 
overexpressed in nearly every human tumor tested.12 
Unlike normal cells but similar to stem cells, cancer cells have the ability to 
migrate through the bloodstream, allowing a small population of cancer cells (presumably 
cancer stem cells) to invade adjacent tissues and form tumors. This process causes 90% 
of human cancer deaths.13 After decades of investigation, significant progress has been 
made to characterize several classes of protein components involved in this invasive and 
metastatic process, such as cell adhesion molecules (e.g., E-cadeherin, integrin) 14 and 
chemokine receptors. 15 For instance, ectopic expression of integrin α4β1 in mouse 
melanoma is sufficient to retain tumors in situ.16 In addition, downregulation of E-
cadeherin and upregulation of vimentin (one type of intermediate filaments) enable the 
migration of cancer cells through a process of epithelial-mesenchymal transition. 
Moreover, several blood and solid cancers overexpress chemokine receptors to favor this 
process.17 
In a normal tissue, cellular function and proliferation are restricted by the 
vasculature which supplies oxygen and nutrients to cells, whereas tumor tissue gains the 
capability of angiogenesis, which leads to a sustained vasculature through which cancer 
cells evade the limitation of nutrient supply and grow consistently. Due to the rapid and 
defective angiogenesis, the vessels become leaky and increase the permeability to some 
macromolecules, which facilitates the passive delivery of various anticancer drugs.18 This 
phenomenon is termed enhanced permeability and retention (EPR) effects.19 Two protein 
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families play critical roles in the acquisition of angiogenic capability for tumor: vascular 
endothelial growth factor (VEGF) family,20 and acidic and basic fibroblast growth factor 
(aFGF and bFGF) family,21 which are upregulated in various types of tumors.20a 
Cancer Treatments 
Although tremendous efforts have been dedicated to cancer biology research and 
substantial progress has been made, approximately 1.5 million new cancer cases, and 
more than 0.5 million deaths from cancer were reported in the United States in 2009.2a 
Effective cancer therapy confronts at least four challenges: (1) Tumor can originate from 
various tissues and as a result there are more than 100 distinct types of cancer; (2) The 
fact that tumorigenesis is a combinatory outcome of genetic and epigenetic alterations 
makes it  impossible to have a universal treatment suitable to every scenario of tumor; 
and  therefore, it is proposed that cancer therapies should be as diverse as the diseases 
themselves; 22 (3) Current prognostic and diagnostic techniques are insufficient; (4) 
Classic chemotherapy drugs have undesired cytotoxicity, which causes the death of both 
normal and cancerous cells.  
Generally speaking, there are three standard approaches for cancer treatment: 
surgery, radiation and chemotherapy. The type, size, location, and stage of cancer 
determine which approach to be used, and in most cases, they are combinatorially 
employed. Surgery is a physical process to remove a tumor if it can be clearly localized. 
For several types of cancer, surgical removal of a tumor may be sufficient to cure the 
cancer patient in the case that cancer cells have not invaded into other tissues and tumor 
tissue has been incised as much as possible. Cancer metastasis contributes to the tumor 
recurrence and is the major reason for death of cancer patients.  
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Radiation therapy takes advantage of high-energy radiation (i.e., X-rays, gamma 
rays, and charged particles) to cause DNA damage and thereby killing cancer cells. 23 
Radiation may be employed in the form of beams outside the body (external-beam 
radiotherapy) or be implanted into the tumor (internal radiotherapy). More than half of all 
cancer patients receive radiotherapy during the course of treatment. In most cases, 
radiotherapy is used in a combination with other types of therapeutics. However, 
radioactive illumination, no matter from outside or inside the body, will do harm to DNA, 
evoking mutagenesis or cell death at the nearby tissues. The mutated cells have a high 
likelihood to give rise to a new tumor, which undermines the effectiveness of this 
approach. The severity of side effects is dependent on the distance between the 
illuminated tumor and normal tissue, and the duration/intensity of radiation beams. 
Chemotherapy is perhaps the most commonly used means for cancer therapy. It is 
often combinationally applied to post-surgery patients to treat the remaining or migrated 
cancer cells that render tumor recurrence. Cancer drugs are hypersensitive to the rapidly 
proliferating cells, including cancerous cells and a small portion of normal cells (e.g., 
blood cells). This non-targetability of chemotherapy leads to certain undesired symptoms 
(side effects) including pain, diarrhea, hair loss, nausea, anemia, etc. 
Most traditional chemotherapeutic drugs are derived from natural sources or 
synthetic structural modifications. For example, paclitaxel (Taxol) was originally derived 
from the bark of Pacific yew tree and is used for treatment of ovarian and breast cancers. 
Camptothecin (CPT) is isolated from the bark and stem of happy tree. 24 Taxol can impair 
the microtubule function which is critical for cell division, and therefore serves as a 
mitotic inhibitor. CPT is the inhibitor of DNA topoisomerase I and shows remarkable 
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anticancer activity. Currently, two CPT analogues, topotecan and irinotecan, hold great 
promise in treatment of several types of tumors for their better water solubility and less 
cytotoxicity.25 Taxol and CPT are two representative chemotherapeutic drugs of this 
approach. 
Besides these three standard approaches, several novel strategies have emerged 
and shown great potential in cancer therapy. Proton therapy derived from radiation 
therapy is the latest advancement in the treatment of various types of tumors. It uses a 
beam of protons to destroy cancer cells without harming healthy cells and thereby 
reduces the side-effects of conventional cancer treatments.26 Gene therapy was initially 
designed as a means to correct gene defects in hereditary diseases,27 and currently is one 
of potential strategies for cancer treatments. The first gene therapy clinical trial began in 
1990 by introducing adenosine deaminase gene to the T cells of two children with severe 
combined immunodeficiency (SCID).28 From then on, hundreds of clinical studies have 
been conducted with almost 70% of these studies being in the area of cancer gene 
therapy.29 Because malignant transformation initiates from genetic alterations occurred in 
oncogenes and tumor suppressor genes, we can in principle manipulate these genes 
through cancer gene therapeutic techniques to restore the cell’s normal gene function.  
Other innovative cancer therapeutic approaches include photodynamic therapy 
(destroying cancer cells through a photosensitizing drug activated by specific 
wavelengths of light),30 vaccine therapy (treating cancer cells by boosting immune 
response),31 and targeted therapy (tumor–directed drug delivery).32 
Targeted gene therapy, one of cancer therapy strategies, combines the strengths of 
gene therapy and targeted therapy, thereby leading to some advantages over conventional 
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cancer treatment approaches in experimental and clinical studies.33 This treatment may 
have significant impact on future diagnostics, therapeutics of cancer, and others genetic 
diseases.  
Cancer Stem Cells  
The hypothesis of cancer stem cells (CSCs) originated more than a hundred years 
ago when it was proposed that the “misplaced” embryonic stem cells (ESCs) during the 
embryonic development could be the source of cancer. 34 Later evidence in mice and 
humans has indicated that a single cancer cell can generate a heterogeneous tumor,35 
suggesting the existence of cancer stem cells. CSCs harbor the self-renewal ability and 
can give rise to the neoplasm at high efficiency.36 Meanwhile, over the past few years, 
researchers have isolated and identified CSCs from human and mouse leukemia, as well 
as from epithelial tumors such as the skin, breast, brain, colon, head and neck tumors.37  
Three models have been proposed to explain the formation of CSCs. The first 
states that one critical mutation (e.g., the one that breaks the asymmetric division pattern) 
triggers the “cascading transformation” from stem cells to cancer cells. The second model 
regards that the accumulation of genetic alterations in stem cells leads to the 
transformation of CSCs. The third considers that the dedifferentiation of cancer cells 
through epithelial-mesenchymal transition results in CSCs.38 Each theory rationalizes 
under a certain scenario. 
Although researchers have successfully identified, isolated, and cultured the 
hemacytometic CSCs, and several critical components in acquiring self-renewal of CSCs 
have been demonstrated, the mechanism underlying CSCs acquired capabilities of 
metastasis, and apoptosis-resistance is rarely known. 39 To address this issue, efforts have 
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been dedicated by conducting gene profiling techniques (e.g., microarray to 
systematically compare cancer cells and CSCs, or stem cells and CSCs.39-40 
CSCs might lead to tumor recurrence because of their drug resistance and 
capability of metastasis. Therefore the identification and characterization of CSCs from 
various tumors are of significant importance for the improvement of cancer therapy.41 
Further understanding of CSCs has implications for the development of more innovative 
and efficient approaches for cancer treatment.41a 
Cancer and microRNA (miRNA) 
miRNA is a class of evolutionarily-conserved, endogenous, noncoding, small 
RNA with 20-23 nucleotides (nt) in length.40c Since its discovery in the early 2000s,42 
miRNA has walked its way into virtually every corner of the biology field. It regulates 
the expression of genes involved in the control of development, proliferation, apoptosis, 
and stress response at translational and posttranslational levels. miRNAs manipulate 
more than 60% of human genes43 by inhibiting ribosome function, decapping the 5’-cap 
structure (cleavage of 5’-cap of mRNA cause translation repression), deadenylating the 
poly(A) tail, and degrading the target mRNA.44 
By 2006, more than 400 miRNAs have been experimentally identified in 
mammalian genomes; 45 whereas an estimate shows 1000 miRNAs or more exist in 
vertebrate and about 100 in invertebrate.45-46 In addition, bioinformatics prediction shows 
more than 30% human genes may be under the regulation of miRNAs.47 Strikingly, an 
individual miRNA has the ability to control the expression of several to hundreds of 
mRNAs it binds to through an imperfect sequence complementarity.  
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Altered miRNA expression profile and several other lines of evidence indicate the 
critical role of miRNAs in cancer biology.48 For example, it has been found that the 
global miRNAs expression in cancer is downregulated and inhibited biogenesis of 
miRNAs will lead to tumorigenesis, which suggests the suppressive role of miRNAs in 
cancer.49 How miRNAs regulate tumorigenesis has remained poorly understood. 
However, recent research starts to yield clues. Hannon and colleagues identified a new 
family of miRNAs, miR-34a-c, through comparing miRNA expression profiles of wide-
type and p53-dificient (p53 is a tumor suppressor) cells. 49a Their findings suggested 
miR-34 may act with other effectors to inhibit cancer proliferation through participating 
p53 network that inhibited tumor formation. 49a Additionally, Piccolo and coworkers 
found another miRNA family, miR-103/107, which reduces the miRNA biosynthesis by 
inhibiting Dicer (a key component of siRNA/miRNA process) expression. 49b The data 
demonstrate a new pathway where cancer cells downregulate miRNAs syntheses through 
Dicer, which in part explains the reduced expression of global miRNAs.49b 
In addition, other miRNAs have been identified and demonstrated as tumor 
suppressors.50 For instance, downregulation of let-7 is associated with tumor progression 
and poor prognosis of lung cancer patients. Expression of let-7 also prevents tumor 
sphere formation of breast cancer cell lines and inhibits tumorigenicity in an in vivo 
xenograft tumor assay.49d On the contrary, miRNAs, such as miR-21, miR-106a, and 
miR-155, have oncogenic activities.51 
Overall, miRNA holds potential to influence cancer therapy in different ways. 
First, along with the technological advances that facilitate miRNA expression profiling in 
tumors, miRNA expression signatures could be identified and utilized as helpful 
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biomarkers for cancer diagnostics, which would render a powerful tool for cancer 
prevention and therapeutics.52 Second, increasing lines of evidence suggest that 
sequence-specific knockdown of oncogenic miRNAs would result in favorable anticancer 
effects, demonstrating the promising potential of miRNA-based cancer therapy.50 
 
RNA Interference (RNAi) 
Since its discovery,53 RNAi research within biology and medicine have enjoyed 
rapid development.54 RNAi process is triggered by short RNA, such as small interfering 
RNA (siRNA), microRNA (miRNA), piwiRNA (piRNA), that is homologous to the 
target genes being suppressed.55 Due to its sequence-specificity and knockdown potency, 
RNAi has been applied to gene function and therapeutic applications.  
The Discovery of RNAi 
 Small RNA-mediated gene silencing phenomenon was first observed in petunia 
when an exogenous transgene designed to increase gene expression actually induced the 
gene silencing of the homologous endogenous gene.56 Unfortunately, this unexpected and 
intriguing result was ignored and explained by co-suppression or post-transcriptional 
gene silencing (PTGS).57 It was not until 1998 that the secret of RNAi was uncovered by 
Andrew Z. Fire and Craig A. Mello when they injected long double-stranded RNA 
(dsRNA) into the nematode C. elegans as well as single strand sense or antisense RNA.53 
They found that only dsRNA initiated a potent and specific degradation of endogenous 
mRNA containing the same sequence as dsRNA trigger. The groundbreaking discoveries 
of RNAi in nematodes let researchers rethink of PTGS in plants, and proved that RNAi 
existed in both nematodes and plants.58 However, investigators could not find RNAi in 
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mammals because long dsRNA induced the activation of interferon response pathway 
and the inhibition of global protein synthesis.59 Tuschl and colleagues demonstrated that 
short dsRNA rather than long one could inhibit gene expression.60 Soon RNAi was 
observed in Drosophila melannogaster,61 trypanosima,62 and vertebrates.63 We now 
understand that RNAi is an evolutionally conserved mechanism in eukaryotes. The 
discovery of RNAi has revolutionized gene function research and biomedical research. 
RNAi Mechanism  
The RNAi pathway can be divided into two major steps: initiation and activation 
as shown in Figure I-1. In the first step, a RNase III type enzyme termed Dicer 64 cleaves 
the longer dsRNA to smaller RNA that is typically portrayed by ~21 base pair (bp) in 
length containing 2 nt overhangs with 5’ phosphate and 3’ hydroxyl terminals. 
Subsequently, one strand of siRNA duplex (guide strand) is incorporated into a complex 
called RNA-induced gene silencing complex (RISC),65 which binds to complementary 
mRNA substrates and manipulates gene function. If the guide strand binds to the 
corresponding sequences in the open reading frame (ORF) of mRNA with a complete 
base paring (e.g., siRNA or miRNA), it will induce site-specific mRNA degradation. 
More precisely, RISC cleaves mRNAs at 10 nt from the 5’ end of the guide strand.60, 66 If 
the guide sequence is not fully complementary to the sequence of mRNA (i.e., miRNA), 
which normally occurs at the 3’ untranslated regains (UTRs), the RNA will trigger 
translational repression.67 In another word, RNAi can resulted from either siRNA or 
miRNA, depending on the degree of the complementarity between the guide RNA and its 
target mRNA. If the complementarity is low, the guide RNA will go into miRNA 
pathway, leading to translational inhibition; whereas the perfect base pairing match will 
  
lead to siRNA pathway, causing the cleavage of mRNA. Actually, 
biochemically or functionally indistinguishable from siRNA pathway because 
some essential factors which are often encoded by multigene families conserved among 
eukaryotes.67  
 
Figure I-1. Mechanisms of RNA inference.
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Moreover, siRNA may nonspecifically target unrelated genes with only partial sequence-
complementarity. Therefore, a rational design of siRNA sequence is a prerequisite for 
performing reliable gene knockdown.72 
In the early 2000s, a set of empirical rules based on the first identified functional 
siRNAs was proposed and influenced siRNA design profoundly.63b Today, some of these 
criteria are still being utilized in several siRNA selection/design tools. However, more 
powerful, comprehensive tools have emerged based on the following advances : (i) 
further understanding of RNAi mechanism, (ii) statistical analysis of libraries of siRNAs 
with experimentally determined efficiency;73 and (iii) the rapid development of 
bioinformatics.74 Some research groups have collected published functional siRNA 
sequences and established open-access databases;75 while a few biotechnology 
companies, such as Ambion, Qiagen, and Invitrogen, provide pre-designed or custom 
siRNAs synthesis services.  
Despite the availability of these sources, it is necessary for investigators to know 
some criteria in the case of choosing an appropriate tool or selecting a siRNA candidate 
from a list. There are four typical rules as an important guideline in the considerations of 
effective and specific siRNA:55, 70 (1) Sequence asymmetry: siRNAs symmetry in 
structure but not in sequence shows improved efficacy and specificity.55 (2) siRNA 
duplex stability: siRNAs with G+C content between 30% ~ 52% keep the balance 
between structure stability and release flexibility. Typically, G+C content lower than 
30% will destabilize siRNA duplexes and reduce the affinity for target mRNA binding; 
whereas higher than 52% may impede RISC loading and /or cleavage-product release.70 
(3) Target accessibility: the local secondary structures of target mRNAs might restrict the 
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accessibility of RISC, reducing or abolishing siRNA efficiency.76 (4) Sequence features: 
single nucleotide at different positions will affect siRNAs performance dramatically. For 
instance, U/A at position 1, A/U at position 10, C/G at position 19.55 Additionally, some 
other factors, such as thermodynamic consideration and BLAST search, are contributing 
to the rational design of siRNAs. 
RNAi Application  
The ability of siRNA to silence gene expression as a powerful investigational tool 
has been intensively explored in dissecting gene function and blocking disease-causing 
gene expression.65, 77 
RNAi has been successfully applied to systematic genome-wide screening in 
many species, such as C. elegans 78 and Drosophila 65. High-throughput techniques 
combining the strengths of RNAi, bioinformatics and genomics, offer rapid annotation of 
genomes with functional information on each gene readily.79 In addition, siRNAs hold 
great potential as gene therapeutic agents for treating a  wide range of diseases, such as 
cancer, neurodegenerative disorders, and viral infection,  where aberrant gene expression 
occurs.80 For instance, downregulated expression of VEGF, an important factor for 
pathological angiogenesis,81 through RNAi technique suppressed tumor angiogenesis and 
growth in PC-3 (a human prostate cancer cell line) xerograph model.82 
Overall, compared to the classic genetic and reverse genetic approaches, siRNA 
has incomparable advantages in functional genomics and as therapeutic applications.83 
Classical genetic approaches study the gene function by identifying gene mutations, and 
conventional reverse genetic methods involve the disruption of a known gene (i.e., 
knockout) to study the effect on a function or pathway. Both are time-consuming and 
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expensive. In contrast, the function of an unknown gene through RNAi technique could 
be revealed in several days.80 siRNA possesses the high specificity and potency in 
inducing gene silencing with a sequence-dependent manner. The accessibility of 
genomics sequencing of many key organisms accelerates the development of nucleic 
acid-based RNAi in gene function research.84 
siRNA Delivery  
An appropriate delivery strategy that enables siRNA translocation and balances 
siRNA stability and activity is the key to a successful siRNA application. siRNA delivery 
can be divided into two classes: in vitro and in vivo delivery. The latter include two major 
routes according to biodistribution: local and systemic administration. Local 
administration, as the name implies, is a route by which siRNA or drug is directly 
delivered to a localized area of the body (e.g., tumor) with topical effects. This strategy 
uses a low dose of substance but achieves relative high concentration at the intended site; 
and therefore, reduces the risks of systemic side effects.85 In contrast, systemic 
administration refers to deliver drugs or substances through either enteral (digestive tract) 
or parenteral (intramuscular or intravenous injections) route. The choice between these 
two administrations depends on tissues location and cell type being targeted.86  
According to the endurance of RNAi effects, siRNA delivery can be sorted into 
transient and stable delivery. In other words, siRNA can be delivered to cells either 
exogenously as synthetic agents or endogenously as gene-encoding siRNAs.87 For the 
former, RNAi effect is achieved through exogenous delivery of chemical or transcripted 
siRNA and normally exists for a few days before the degradation of siRNAs. As for the 
latter, siRNA is often delivered by viral plasmid vectors which have the capability of 
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being integrated into the host’s genome, and thereby, RNAi effects can last for weeks or 
even longer. This strategy is preferred for siRNA library construction and systematic 
genome-wide functional screening. Besides, for some chronic diseases which need lasting 
therapeutics and low toxicity, the stable transfection is advantageous. Short hairpin 
siRNAs (shRNAs) are commonly used under this strategy. However, those methods 
based on the plasmid which will be expressed under the host’s transcription system pose 
a safety issue.  
siRNA delivery systems can be divided into viral- and nonviral-based delivery. 
Due to the high efficiency of ferrying DNA/RNA into the cells, viral delivery has been 
intensively investigated for gene therapy. There are at least four classes of virus in this 
arena: retrovirus, adenovirus, baculovirus, and lentivirus.88 Despite of high transduction 
efficiency, viral-based delivery system in vivo is limited by safety concerns. For example, 
retroviruses could be integrated into the genome of the host cells, which potentially 
increases the risk of carcinogenesis. Another issue is the transduction efficiency of the 
retroviral vector is correlative with the activity of cell division.  
The lack of genomic integration of adenoviral vectors provides a safety advantage 
over retrovirus vectors. As a result, many adenovirus-based clinical trials occur,89 and 
several studies report that the local administration of adenoviral vectors has achieved 
significant therapy effects. However, therapeutic effects from adenoviral vectors, which 
are generally lost after several cell divisions, are moderate and short-lived compared to 
those from the retrovirus vectors. In addition, this approach is impaired by dose-
dependent liver toxicity.90 In contrast to baculovirus, lentiviral vector is a promising 
strategy owing to its relative bio-safety, less mutagenesis risk, and less pathogenesis.91   
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Nonviral based delivery strategies, such as (co)polymer, Au nanoparticle (AuNP), 
liposome, polyarginine, polylysine, polyethylenimine (PEI), hydrogel, dendrimer, hold 
tremendous promise.92 Some liposome-based, commercial reagents (e.g., Lipofectamine, 
DharmaFECT) have been routinely used for siRNA delivery into various types of cancers 
in vitro.93 However, their applications in vivo are hurdled by cytotoxicity and instability 
in serum.85 PEI is another widely used transfection agent for many years.94 Despite its 
variable performance, it is a useful tool for delivering antisense oligodeoxyribonucleotide 
(As-ODN), DNA plasmid, and siRNA etc.95 Furthermore, modified PEI increases the 
efficiency and specificity of delivery.96  
Most of these nano-scale carriers contain cationic groups which can bind to 
anionic phosphate backbone of the nucleotides via electrostatistics and facilitate the 
cellular uptake of complexes without target specificity. The complexes (i.e., lipoplex, 
polyplex) can be adjusted to be cationic, anionic, or neutral in terms of nitrogen (cationic 
group) to phosphate (anionic group) ratio (N/P ratio). By the nature of negatively-charged 
cell membrane, cationic complexes (N/P > 1) have the tendency to penetrate the 
membrane easily; whereas anionic complexes (N/P < 1) normally have poor transfection 
efficiency. As for neutral complexes, they normally need hydrophilic groups, such as 
hydroxyl group, to maintain water solubility.97  
Delivery of siRNA is intended to downregulate abnormal gene expression through 
RNAi machinery in diseased cells. Although cellular penetration of siRNA has been 
achieved by efficient delivery strategies, therapeutic effects of siRNA cannot be achieved 
until it is in the desired cells. For this reason, the development of cell- or tissue-specific 
delivery must be resolved prior to clinical development of siRNA therapeutics. 
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Targeted siRNA Delivery 
Although significant progress has been made in cancer prognosis, diagnosis, and 
treatment, cancer is still one of the most devastating diseases. One of the challenges we 
are facing is the non-targetability of the conventional cancer treatments that cause cell 
death indistinguishably in both normal and malignant tissues. This Achilles’ heel elicits 
side effects and compromises the effectiveness of common treatments. To address this 
issue, a number of novel strategies that aim at homing of drugs to malignant cells through 
the mediation of targeting moieties have emerged and offer great promise. Targeting 
ligands applicable to cancer therapy mainly include antibodies,98 peptides,6a, 99 
aptamers,99a, 100 and vitamins.7b, 101 
Antibody-Based Delivery 
Antibodies, immunoglobulin proteins, are produced by B lymphocytes to bind 
foreign objects (antigens), such as viruses, bacteria, exogenous proteins, microorganisms, 
and toxins. Numerous antibodies have been generated and commercialized by injecting 
an antigen into a mammal (e.g., rabbit, goats). Successful production of specific antibody 
depends on several factors of antigen, such as chemical characteristics of antigen, the size 
of antigen (> 5 KDa), and its difference from an animal’s own proteins.  
In the past decades, development of therapeutic and diagnostic antibody is among 
the fastest growth in biopharmaceutical area by the virtue of its high specificity and 
affinity to target various antigens.102 More than 18 monoclonal antibodies have been 
commercialized. For example, trastuzumab (Herceptin®), rituximab (Rituxan®), and 
alemtuzumab (Campath®) have been routinely used in clinical treatment of breast cancer 
and leukemia.103 Additionally, over 100 therapeutic monoclonal antibodies are currently 
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under investigation, demonstrating the tremendous biomedical potential of this 
strategy.104 
Due to the exquisite specificity of target recognition and high binding affinity 
between antibody and antigen, many antibodies have been conjugated to nanoparticle 
carriers for targeted siRNA/drug delivery. Many therapeutic agents have been transported 
into diseased cells specifically through this approach. These agents contain 
chemotherapeutic drugs, siRNAs, and As-ODNs.98b, 98d, 105 For example, Song et al. 
designed a protamine-antibody fusion protein for delivering siRNAs to HIV-infected 
cells.98d The carrier contains the C-terminus of the heavy chain fragment of an antibody 
against HIV-1 envelope protein (GP160), and polycationic protamine for complexing 
siRNA. A cocktail of siRNAs against c-Myc (an transcriptional factor), MDM2 (an 
negative regulator of the p53), and VEGF had been administered to tumor cells in mice 
engineered to express GP160, exhibiting potent antitumor effects.98d Despite promising, 
antibody-based delivery possesses some setbacks, such as immunogenicity, high cost, 
and difficult conjugation chemistry. 
Peptide-Based Delivery 
Among many strategies for siRNA delivery, peptide-based delivery has received 
significant attention.106 Such cationic and short peptides (motifs) interact with the 
membrane receptors or proteoglycans which elicit cellular uptake via endocytosis.107 
Although the underlying mechanisms of internalization remain controversial, those 
peptides have been applied to deliver a broad spectrum of therapeutic agents.99b, 99d, 108 
Peptides with arginine-glycine-aspartic acid (RGD) motif have been used to target 
drugs, siRNA, imaging agents, and other diagnostic agents to the tumor cells expressing 
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αvβ3 integrin. Integrin is a heterodimeric cell adhesive protein (with two subunits α and β) 
anchored to the plasma membrane.109 The ligands of integrin include collagen (a fibrous 
protein constituent of bone, cartilage, tendon, and other connective tissue) and fibronectin 
(an extracellular matrix glycoprotein) 110 with characterized RGD motif. Importantly 
integrin receptors are overexpressed on endothelial cells in a tumor vasculature due to its 
crucial role in angiogenesis. For this reason, RGD-mediated targeted delivery has been 
developed to deliver diagnostic or prognostic agents specifically to tumor.99c For 
example, PEGylated PEI with RGD group directs the delivery of siRNA against VEGF 
into tumor with significant inhibitory effects of the tumor growth and reduction of 
angiogenesis after intravenous administration.111 
TAT peptide, a fragment of ligands which can be incorporated into the HIV-
infected cells and concentrated in nuclei, is characterized by cationic peptides, 
YGRKKRRQRRR.112 TAT-siRNA conjugate has been successfully synthesized and 
effectively delivered with silencing the expression of exogenous enhanced green 
fluorescence protein (EGFP) and endogenous cyclin dependent kinase 9 (CDK9).113 TAT 
peptide has been applied to deliver DNA 114 and protein.112  
Cell penetrating peptides (CPPs) which are also known as protein transduction 
domains (PTD) or membrane transduction sequences, are short (~30 amino acids) 
cationic peptide chains rich in arginine and/or lysine residues.108c CPPs have the ability to 
transport linked antisense and siRNA molecules as cargoes into cytosol thereby achieving 
oligonucleotide-based therapeutics. Several lines of evidence have shown that CPP-
antisense oligonucleotide conjugates can be taken up by cells and effectively regulate 
gene expression in vitro and in vivo.115 Although not as potent as cationic lipid agents in 
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complexing siRNAs, CPP-based delivery strategies have substantial advantages in cell 
penetration potential.115-116 This was highlighted in a recent study where the systemically 
delivered siRNA-peptide conjugates crossed blood-brain barrier (BBB).117 
Aptamer-Based Delivery 
Aptamers are normally short nucleic acids that have stable three-dimensional 
shapes and can bind to targeted molecules tightly and specifically.118 An aptamer against 
a target (such as ligands, protein, chemicals, etc.) is selected and identified from 
combinatorial nucleic acid libraries through a technique called systematic evolution of 
ligands by exponential enrichment (SELEX).119 In the past two decades, SELEX has been 
widely used, and numerous aptamers have been explored in both diagnostic and 
therapeutic applications.120  
Aptamer targeting cell surface proteins has been confirmed a promising delivery 
strategy because of its advantages, such as lack of immunogenicity in vivo, convenient 
synthesis and modification, relatively small size, rapid in vitro selection process, and 
large quantities produced with relatively low cost.118 By virtue of these properties, a wide 
range of cargoes has been successfully delivered in a cell-specific manner, including 
siRNAs,121 enzymes,122 radionuclide,100d virus ,123 toxins,124 anti-cancer drugs.125 
Aptamer against the prostate-specific membrane antigen (PSMA) is one of the 
classical aptamer. PSMA is a cell surface antigen overexpressed in prostate cancer cells 
and in tumor vascular endothelium.126 Several groups have constructed distinct aptamer-
siRNA conjugates that have been delivered into tumors with potent efficacy 121d (Figure 
I-2). In another example, Neufeld and colleagues have used aptamer against a transferrin 
receptor (a protein regulates the importation of iron into cells) for delivering α-L-
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aminobenzoate (PABA), and glutamate moieties (Figure I-3). Pteroic acid (PA) is 
analogous to FA without glutamate group. The pteridine ring of folate can exist in 
tetrahydro-, dihydro-, and fully oxidized forms. Plant folates have γ-linked polyglutamyl 
tails of up to approximately six residues.130 
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Figure I-3. The structure of folate. 
 
Folate is a vital cofactor to transfer 1-carbon groups in de novo synthesis of 
nucleotides. Therefore, the deficiency of folate will induce DNA strand breakage, 
increase uracil misincorporation into DNA, impair DNA repair and stimulate 
apoptosis.131 In addition, folate also plays an important role in amino acid metabolism, 
including serine, glycine, methionine and histidine metabolism. That is probably why 
some cancer cells overexpress FR to acquire more vitamin folate, so that they can escape 
the limitation of cell proliferation.132  
Receptor-mediated folate uptake was first found about two decades ago.133 
Cellular uptake of folate in animals is through either FR or reduced folate carrier (RFC).7a 
FR is a glycosylphosphotidylinositol (GPI)-anchored glycoprotein 101s and includes three 
homologous isoforms, FR-α, FR-β and FR-γ, with distinct expression patterns.134 FR-α is 
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the major type expressed by tumors.135 RFC is a membrane-spanning protein,131 and most 
of the antifolate drugs, such as methotrexate, ralititrexed, and lometrexol, are rapidly 
transferred across the plasma membrane by RFC, leading to inhibition of their target in 
both tumors and normal proliferating tissues.131  
Endocytosis mediates the internalization of folate or folate conjugates in FR-
expressing cells (Figure I-4). Firstly, folate conjugates bind to FR on cell surface and 
induce the formation of an intracellular compartment called an endosome, to which they 
internalize and traffic.101n Once an endosome transports to cytosol, it triggers 
acidification under the aid of proton pumps, which decrease pH to 4.3~6.9 (most 
frequently, pH~5.0).136 The change of pH results in the release of folate-drug conjugates 
from FR and the breakdown of compartments (i.e., endosomal escape). FR on the 
compartment could be recycled back to the plasma membrane and facilitate the next 
round transportation.  
 
Figure I-4. The process of folate conjugate uptake via receptor-mediated endocytosis.  
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FR responsible for the internalization of FA conjugates has been supported by 
experiments where the uptake is abolished by: (i) excess free FA, (ii) FR antibody, (iii) 
FR negative cells, (iv) the cleavage of GPI anchor with phosphatidylinositol-specific 
phospholipase C (PLC).137 On the other hand, inhibitor studies on several endocytic 
proteins have suggested that receptor-mediated endocytosis is engaged in the entry of 
folate conjugates.138 
FR-mediated delivery has some great advantages: (i) Normal cells use RFC to 
transport reduced FA; whereas cancer cells utilize FR to uptake oxidized folates, or 
folates conjugates,139 (ii) The cargo of FA, no matter how big or small, will not affect 
binding affinity (Kd = ~10-10 M) 137, 140 and endocytosis, (iii) FA conjugate could be 
released into the cytosol respond to the pH changes, and consequently exert their 
functions (FigureI-4),101j (iv) Due to the low molecular weight of folate, FA-conjugates 
facilitate the cellular penetration in solid tumors,86 (v) The density of FR in malignant 
cells appears to increase as the stage/grade of the cancer worsens,139 (vi) The carboxyl 
group of glutamate(s) (Figure I-3) has structural flexibility for chemical conjugation and 
release,141 (vii) FA can be alternatively substituted by Pte (Figure I-3) without 
compromising binding affinity and delivery efficacy.  
High expression levels of FR-α in tumor, such as ovary, cervical, mammary 
gland, breast, colon, prostate, lung, kidney, nose, throat, and brain, make FR-based 
delivery attractive for biomedical application. For example, MORAb-003, a monoclonal 
antibody against FR-α, is under phase II clinical trial in ovarian cancer patients, which 
has shown cellular cytotoxicity via non-immune mediated cell growth inhibition under 
folate-deficient conditions.142 In addition, several FA-linked drugs are under phase I to 
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phase II clinical trials.143 Taking FA-tubulysin derivatives as an example, this group 
includes tubulysin A hydrazide (EC0510), tubulysin B hydrazide (EC0305), tubulysin B 
ester (EC0302), and N,O-acetal derivative of natural tubulysin (EC0317).144 Tubulysin is 
a type of tetrapeptide that has high cytotoxicity and effective antiproliferative activity 
against multiple cancer cell lines.145 EC0305, one of the promising conjugates of the 
group, shows dose-dependent antitumor activity (IC50 = 1-10 nM in M109) and favorably 
low toxicity 144. Two other FA conjugates, EC131 (FA-maytansionid) 146 and EC145 
(FA-desacetylvinblastine monohydrazide),144, 147 act as tubulin inhibitors by interfering 
with the formation of microtubulin and exhibit great antitumor potential. These 
undergoing investigations have demonstrated the FR-targeting delivery holds great 
potential in biomedical applications. 
Additionally, FA has been applied to deliver a wide range of drugs or therapeutic 
or diagnostic agents into various tumors. The cargoes include siRNAs,101b ribozymes,148 
anti-cancer drugs,149 radioactive/magnetic resonance imagining agents,101d, 150 
oligonucleotides,151 radiotherapeutic agents,148 protein toxins, 101o, 101q chemotherapeutic 
agents,101m immunotherapeutic agents,143 and liposomes with entrapped drugs.101l, 149  
Typical FR-positive cancer cells include KB (human nasopharyngeal epidermoid 
carcinoma cell line), SKOV-3 (human ovarian carcinoma cell line), SW620 (human 
colorectal carcinoma cell line), etc. However, A375 (Human malignant melanoma cell 
line), A431 (Human epithelial carcinoma cell line), and A549 (Human lung carcinoma 
cell line) express little FR,101j and are normally used as FR-negative control cells in 
studies. 
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siRNA Targets for Cancer Therapeutics 
Sequence-specific gene silencing through siRNAs has become a standard 
approach for therapeutic application. Many diseases result from abnormal gene 
expression. siRNA technique has the ability to restore cell’s normal gene function.  In 
cancer cells, genes that are associated with cell proliferation, apoptosis, metastasis, 
angiogenesis, and drug resistance are potential siRNA targets for therapeutic 
intervention.152 Three genes, VEGF, survivin (Sur), and caspase 8 associated protein 2 
(CASP8AP2), are involved in angiogenesis and apoptosis, and are discussed below.  
VEGF and Tumor-Specific Angiogenesis 
VEGF, EGF, and FGF represent the most widely recognized oncogenic growth 
factors.86 Among them, VEGF plays as a crucial regulator for blood vessel formation 
including vasculogenesis (the formation of new blood vessels when there are no pre-
existing ones) and angiogenesis (the formation of new blood vessels from pre-existing 
endothelium),153 showing pleiotropic responses on migration, proliferation, tube 
formation, and survival of endothelial cells.154 Knockout of VEGF in embryonic cells 
results in despaired vasculogenesis and embryo lethal.155 Angiogenesis is the second 
phase of embryological development under physiological conditions.20b Recent evidence 
indicates that VEGF signaling plays a vital role in tumor growth, intraocular neovascular 
disorders and other conditions due to induced angiogenesis.156  
VEGF, characterized by the intrachain and interchain disulfide bonds between 
eight cysteine residues at conserved positions,153 has two monomers which form a dimer 
in an anti-parallel fashion with the receptor-binding sites located at each pole of the 
dimer.157   
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In mammals, there are five members in this family, termed VEGF-A, VEGF-B, 
VEGF-C, VEGF-D, and placental growth factor (PGF). Each member has several 
different splice variants and processed forms with distinct expression pattern. Human 
VEGF-A gene contains eight exons separated by seven introns,158 and has at least five 
isoforms designated by their expected amino acid length, which are VEGFA121, 
VEGFA145, VEGFA165, VEGFA189 and VEGFA206.153 VEGFA121 lacks the residues 
encoded by exon 6 and 7; while VEGFA165 lacks the residues encoded by exon 6 and is 
the predominant isoform158. The longest VEGF-A transcript in human is 3665 nt long and 
encodes VEGF206. VEGF-A is a key mediator of blood vessel growth; whereas VEGF-C 
and VEGF-D regulates lymphatic angiogenesis.159 In addition, VEGF-A, specifically 
acting in endothelial cells, has various effects, such as mediating increased vascular 
permeability, stimulating angiogenesis, vasculogenesis and endothelial cell growth, 
promoting cell migration, and inhibiting apoptosis.20b  
VEGF receptor family includes VEGFR1, VEGFR2, VEGFR3, and two 
coreceptors, heparin sulfate proteoglycan and neuropilin, which are defined as VEGF-
binding molecules, but lack of VEGF-induced catalytic function.160 VEGFR1, a soluble 
or membrane-bound protein, is the receptor of PGF during angiogenesis;161 whereas 
VEGFR2 and VEGFR3 are essential for the functions of vascular endothelial and 
lymphendothelial cells, respectively.  
Malignant cells up-regulate the expression of VEGF(R) to induce the formation of 
blood vessels through which oxygen and nutrients are transported to tumor and 
eventually facilitate it escaping the limitation of growth supplies. Therefore, 
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downregulation of VEGF or/and VEGFR expression can diminish angiogenesis by 
cutting down blood vessel development, and ultimately shrink a tumor.162  
This rationale has been applied to treat various cancers and neovascularization 
age-related macular degeneration (AMD) 163 with pharmaceutical success.153 Two drugs 
aimed at VEGF, bevacizumab (Avastin), a humanized monoclonal antibody, and 
pegaptinib (Macugen), a PEGylated aptamer has been approved by U.S. Food and Drug 
Administration (FDA) to treat various types of cancer and AMD, respectively.2b Two 
other drugs, sorafenib (Nexavar) and sunitinib (Sutent) as molecular antagonists of 
VEGFRs have also been approved by FDA for treatment of kidney and liver cancer.2b  
Apart from these commercialized drugs, a multitude of VEGF(R)-targeted, 
siRNA-based therapy are currently being investigated.85 For example, a siRNA 
compound, Sirna-027, has disrupted the VEGF pathway and reduced neovascularization 
by a direct intravitreal (inside an eye) administration.164 Moreover, Kim and colleagues 
reported that cocktailed siRNAs targeting three genes (VEGFA, VEGFR1, and VEGFR2) 
could block angiogenesis from herpes simplex virus (HSV) infection, which caused 
neovascularization or stromal keratitis.165 Taken together, VEGF and its receptors are key 
regulators of the process of angiogenesis, which makes them attractive therapeutic targets 
with demonstrated success.  
Survivin and Anti-Apoptosis 
Since the discovery of survivin in 1997,166 a keen interest and intensive attention 
have been focused on this unique protein because of its dual-function as a suppressor of 
apoptosis and a regulator of cell division. 167 Survivin is a member of inhibitor of 
apoptosis proteins (IAPs) family and a component of a chromosome passenger complex 
  
(CPC). It regulates several important biological processes, including 
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some tumors and it appears to be involved in cancer resistance. Based on these findings, 
survivin has been proposed as an attractive target for cancer therapy. Some preclinical 
studies have demonstrated that downregulation of survivin expression reduced tumor 
growth potential, increased the apoptotic rate, and improved the sensitivity of malignant 
cells to chemotherapeutics.171 In addition, several survivin inhibitors have been 
developed as anticancer therapeutic tools and entered clinical trials.167b YM155, one of 
them, was discovered through screening assay with a survivin-promoter luciferase 
experiment.172 It specifically suppresses survivin transcription and translation in several 
cancer cell lines with robust antiproliferative activity in vitro and in vivo.173  
However, in some preclinical experiments, downregulation of survivin expression 
and function through RNAi technique results in modest antitumor activity, indicating the 
need of synergic treatment. Following this notion, several components, such as 
topoisomerase inhibitors,174 alkylating agents,175 and UCN-01 (a small molecule inhibitor 
for protein kinase C, and cyclin-dependent kinase),176 have been identified and 
combinatorially utilized with survivin-specific siRNA to increase the inhibitory effects on 
cancer cell proliferation.  
Inhibition of survivin expression does not induce significant apoptosis. Instead, it 
leads to aberrant chromosome and aneuploidy, suggesting its role as a mitotic regulator 
associated with CPC. CPC contains at least four proteins: survivin, aurora, borealin, and 
INCENP.177 The interaction between aurora and survivin is supported by the correlation 
of decreased survivin and mislocalized aurora B in dying cells.178 Data also show that 
repression of survivin expression will render cell mitotic catastrophe, a form of cell death 
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that results from aberrant mitosis.179 In these cells, the location of survivin on 
chromosome is altered and severe spindle defects emerge.4, 179 
Caspase 8-Associated Protein 2 
Caspase 8-associated protein 2 (CASP8AP2) is a human apoptotic protein, 
homologous to FLASH (FLICE-associated huge protein) in mouse and CED-4 in C. 
elegans. Currently, we know little about CASP8AP2, and major knowledge about this 
protein comes from studies of FLASH.  
FLASH was first identified in 1999 by screening a mouse T-cell complementary 
DNA (cDNA) library with two-hybrid system and tandem dead effector domains (DEDs) 
of caspase 8 as a probe.180 FLASH is constitutively expressed in adult mouse tissue as 
two transcripts of approximate 4.7 kb and 7 kb, and translated into a ~220 kDa 
protein.180-181 FLASH contains a DED-recruiting domain, which is able to bind to DED(s) 
of caspase 8 and Fas-associated protein with dead domain (FADD).182 Studies suggested 
that FLASH may be a component of the death-inducing signaling complex (DISC) 183 
that includes Fas receptor, Fas-binding adapter, and caspase 8, and plays a regulatory role 
in Fas-mediated apoptosis.  
Presently there is some research on CASP8AP2. For example, Kittler et al. 
generated a genome-scaled, endoribonuclease-prepared short interfering (esi)RNAs 
library to screen the genes essential for the cell division.184 CASP8AP2 was identified 
through cell viability screening followed by video-microscopy assay with 36 other genes 
that are critical for cell mitosis.184 Downregulation of CASP8AP2 caused cell death, 
indicating the role of CASP8AP2 as an apoptotic co-repressor. Interestingly, the function 
of CASP8AP2 in acute lymphoblast leukemia patients appears different. Flotho et al. 
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found that low expression level of CASP8AP2 was correlative with a high rate of 
leukemia relapse. By contrast, high expression level was associated with a reduced 
capacity of leukemic lymphoblasts to grow in vitro.185 Their interesting results implied 
that CASP8AP2 was a prognostic factor for leukemia relapse.186  
These “contradictory” results indicate the dual function of CASP8AP2, similar to 
FLASH which is capable of regulating apoptosis induction and activation of the anti-
apoptotic NF-κB (an important transcriptional factor) pathway.181, 187 The data from 
FLASH studies indicate that the subcellular compartmentalization of this protein could 
play a critical role in its function determination.181 When FLASH locates in cytoplasm, it 
mediates apoptotic function in association with caspase at mitochondria; while in the 
nucleus, it mediates the NF-κB pathway or is assembled into Cajal bodies (a sub-
organelle found in the nucleus of proliferative cells),187b fulfilling the non-apoptotic 
function. 
 
Transcription-Coupled RNA Conjugation System 
Our lab has been interested in RNA catalysis, conjugation, and function.101a, b, 128, 
188
 A versatile transcription system has been developed recently using a functional group 
linked adenosine analog (R-A, R: functional group, A: adenosine) as a transcriptional 
initiator (FigureI-6). Through this approach, more than 80% transcript RNA may be 
linked with R through one-step in vitro transcription under the T7 Φ2.5 promoter.188e 
Moreover, a number of R-A conjugates have been synthesized for 5’-RNA labeling. The 
R groups include folate,128 amines, coenzyme, FAD, NAD,188g, h biotin,188f and 
fluorophore.188b 
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5' TAATACGACTCACTATTAGGA-
    ATTATGCTGAGTCATAATCCT-
DNA template
possessing T7 
promoter
T7 Class II Promoter
        R-A; NTPs
T7 RNA polymerase
Trancription starts
 from the A in red
R-AGGA- RNA transcript
                      R-A = Adenosine Derivative 
  R group can be folate, biotin, CoA, fluorophore, NAD, etc.
 
Figure I-6. Adenosine derivative-initiated, one-step in vitro transcription. 
 
In addition, our lab has discovered an RNA bioconjugation method under aqueous 
solutions where thio-RNA (HS-RNA) can be linked to functional groups by imidazole 
catalysis with up to 100% yields in 10 minutes.188j The preparation of thio-RNA gives us 
another way to modify RNA simply and efficiently by transcription under T7Φ 2.5 
promoter.188e 
Although chemical synthesis of siRNA is an easy way with high purity, in vitro 
prepared RNA is cheaper and more flexible.188f, 189 Typically, the procedure is described 
as following: (i) DNA templates possessing the T7 Φ2.5 promoter and the sequence for 
siRNA are rational designed and chemically synthesized; (ii) DNA then is utilized as 
transcriptional templates to generate two strands of RNA by T7 polymerase; (iii) two 
strands of RNA are annealed to form a duplex.  
This strategy has been applied to synthesize a diverse functional group conjugated 
RNAs for function or imaging studies. For example, a chimeric FA conjugated pRNA-
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siRNA has been generated by this method and shown significant RNAi efficacy.128, 190 
Overall, this facile and efficient approach combines RNA synthesis with 
modification/labeling through one-step transcription, thereby making the method 
particularly useful in RNA bioconjugation and analysis. 
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CHAPTER II 
OJECTIVES OF RESEARCH 
Taking the advantage of the great advantages (i.e., specificity, and efficiency) of 
RNAi technique, siRNA-based cancer therapeutics has progressed rapidly and moved 
into clinical trials. Nevertheless, RNAi clinical application is still impeded by lacking of 
cell- and tissue-specific delivery. Capitalizing on overexpressed FR in cancer cells but 
not in normal cells, RNA labeling/conjugation chemistry by one-step transcription, and 
synthesis of FA-block copolymer, we have a great opportunity to combine these advances 
to develop cancer cell-targeted siRNA delivery technique and achieve specific gene 
knockdown.  
We hypothesize that FA-linked siRNA or siRNA complexes with FA-copolymer 
would enter cancer cells with FR-dependency and targetability, activate RNAi pathway, 
and knockdown targeted gene (e.g., survivin and CASP8AP2) expression, through which 
we can suppress cancer cell proliferation or induce cancer cell into apoptosis. The overall 
goal of this research is to develop a strategy that can achieve FR-mediated siRNA 
targeted delivery to cancer cells with demonstrated inhibitory effects on cell growth. The 
specific objectives of this research are: 
1. Preparation of FA conjugated siRNA (FA-siRNA) with potent RNAi efficacy.  
To achieve this goal, each siRNA targeting a specific gene has to be rationally 
designed through a selective tool that has integrated a set of proper criteria for 
increasing the efficiency, specificity, and reducing off-target effects. Both FA 
conjugated and non-conjugated siRNA will be synthesized by our efficient one-
step in vitro transcription under T7 Φ2.5 RNA promoter.  
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2. Delivery of FA-siRNA and FA-polymer/siRNA to FR-expressing cancer cells.  
To better assess siRNA delivery, a luciferase reporter gene was introduced and 
integrated into the genome of FR positive KB cells to establish a stable 
transfected cell line. Taking advantages of bioluminescence, we examine and 
optimize the transfection condition for both FA-siRNA and FA-polymer/siRNA 
with enhanced sensitivity and accuracy of detection. Furthermore, several 
analyses will be conducted. For example, fluorophore-labeled siRNA will be 
utilized to dissect the internalization of siRNAs through confocal laser scanning 
microscopy (CLSM) and flow cytometer. On the other hand, polymer 
encapsulation provides protection of siRNA against enzymatic degradation and 
therefore increases the half-life of siRNA which can be analyzed by gel 
electrophoresis and UV/vis spectrometry. In addition, FR-dependency of the 
delivery is one of the predominant advantages of our delivery system over the 
other non-specific delivery strategies. FR-assisted siRNA delivery will be 
examined by experiments where the internalization of FA-siRNA or conjugates is 
blocked by: (i) competition from excess free FA; (ii) substitution of FR negative 
cells (e.g., A549) for FR positive cells (e.g., KB); (iii) substitution of non-FA 
conjugated siRNA and polymer for their FA conjugated counterparts.  
3. Achieving significant gene knockdown by delivery of FA-polymer/siRNA 
complexes and cell growth inhibition/apoptosis.  
Once the complexes enter cells through endocytosis, they will escape from the 
endosome and release the siRNA cargo, which will be processed by Dicer, 
incorporated into RISC and trigger homologous mRNA degradation. Therefore 
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potent gene downregulation is the goal of our targeted delivery, which will be 
tested by real-time PCR and luciferase assay. Moreover, due to the pivotal role of 
our selected siRNA targets in tumor angiogenesis (i.e., VEGF), and anti-apoptosis 
(i.e., survivin, CASP8AP2), downregulation of their expression will inhibit tumor 
proliferation, which will be evaluated by morphological observation, cell viability 
assay, and apoptosis assay. in vivo (i.e., xenograft model) assessment is one of the 
future goals. 
4. Application of the FA-copolymer/siRNA delivery system.  
Theoretically, rationally designed and efficiently internalized siRNA could 
knockdown the expression of any gene in the genome; furthermore, our targeted 
siRNA delivery system could facilitate siRNA regardless of sequence and pattern 
to enter any FR-expressing cancer cells. To examine its rationality, three types of 
FR positive cells (KB, HeLa, and SKOV3), and six siRNA targeted genes 
(Survivin, CASP8AP2, VEGF, VEGFR, Luciferase, and GFP) have been 
investigated.  
5. Monitor siRNA uptake and intracellular trafficking processes. 
The efficiency of siRNA cellular delivery is one of the key factors for the efficacy 
of RNAi. An evaluative system should answer the following questions: (i) 
whether siRNA complexes have bound to and entered cells; (ii) how to 
distinguish specific and non-specific binding; (iii) how to confirm siRNA is inside 
the cell; (iv) whether siRNA has been escaped from the endolysosome; (v) more 
importantly, how to quantitate cellular events whereby we can optimize siRNA 
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delivery. A CLSM-based real-time imaging platform will be used to assess these 
processes. 
6. Establishing the correlation between FR expression level and delivery efficiency 
of FA-conjugates.  
FR-dependence is the key for siRNA specific delivery in our investigation. 
Therefore clarification of the correlative relationship between FR expression and 
uptake efficiency is of practical importance.  To achieve this goal, experiments 
will be performed that compare the efficiencies of binding, internalization, and 
gene knockdown upon transfection of FAPol13/siRNA in three cell lines (KB, 
HeLa, and SKOV3) that exhibit different FR expression levels.  
 Successful completion of these objectives is outlined in the following chapters. 
For example, synthesis of FA-linked siRNA and specific delivery of FA-siRNA in Gluc-
KB (objective 1 and part of objective 2) are described in Chapter IV. Cancer specific 
siRNA delivery via FA-conjugated polymer (objectives 2 and 3) is detailed in Chapter V. 
 
  
40 
 
 
 
CHAPTER III 
MATERIAL AND METHODS 
Instrumentation and Equipment 
Name – Model (Company) 
Accumet Basic pH meter – AB15 (Fisher Scientific)  
Analytical Balance – HR 60 (A & D Co)  
Autoclaves – 2021 and 3031 S (Amsco Eagle series)  
Balance – XP 1500 (Denver Instrument)  
Electrophoresis Power Supply – EC 154 (E-C Apparatus Corporation)  
Freezer –20 ˚C (Frigidaire)  
Freezer –86 ˚C (Forma Scientific)  
Geiger Counter – GSM 110 (Wm. B. Johnson and Associates, Inc.)  
Gel Documentation System with Transilluminator – EDAS 290 (Kodak)  
Gel Documentation System – Universal Hood II (BioRad) 
Biohazard Safety Cabinet – LA2-4A2 (ESCO) 
CO2 Incubation – MCO-17AC (SANYO) 
Confocal Laser Scanning Microscope – LSM 510 (Carl Zeiss) 
Flow Cytometer – C6 (Accuri) 
Fluorescent Microscope – Eclipse 50i (Nikon) 
Heating Block – 12359030 (VWR) 
Incubator (Labline Instruments Inc.)  
Liquid Scintillation Counter – 425 034 (Hidex)  
Microcentrifuge – 5415 C and 5451 D (Eppendorf)  
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Microcon Centrifugal Filter Devices – M10 & M30 (Millipore)  
Phosphorimager/Molecular Imager FX – 729 (BioRad)  
Phosphorimager/Fluorimager – Typhoon 9400 (Amersham Biosciences)  
Pipettes – P-1000, P-200, P-20, and P-2 (Gilson)  
Pump – D 25 (Precision Scientific)  
Pump – RV3 (BOC Edwards)  
Scintillation Counter – 425 034 (Hidex)  
Spectrophotometer – V 530 (Jasco)  
Stirrers and Heaters (Nuova Thermolyne and Corning)  
Thermocycler – Mastercycler (Eppendorf)  
Vertical Gel Apparatus – V16 (GibcoBRL)  
Heating Circulator – WA01A11B (PolyScience) 
Horizontal Electrophoresis System – FB-SB-710 (Fisher Scientific) 
Horizontal Electrophoresis System – Mini-sub Cell GT (BioRad) 
Vortexer – G560 (VWR)  
Microplate Reader – Synergy 2 (BioTek) 
Real-time PCR Machine – MX3000p (Stratagene) 
Spetrophotometer – ND-1000 (Nanodrop) 
Steam Sterillizer – 3031-S (Amsco) 
Steam Sterillizer – Lab 250 (Amsco) 
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Chemicals, Reagents, and Kits 
Name (Company) 
3'-Mercaptopropionic acid (Sigma-Aldrich) 
Acrylamide (40%) (BioRad) 
Agar (DIFCO) 
Agarose (Fisher Scientific) 
Beta-Mercaptoethanol (Sigma-Aldrich) 
Bromophenol blue (Sigma-Aldrich) 
Calcium Chloride (Sigma-Aldrich) 
DAPI (Sigma-Aldrich) 
DharmaFECT (Dharmacon)  
DMSO (Sigma-Aldrich) 
DTT (Promega) 
EDTA (Sigma-Aldrich) 
Ethanol (Sigma-Aldrich) 
Folic Acid (Sigma-Aldrich) 
Glycerin (Fisher Scientific) 
HEPES (Sigma-Aldrich) 
Hoechst 33258 (Sigma-Aldrich) 
Hydrochloric Acid (Fisher Scientific) 
Lipofectamine 2000 (Invitrogen) 
Lysotracker Green (Invitrogen) 
Magnesium Chloride (Fisher Scientific) 
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Manganous Chloride (Sigma-Aldrich) 
MMLV reverse Transcriptase (Promega) 
Opti-Mem cell Medium (Gibco) 
pAcGFP-Mem-Hyg (Clontech)  
Parafilm (Pechiney) 
Paraformaldehyde (Sigma-Aldrich) 
pCMV-Gluc (New England Biolab) 
Potassium Chloride (Fisher Scientific) 
Potassium Phosphate dibasic (Fisher Scientific) 
Propidium Iodide (Abcam) 
Riboshredder (Epicentre) 
RNasin (Promega) 
SDS (Sigma-Aldrich) 
Sodium Acetate (Sigma-Aldrich) 
Sodium Chloride (Fisher Scientific) 
Sodium Hydroxide (Sigma-Aldrich) 
Sodium Phosphate Dibasic (Fisher Scientific) 
Sodium Phosphate Monobasic (Fisher Scientific) 
T4 RNA Ligase (Promega) 
T7 RNA Polymerase (Epicentre) 
Taq DNA Polymerase (Promega) 
Tetramethylethylenediamine (TEMED) (USB) 
Top10 One Shot Competent E. coli Cell (Invitrogen) 
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Tris (Fisher Scientific) 
Tris/Borate/EDTA (TBE) Buffer (10x) (BioRad) 
Triton X-100 (Sigma-Aldrich) 
Trizol (Invitrogen) 
Trypan Blue (Sigma-Aldrich) 
Tryptone (DIFCO) 
Urea (Fisher Scientific) 
Yeast Extracts (DIFCO) 
Cell Culture Materials 
100 mm Cell Culture Dishes (FALCON) 
35 mm Cell Culture Dishes (FALCON) 
6-Well Cell Culture Plates (FALCON) 
12-Well Cell Culture Plates (FALCON) 
24-Well Cell Culture Plates (FALCON) 
48-Well Cell Culture Plates (FALCON) 
96-Well Black Plates (Costar) 
96-Well Plates (FALCON) 
96-Well White Opaque Plates (Costar) 
Antibody against Human Folate Receptor (Abcam) 
Chambered Slide (Nunc) 
Glass-Bottomed Cell Culture Dishes (MatTek) 
Fetal Calf Serum (Hyclone) 
Folate Deficiency RPMI 1640 Medium (Gibco) 
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G418 (Sigma-Aldrich) 
Heparin (Sigma-Aldrich) 
Hygromycin (CalBiochem) 
M-PER Mammalian Protein Extraction Reagent (Thermo) 
Phosphate Buffered Saline (Hyclone) 
Penicillin (Millipore) 
RPMI 1640 medium (Gibco) 
Streptomycin (Millipore) 
Trypsin (Invitrogen) 
Kits 
AmpliScribe T7 High Yield Transcription Kit (Epicentre)  
Celltier 96 Aqueous One Solution Cell Proliferation Assay (Promega)  
Gaussia Luciferase Assay (New England Biolabs) 
Micro BCA Protein Assay (Thermo) 
T7 Transcription Kit (Epicentre) 
Wizard® Plus Minipreps DNA Purification System (Promega) 
Wizard® SV Gel and PCR Clean-Up System (Promega) 
Dual-Luciferase Reporter Assay System (Promega) 
 
 
 
 
 
46 
 
 
 
Buffers and Commonly Used Reagents 
Table III-1. 5X RT Buffer (1mL pH 8.3) 
Components 5X Concentration 1X Concentration 
250 µL 1 M Tris, pH 8.3 250 mM 50 mM 
250 µL 1 M KCl 250 mM 50 mM 
50 µL 1 M MgCl2 50 mM 10 mM 
20 µL 1 M DTT 2 mM 0.4 mM 
430 µL Water 
  
 
Table III-2. Denaturing Gel Running Dye (10 mL) 
Components  Concentration  
4.2 g Urea  7 M  
1 mL 10X TBE buffer  1X 
Bromophenol blue 0.05% 
Xylene Cyanole 0.05% 
4 mL Water  
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Table III-3. Native Gel Running Dye (10 mL) 
Components Concentration 
5 mL glycerol 50% 
1 mL 10X TBE buffer 1X 
Bromophenol blue 0.05% 
Xylene Cyanole 0.05% 
4 mL Water  
 
Table III-4. Denaturing Gel Mix (1 L) 
Components Concentration 
420 g Urea 7 M 
100 mL 10X TBE buffer 1X 
200 mL 40% Bis-acrylamide (19:1) 8% 
Add water to 1 L 
 
 
Table III-5. Native Gel Mix (1 L) 
Components Concentration 
1 mL 10X TBE buffer 1X 
200 mL 40% Bis-acrylamide (19:1) 8% 
700 mL water 
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Table III-6. SOC Medium (250 mL, pH 7.0)  
Components Concentration 
5 g tryptone 2% 
1.25 g yeast extract 0.5% 
625 µL 4 M NaCl 10 mM 
156 µL 4 M KCl 2.5 mM 
240 mL Water 
 
 
Note. Autoclave at 121°C for 20 min, cool down to ~40 ºC and then add 2.5 mL of filter sterilized 2 M MgCl2 and 5 mL of filter 
sterilized 1 M glucose. Prior to autoclaving, adjust the pH to ~7.0 with sodium hydroxide. 
 
Table III-7. LB Liquid Buffer (1 L, pH 7.5~8)  
Components Concentration 
10 g Tryptone 1% 
5 g Yeast extract 0.5% 
10 g NaCl 1% 
800 mL Water 
 
 
Note. Autoclave at 121 °C for 20 min, cool down and store in 4 °C refrigerator. Prior to autoclaving, adjust the pH of LB with sodium 
hydroxide. For solid LB medium preparation, just add 15 g of agar (1.5%) to the above liquid (1 L) before autoclaving. When the 
temperature of medium is approximate 40 ºC, add proper antibiotics (i.e Ampicillin or Kanamycin), and pour it into plates (25 
mL/plate) in the hood. Allow it cool down to room temperature. Invert and store in 4 °C refrigerator. 
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Table III-8. RNA Precipitation Buffer (10 mL)  
Components Concentration 
50 µL 0.2 M EDTA 1 mM 
1 mL 5 M NaAC 0.5 M 
8.95 mL Water  
 
Table III-9. 10X DNA Anneal Buffer (10 mL, pH 8.0)  
Components 10X Concentration 1X Concentration 
500 µL 0.2 M EDTA 10 mM 1 mM 
1 mL 5 M NaCl 0.5 M 50 mM 
1 mL 1 M Tris, pH 8.0 0.1 M 10 mM 
7.5 mL Water   
 
Table III-10. T7 RNA Transcription (100 µL) 
Components Concentration 
10 µL 10X T7 buffer 1X 
5 µL 0.1 M DTT 5 mM 
4 µL 25 mM NTPs 0.1 mM 
10 µL 4 µM DNA template 0.4 µM 
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Table III-10 (continued). 
Components Concentration 
10 µL 50 u/µL T7 RNA polymerase 5 unit/µL 
61 µL water  
 
Note. Incubate the above reaction mix at 37 ºC for 4 h. To get RNA with 5' adenosine-folate, add 1 µL of 40 mM FA-HDAAMP and 
replace 25 mM NTPs with 1:4 NTPs (25 mM GTP, 25 mM CTP, 25 mM UTP, and 6.25 mM ATP). 
 
Table III-11. High Yield T7 RNA Transcription (100 µL) 
Components Concentration 
10 µL 10X T7 buffer 1X 
10 µL 0.1 M DTT 10 mM 
30 µL 25 mM NTPs 0.75 mM 
5 µL 4 µM DNA template 0.2 µM 
10 µL AmpliScribe Enzyme Solution 10% v/v 
35 µL water 
 
 
Note. Incubate the above reaction mix at 37 ºC for 2 h. 
 
Table III-12. Reverse Transcription (20 µL) 
Components Concentration 
4 µL 5X RT Buffer 1 X 
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Table III-12 (continued). 
Components Concentration 
0.8 µL 25 mM dNTPs 1 mM 
0.4 µL 50 µM Primers 1 µM 
1 µL 1 µM Total RNA 50 nM 
1 µL of 10u/µL MMLV reverse transcriptase 0.5 u/ µL 
12.8 µL water 
 
 
Note. Incubate at 85 ºC for 2 min. Cool down. Add 4 µL 5X RT buffer and 1 µL of 10u/µL MMLV reverse transcriptase. Incubate at 
42 ºC for 1 h. 
 
Table III-13. Real-Time PCR (20µL) 
Components  Concentration 
10 µL 2X SYBR Solution 1 X 
2 µL 2 µM Primers 0.2 µM 
0.2 µL cDNA  N/A 
7.8 µL Water 
 
 
Note. Amplification was started at 95°C for 10 min to activate the DNA Polymerase, followed by 40 cycles of PCRs: at 95°C for 10 s, 
at 60°C for 20 s, and at 72°C for 30 s, and one more cycle of PCR: at 95°C for 60 s, at 55°C for 30 s, and at 95°C for 30 s. 
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Experimental Protocols 
Cell Culture   
All cell lines were maintained in folate free RPMI 1640 (Gibco) cell medium 
supplemented with 10% fetal calf serum (FCS) (HyClone), 100 units/mL penicillin, and 
100 µg/mL streptomycin (Millipore) at 37 °C in 95% air humidified atmosphere and 5% 
CO2. 
Preparation of Polymer/siRNA Complexes 
FAPol13(Pol13)/siRNA. Neutral polyplexes (N/P = 1) were prepared as followed. 
Briefly, 3 µL of 10 µM Cy3-labled anti-human survivin siRNA or anti-luciferase siRNA 
(59 nt) was mixed with 1.5 µL of 50 µM FAPol13 or 1 µL of 50 µM Pol13 at an N/P ratio 
equal to 1.0.  Polyplexes were immediately vortexed to ensure homogenous mixing and 
equilibrated at room temperature for 10 min before addition to the cell medium (300 µL). 
AuNP/siRNA. Complexes (Au nanoplexes) were prepared by adding 1.36 µL of a 
25 µM survivin siRNA stock to the 6.64 µL solution of AuNPs. Complexation solutions 
were immediately vortexed following RNA addition and allowed to incubate at room 
temperature for 30 min before cell testing or electrophoresis analysis. 
Transfection 
The siRNAs were transfected into mammalian cells by commercial agents (i.e., 
DharmaFECT; Lipofectamine 2000) according to manufacturer’s recommendations as a 
positive control. Typically, cells were plated into the dish or plate 24 h prior to treatment 
with approximate 40% confluency. Two microliter of Lipofectamine and 6 µL of 10 µM 
siRNA were mixed with 50 µL of Opti-Mem medium at room temperature for 5 min; 
then two solutions were mixture together and sit for 20-30 min before adding into 500 µL 
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of medium (total 600 µL, therefore, [siRNA] = 100 nM, Lipofectamine = 0.33% (v/v)).   
The medium was replaced with fresh one and cells were kept culture for predetermined 
time.  
Confocal Microscopy  
For imaging, cells were plated in chambered coverglass wells, transfected with 
fluorophore-labeled siRNAs, rinsed, and visualized by a Zeiss LSM 510 confocal laser 
scanning microscope (Carl Zeiss Inc., Thornwood, NY) with 40×/1.3 or 63×/1.4NA oil 
lens. A 405-nm diode laser was used to excite Hoechst and fluorescence emission was 
detected with a band pass filter of 420-480 nm. For Cy3, an excitation wavelength of 543 
nm (He-Ne laser) was used and fluorescence emission was obtained using a long pass 
filter of 560 nm. For FAM, an excitation wavelength of 488 nm (Ar laser) was used, and 
fluorescence was obtained utilizing a long pass filter of 505 nm. Images were processed 
via LSM image Examiner software (Carl Zeiss Inc., Thornwood, NY). Further analysis of 
associated fluorescence was carried out using ImageJ software 191 as following: total 
associated fluorescence was determined from 30-50 cells (for 63× lens), 75-100 cells (for 
40× lens) in at least 5 distinct fields per treatment and corrected by subtracting local 
background fluorescence from nearby cell-free area. 
Time-Lapse and Z-Stack Imaging  
KB cells were seeded on chambered coverglass to ~45% confluency for 24 h. 
Polyplexes were then directly added to the cell medium to give a final siRNA 
concentration of 20 nM. The dish was immediately put into a heated block holder set at 
37 °C. The focal plane was fixed on a cleared bright field plane and confocal images 
were taken every 10 min for a total of 80 min. Prior to z-stack scanning the cells were 
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allowed to incubate for 40 min, after which the cells were washed 3 times with pre-
warmed phosphate buffer saline (PBS) and the cell medium was replaced. Hoechst 33258 
was added to stain the nuclei (1 µg/mL) 20 min before observation. Z-stack scanning was 
then performed by adjusting the focal plane from the bottom to the top of the cells in 2 
µm or 1 µm increments. 
Colocalization  
KB cells were first cultured for 24 h on chambered coverglass before the addition 
of polyplexes. Polyplexes were added to the cell medium to give a final Cy3-labled 
siRNA concentration of 100 nM and allowed to incubate for 1 h. After 1 h treatment the 
cell medium was replaced, thereby removing any unbound or free polyplexes from 
solution.  Confocal images were taken at different incubation times, 1 h, 6 h, 24 h, and 48 
h. In order to visualize the endosomal compartments, lysotracker was added 30 min prior 
to each imaging event.  The chambered coverglass was placed onto a heated sample 
holder at 37 °C and imaging process was about 40 min each time. After each imaging 
event the cell medium was replaced and the cells were returned to the cell culture 
incubator for another time period observation. 
Synthesis of siRNA against Gaussia Luciferase  
siRNA against Gluc was synthesized through in vitro transcription according to our 
published procedure. 188e-h DNA template oligonucleotides containing the T7 φ 2.5 promoter 
sequence were purchased from Integrated DNA Technologies. In vitro transcription was 
conducted with AmpliScribe T7 high yield transcription kits using the following DNA 
templates (Sequences refer to 2.5). RNA transcripts were gel-purified, quantified by UV/Vis 
spectrometry, annealed and then stored at -80 °C.  
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Total RNA Extraction 
Adhesive cells were washed with PBS once before being lysed in Trizol by 
repetitive pipetting. Use 0.5 mL of reagent per 3.5cm dish (~ 106 cells). Incubate the 
homogenized samples for 5 min at 15-30° C to permit complete lysis. Add 0.1 mL of 
chloroform per 0.5 mL of Trizol reagent. Transfer the samples into tubes, cap them 
securely. Shake tubes vigorously by hand for 15 seconds and incubate them for 5 min. 
Centrifuge the samples at 12,000 × g for 15 min. Following centrifugation, the mixture 
separates into a lower red, phenol-chloroform phase, an interphase, and a colorless upper 
aqueous phase. RNA remains exclusively in the aqueous phase. The volume of the 
aqueous phase is about 60% of the volume of Trizol. Transfer the supernatant (the upper 
phase) carefully to a new tube (the organic phase would be saved for DNA/protein 
isolation according to the manual). Precipitate the RNA from the aqueous phase by 
mixing with isopropyl alcohol. Use 0.25 mL of isopropyl alcohol per 0.5 mL of Trizol. 
Incubate samples at 15 to 30°C for 10 minutes and centrifuge at 12,000 × g for 10 min. 
Remove the supernatant. Wash the RNA pellet once with 1mL of 75% ethanol. Vortex 
and centrifuge at 7,500 × g for 5 min. Dry the RNA pellet briefly (do not too dry) and 
dissolved it in DNase/RNase-free H2O and quantitate by Ab260. The quality of the 
extracted RNA would be evaluated by A260/280 ratio. 
Real-Time PCR 
Total RNA was extracted from 4 types of cells with Trizol following the 
manufacture’s protocol and mRNAs were converted to cDNA through reverse 
transcription with MMLV reverse transcriptase (Promega). Finally, real-time PCR was 
performed with on MX3000P (Stratagene). A typical reaction mixture (20 µL) includes: 
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10 µL of 2X SYBR Green Mix (Sigma-Aldrich), 2 µL of 2 µM primer pair (final 
concentration = 200 nM), 0.2 µL of cDNA, and 7.6 µL of DNase/RNase-free H2O. 
Amplification was started at 95°C for 10 min to activate the DNA Taq, followed by 40 
cycles of PCRs: at 95°C for 10 s, at 60°C for 20 s, and at 72°C for 30 s, and one more 
cycle of PCR: at 95°C for 60 s, at 55°C for 30 s, and at 95°C for 30 s.  
DNA/RNA Purification 
Precipitation. If the DNA/RNA is relative pure, we can precipitate them by adding 
3 parts of 0.5 M of NaAc (pH 5.2) and 7 parts of ethanol. After mixing and incubation for 
at least 30 min at -20 ºC, the sample is centrifuged for 6 min at 14,000 RPM. Remove 
ethanol and dissolve the sample in DNase/RNase-free H2O. 
Column filtration. Load sample volume up to 0.5 mL on to microcon M10 or M30 
and centrifuge at 14,000 RPM till the filter is almost dry. Wash the filter with two times 
of 200 µL water. Invert filter into a clean 1.5 mL Eppendorf tube and spin briefly (~10 
seconds) to collect the sample. 
PAGE purification. DNA or RNA sample is first separated by 8% denaturing 
PAGE. The objective sample band is visualized, cut from the gel and then transferred to a 
fresh 1.5 mL Eppendorf tube. The gel is then crushed and DNA or RNA is extracted from 
the gel by adding 400 µL of 0.5 M NaAc in 1 mM EDTA and heating at 70ºC for 7-10 
min to melt the gel. Centrifuge and transfer the liquid to a clean tube. Add 900 µL of 
ethanol to the tube and incubate the solution at -20 ºC for at least 30 min. Remove 
ethanol and dissolve the sample in DNase/RNase-free H2O. 
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Flow Cytometry 
The expression levels of human folate receptor in cells, the absorption of 
polyplexes in cells, and the inhibition of polyplexes binding to cells were assessed by 
flow cytometer. For human folate receptor quantification, cells plated in 12-well plate 
were harvested, washed, and resuspended to approximately 1~5 × 106 cells/mL in ice-
cold PBS. Add 100 µL of cell suspension to the tubes and mix with 1 µg/mL folate 
binding protein antibody (AbCam). The tubes were put on the ice in dark for 30 min, and 
the cells were spin down at 2000 g for 5 min and washed with ice cold PBS twice. The 
cells were then suspended in PBS with 1 µg/mL (400× dilution) goat anti-mouse FITC-
IgG antibody (Santa Cruz Biotechnology Inc) for 30 min at room temperature in dark. 
The cells were collected by centrifugation at 1,200 × g for 5min, washed with ice-cold 
PBS three times before flow cytometer detection. The cells were gently vortexed and 
introduced into a C6 flow cytometer (Accuri, Ann Arbor, MI) equipped with a 488-nm 
solid state laser. Data for 10,000 fluorescent events were obtained before or after gating 
by recording forward scatter (FSC), side scatter (SSC) through channel 1 (530/15 nm) for 
FAM and FITC, or channel 2 (585/20 nm) for Cy3 using CFlow Plus software (Accuri). 
For absorption and inhibition experiments, cells were prepared by plating cells in 
12-well plates 24 h prior with ~40% starting confluency. Cells were transfected with 
neutralized (N/P = 1) polyplexes of FAM-labeled siRNA or Cy3-labeled siRNA (final 
siRNA concentration = 100 nM). Two hours of incubation or twenty four hours of 
incubation were performed for binding and inhibition experiments.  After that, the cells 
were detached, centrifuged, washed with PBS twice, and ready flow cytometer detection.  
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Preparation of Plasmid DNA  
E. coli (TOP10, Invitrogen) were transformed with plasmid DNA (i.e., pCMV-
Gluc) and selected in an ampicillin rich LB solid medium (or SOC medium) at 37ºC 
overnight. A single clone of transfected E. coli was proliferated in LB liquid media in 
37ºC overnight with vigorous agitation. The cells were harvested and plasmid isolation 
and purification were performed consequently with Wizard® Plus Minipreps DNA 
Purification System kit (Promega) according to the manufacturer’s protocol as followed. 
Transfer the E. coli cells cultured in LB or SOC medium into 1.5 mL Eppendorf 
tubes, and centrifuge them at 10,000 × g for 1 min. Remove the medium completely, and 
add 200 µL of cell resuspension solution for 1 min. Add 200 µL of lysis solution and 
invert the tube 4 times. Then 200 µL of cell neutralization solution was added and mixed 
gently to avoid break the DNA. You may see the precipitation appearing. Centrifuge the 
lysate at 10,000 × g for 7 min. During this time, connect the minicolumn with the barrel 
of a syringe, add in 1 mL Resin solution (Note: make sure there is no crystal inside, 
otherwise heat the solution by 37ºC water bath and cool down to 30ºC before using). 
Transfer the supernatant clear solution into the barrel, and use the plunger to push the 
resin and lysate mixture go through the minicolumn. Wash the plasmid with 2 mL of 
column wash solution (add 320 mL of 95% ethanol before first usage). Dry the column 
by centrifuge at 10,000 × g for 1 min. Dissolve the plasmid DNA by adding 40 µL of 
DNase/RNase free H2O followed by spinning down at 10,000 × g for 20 seconds.  
The purity of plasmid DNA was determined by both A/A280 and A260 ratio and 
agarose gel electrophoresis. The concentration of plasmid DNA was determined by 
spectrometer and the purified plasmid was stored at -20ºC until use. 
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Preparation of Stable Cell Line (Take SKOV3-KB as an Example) 
SKOV3 cell line that stably expresses Gaussia luciferase (Gluc-SKOV3) was 
established. Firstly SKOV3 cells were transfected with pCMV-Gluc by DharmaFECT 
followed by manufacturer’s manual. One day later, the medium was replaced with the 
one containing 0.5 mg/mL antibiotics G418. Cells were first cultured in a 10 cm dish for 
2 weeks. At this time point, the majority (>90%) SKOV3 cells were killed off by G418 
because of lacking the expression of neo. However, a few percent of SKOV3 cells that 
had integrated the pCMV-Gluc plasmid detoxified G418 and survived.  Because the 
resistance to the G418 only indicated the insert of neo gene into the genome of SKOV3, 
but necessarily meant the integrated of Gluc gene, the selection of Gluc activity was 
carried out by seeding the surviving cells at very low density (~1 cell/0.1 mL) and plating 
onto 96-microplates (0.1 mL/well). The selection pressure from the Gl418 remained for 
another 7 days. Positive colonies expressing Gaussia luciferase were screened by 
luciferase assay, propagated, and stored for further experiment. 
Cell Treatment with FAPol13/siRNA Polyplexes for Gene Downregulation Studies  
Gluc-KB cells were seeded in 96-well plates in folate free RPMI 1640 
supplemented with 10% FCS 24 h prior to experiments. Cell treatments included free 
siRNA and FAPol13/siRNA, Pol13/siRNA, and DharmaFECT/siRNA complexes. The 
concentration of siRNA against Gaussia luciferase is 100 nM. Cells were treated for 6 h, 
washed by PBS, and cultured for 2 days. For DharmaFECT group, transfection was 
carried out according to manufacturer’s protocol. Briefly, 10 µL of Optimum buffer 
mixed with 0.25 µL of DharmaFECT solution and 1 µL of a 10 µM siRNA were mixed 
with 10 µL of Opti-Mem buffer separately. After 5 min. the two solutions were mixed 
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and equilibrated for 20 min. The resulting solution was then added to 80 µL of cell 
medium (total 100 µL) and the cells were treated for 6 h before changing medium. 
Gaussia Luciferase Activity Assay  
Gaussia luciferase protein level was measured according to the manufacture’s 
protocol with minor modification. Aliquots (15 µL) of the cell culturing supernatants 
were transported into a white opaque 96-well plate and mixed with 40 µL of Gaussia 
luciferase assay solution. The resulting bioluminescence was immediately measure by a 
Synergy 2 microplate reader (BioTek) and analyzed by Gen5 software (BioTek). 
Cell Viability  
Cell viability tests were performed using CellTiter 96 Aqueous One Solution cell 
proliferation assay (Promega). Five thousands of KB cells were seeded into the 96-well 
microplate 24 h before incubation with FAPol13.  FAPol13 was subsequently mixed with 
the cellular medium at final concentrations ranging from 10 nM to 6 µM. Cells were 
cultured for 2 days before adding 20 µL of CellTiter reagent to each well.  After reagent 
addition the cells were further incubated for 2 hours followed by measuring the 
absorbance at 490 nm by a microplate reader (Synergy2, BioTek) and Gen5 (BioTek).  
Agarose Gel Electrophoresis  
Neutral complexes were prepared at room temperature. Agarose gel (1%) was 
prepared by: 0.4 g of Agarose mix with 40 mL of 1× TBE buffer, heat them, and pour 
them into the casting tray. The gel was pre-run for 30 min. The complexes were mixed 
with gel loading buffer (0.2% bromophenol blue, 1× TBE buffer and glycerol) and loaded 
into the wells. Gel was run for 30 min at 90 V. After staining by ethidium bromide, the 
agarose gel was imaged by a Universal Hood II CCD camera (BioRad). 
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Imaging Processing  
All confocal images were processed via LSM image Examiner software. Further 
analysis of Cy3 and lysotracker fluorophores to examine the fluorescence intense or the 
distribution was carried out using ImageJ software (http://rsbweb.nih.gov/ij/) and JACoP. 
Statistical Analysis 
Analysis of the statistical significance of FR expression was performed by 
Graphpad Prism software using t test. Individual flow cytometric, confocal microscopic, 
and folate-binding assays were repeated at least 3 times to ensure accuracy of results, and 
representative data are shown. 
 
Primers and siRNAs 
Table III-14. Primers for Real-Time PCR  
Gene Name GenBank ID Sequences (5'-3') 
Human Folate Receptor Alpha (hFRα) NM_016725 GGAGGCTCAGACAAGGATT 
TGGTAGAACAGCAGGCATT 
Human Actin Beta (ACTB, ACTβ) NM_001101 CATGTACGTTGCTATCCAGGC 
CTCCTTAATGTCACGCACGAT 
Human Survivin (Sur, Sv) NM_00101227 AGCCCTTTCTCAAGGACCAC 
TCCTCTATGGGGTCGTCATC 
Human Vascular Endothelial Growth Factor A  NM_001025366 TTGCTGCTCTACCTCCAC 
(VEGF-A)  GATGTCCACCAGGGTCTC 
Human VEGF Receptor 1 (VEGFR-1) NP_002010 CTTCGAAGCATCAGCATAAGAAACT 
 TGGTCATCAGCCCACTGGAT 
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Table III-14 (continued). 
Gene Name GenBank ID Sequences (5'-3') 
Human Integrin Alpha V (ITGAV) NM_002210 GTGGACAGTCCTGCCGAGTA 
 GGCTGGGTGGTGTTTGCG 
Human Integrin Beta 3 (ITGB3) NM_000203.2 CTGGAACAACGGTGGAGA 
  TGGCAGGTAGCAGTAAAGAA 
Human ATP-Binding Cassette Subfamily B  NM_000927.3 GTCTACAGTTCGTAATGCTGACGT 
(ABCB1,MDR1)  TGTGATCCACGGACACTCCTAC 
Human Ribonucleotide Reductase M2 (RRM2) NM_001034.3 GCCGCTGCTGAGAGAAAACC 
 TTACTATGCCATCGCTTGCTGC 
Human Caspase 8 Associated Protein 2  NM_012115.3 CTCCTGCTAAAAAGCAACC 
(CASP8AP2)  TCACTGCTAGCCGAGCAACC 
pCMV-Gluc Vector (Gaussia Luciferase, Gluc) AY015993 ACGGATCTCGATGCTGAC 
TCCTATTCCTCCCTGTGC 
pGL3 Vector (Firefly Luciferase, Fluc) U47296 AACACCCCAACATCTTCG 
CGTCCACAAACACAACTCC 
pRL-tk Vector (Renilla Luciferase, Rluc) AF362545 CGAACTGAGATGCCTACAGC 
CGACAGGACTATAAAGATACC 
 
Table III-15.DNA Templates for siRNA Transcription 
Gene Name Stands Sequences (5'-3') 
VEGF-A Sense CGTAATACGACTCACTATTAGGGCAGAATCATCACGGGACGCATCT 
AGATGCGTCCCGTGATGATTCTGCCCTAATAGTGAGTCGTATTACG 
Antisense CGTAATACGACTCACTATTAGGAGATCCGGTTCGTGATGATTCTGCCCTTT 
AAAGGGCAGAATCATCACGAACCGGATCTCCTAATAGTGAGTCGTATTACG 
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Table III-15 (continued). 
Gene Name Stands Sequences (5'-3') 
Gluc Sense CGTAATACGACTCACTATTAGATGTGCAACTTTTGCTACCGCATCT 
AGATGCGGTAGCAAAAGTTGCACATCTAATAGTGAGTCGTATTACG 
Antisense CGTAATACGACTCACTATTAGGAGATGCGGTAGCAAAAGTTGCACATCTTT 
AAAGATGTGCAACTTTTGCTACCGCATCTCCTAATAGTGAGTCGTATTACG 
GFP1 Sense CGTAATACGACTCACTATTAGCGCACCATCTTCTTCGACCGCATCT 
AGATGCGGTCGAAGAAGATGGTGCGCTAATAGTGAGTCGTATTACG 
Antisense CGTAATACGACTCACTATTAGGAGATGCGGTCGAAGAAGATGGTGCGCTTT 
AAAGCGCACCATCTTCTTCGACCGCATCTCCTAATAGTGAGTCGTATTACG 
GFP2 Sense CGTAATACGACTCACTATTAGGGCGATACCCTGGTGAATCGCATCT 
AGATGCGATTCACCAGGGTATCGCCCTAATAGTGAGTCGTATTACG 
Antisense CGTAATACGACTCACTATTAGGAGATGCGATTCACCAGGGTATCGCCCTTT 
AAAGGGCGATACCCTGGTGAATCGCATCTCCTAATAGTGAGTCGTATTACG 
EGFP Sense CGTAATACGACTCACTATTAGCGCACCATGTTCTTCAATTGCATCT 
AGATGCAATTGAAGAACATGGTGCGCTAATAGTGAGTCGTATTACG 
Antisense CGTAATACGACTCACTATTAGGAGATGCAATTGAAGAAGATGGTGCGCTTT 
AAAGCGCACCATCTTCTTCAATTGCATCTCCTAATAGTGAGTCGTATTACG 
RRM2 Sense CGTAATACGACTCACTATTAGGAGAGAGTAAGAGAAATCCGCATCT 
AGATGCGGATTTCTCTTACTCTCTCCTAATAGTGAGTCGTATTACG 
Antisense CGTAATACGACTCACTATTAGGAGATGCGGATTTCTCTTACTCTCTCCTTT 
AAAGGAGAGAGTAAGAGAAATCCGCATCTCCTAATAGTGAGTCGTATTACG 
CASP8AP2 Sense CGTAATACGACTCACTATTAGGAGTACTTCACATTTACCCGCATCT 
AGATGCGGGTAAATGTGAAGTACTCCTAATAGTGAGTCGTATTACG 
Antisense CGTAATACGACTCACTATTAGGAGATGCGGGTAAATGTGAAGTACTCCTTT 
AAAGGAGTACTTCACATTTACCCGCATCTCCTAATAGTGAGTCGTATTACG 
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Table III-16. siRNA Sequences 
siRNAs GenBank ID Sequences (5'-3') 
Gaussia Luciferase AY015993 AGAUGUGCAACUUUUGCUACCGCAUCU 
AGGAGAUGCGGUAGCAAAAGUUGCACAUCUUU 
Renilla Luciferase AF362545 GGUGCCAAGAAGUUUCCUATT 
UAGGAAACUUCUUGGCACCTT 
Firefly Luciferase U47296 GGUGUCGCUCUGCCUCAUATT 
UAUGAGGCAGAGCGACACCTT 
RRM2 NM_001034.3 AGGAGAGAGUAAGAGAAAUCCGCAUCU 
AGGAGAUGCGGAUUUCUCUUACUCUCUCCUUU 
CASP8AP2 NM_012115.3 AGGAGTACUUCACAUUUACCCGCAUCU 
AGGAGAUGCGGGUAAAUGUGAAGUACUCCUUU 
Human Survivin NM_00101227 AGCCCUUUCUCAAGGACCACCGCAUCU 
AGGAGAUGCGGUGGUCCUUGAGAAAGGGCUUU 
VEGF-A NM_001025366 AGGGCAGAAUCAUCACGGGACGCAUCU 
AGGAGAUCCGGUUCGUGAUGAUUCUGCCCUUU 
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Cell Lines 
Table III-17. Cell Lines 
Designation Description ATCC No. or source: Purpose 
KB Human nasopharyngeal carcinoma CCL-17 FR positive cells 
KB-GFP Derivative of KB Generate from KB testing platform 
KB-Gluc Derivative of KB Generate from KB testing platform 
HeLa Human cervical carcinoma CCL-2 FR positive cells 
HeLa-EGFP Derivative of HeLa Gift from Dr. Phil Sharp testing platform 
A549 Human lung carcinoma CCL-185 FR negative cells 
SKOV3 Human ovary carcinoma HTB-77 FR positive cells 
SKOV3-Gluc Derivative of SKOV3 Generate from SKOV3 testing platform 
A2780 Human ovary carcinoma From Dr. Thomas Hamilton MDR testing 
OVCAR-3 Human ovary carcinoma HTB-161 MDR testing 
OVCAR-7 Human ovary carcinoma From Dr. Thomas Hamilton Integrin testing 
OVCAR-10 Human ovary carcinoma Gift from Dr. Thomas Hamilton Integrin testing 
 
 
  
66 
 
 
 
CHAPTER IV 
DELIVERY OF FA-SIRNA TO CANCER CELLS  
AND DOWNREGULATION OF GENE EXPRESSION  
Introduction 
Conventional anticancer drugs, such as cisplatin, paclitaxel, doxorubicin, and 
methotrexate, have been the major chemical agents for cancer treatment. Although they 
all display significant anticancer activities, patients normally suffer side effects due to 
drugs’ cytotoxicity and non-specificity (no gene-targeting specificity and cell-targeting 
specificity).151, 192 In other words, these small molecular drugs treat normal cells and 
malignant cells indiscriminately, which limits the effectiveness of these treatments. The 
recently discovered siRNA can trigger RNAi pathway and induce mRNA degradation 
with high sequence specificity, low cytotoxicity, and potent gene downregulation 
efficiency. By virtue of these properties, siRNA has been utilized as a molecular drug for 
diseases treatment.193  
Although siRNAs hold incomparable advantages and show great promise, the 
inefficient cellular uptake and poor bioavailability of siRNA remain the major obstacles 
that compromise siRNA’s therapeutic application. Moreover, without efficient cell-
specific delivery, biomedical application of siRNA is limited. Employing targeting 
moieties thus provides an opportunity for directed siRNA delivery with enhanced 
efficiency in vitro and in vivo. Valid targeting groups include aptamers,121 antibodies,98c 
peptides,99d, 194 cholesterol, 195 α-tocopherol, 196 and folate. 101b, 128, 197 Among them, FA 
shows unsurpassable advantages as mentioned in Chapter I.  
67 
 
 
 
The use of folate as a therapeutic director has been popularized due to 
overexpression of the folate receptor in several types of tumors (i.e., ovary, brain, lung, 
breast, kidney).198 FA has been successfully employed to deliver siRNAs, ribozymes, 
anti-cancer drugs, imaging agents and antisense oligonucleotides.197, 199 Several lines of 
evidence demonstrate FA-directed siRNAs delivery into cancer cells or tumors. For 
example, a polyvalent, FA-linked, chimeric pRNA (a 117-nt bacteriophage phi29-
encoded RNA, playing a novel and essential role in DNA packaging) had been 
constructed with siRNAs against human apoptosis inhibitor gene — survivin.128 The 
effectiveness and specificity of this chimeric siRNA vehicle has been confirmed by both 
in vitro and ex vivo experiment.128 Zhang et al and his colleagues reported a similar 
strategy involved in the noncovalent attachment of siRNAs to FA-conjugated 
oligodeoxynucleotides via nucleic acid base-paired interactions, and resulted in cell-type-
specific delivery of functional siRNAs into cells with moderate gene knockdown.197   
In addition to the efforts for improving the targeted siRNA delivery, an accurate, 
fast, and convenient method for assessing the RNAi effects is prerequisite. Conventional 
techniques, such as real-time PCR (or quantitative PCR), and Western blot can hardly 
meet these expectations. Thus, a reporter protein-assisted evaluative system based on 
fluorescence (e.g., green luciferase protein, GFP) and bioluminescence system (e.g., 
luciferase) is constructed and described in this chapter.  
GFP and its analogs, such as red fluorescence protein (RFP), yellow fluorescence 
protein (YFP), have revolutionized our understanding of many biological processes at the 
molecular and cellular levels. 200 With suitable GFP fluorescence probes and 
instrumentation (e.g., confocal laser scanning microscope) for functional imaging, we can 
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identify and measure biological events in whole organism in real time. Another rapid and 
accessible reporter system is bioluminescence where luciferases convert chemical energy 
into light.201 Combining with charge coupled device cameras that detect light transmitted 
through tissues/cells has opened the door to sensitive measurements of gene expression 
changes upon RNAi.  
Although fluorescence system has several advantages, such as direct detection of 
fluorescence, easier visualization, it also has some setbacks compared to luciferase 
system for quantitation of RNAi effects, e.g., non-quantitative, no read-out.202 On the 
other hand, despite indirect read-out, enzymatic assay-based detection, and repeated 
measurement, luminescence system is comparably convenient in quantifying the signal 
changes. For these reasons, two systems have been utilized in my research with 
preference to the luminescence system.  
About four decades ago, a series of luciferase that catalyzed luciferin reaction and 
emitted light in the visible range under physiological conditions was discovered and 
characterized.203 Various luciferases share sequence homology in different organisms, 
such as bacteria, fungi, dinoflagellates, radiolarians.204 Firefly (Photinus pyralis) 
luciferase (FLuc), sea pansy (Renilla reniformis) luciferase (RLuc), and Gaussia (Gaussia 
princeps) luciferase (Gluc) are most commonly used luciferases for monitoring gene 
expression.204b, 205 Among them, Gluc catalyzes the oxidation of substrate coelenterazine 
to produce light (470 nm),206 and has been engineered to highly express in mammalian 
cells.206b In addition, compared to FLuc and RLuc, Gluc is a more attractive reporter for 
studying gene expression because of some unparalleled features. Firstly, Gluc generates 
over 1000-fold higher bioluminescent signal intensity than RLuc does. Secondly, Gluc 
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possesses a secretory signal process, and therefore the expression of Gluc can be detected 
from cell medium, omitting the usual cell lysis step. Thirdly, secreted Gluc is very stable 
and can be stored for several days at 4 °C without the loss of activity, which enables the 
convenient multiple samples measurement at different time points.  
Capitalizing on RNA conjugation chemistry through one-step transcription, and 
FR-mediated siRNA targeted delivery to cancer cells, I propose to prepare and study the 
cellular delivery of FA-linked siRNA and assess RNAi effects through reporter system. 
Specifically, I intend to achieve the following goals (Scheme IV-1): (i) rational design of 
siRNA with potent potential to induce gene silencing through the proper online tools; (ii) 
synthesis of the FA-conjugated siRNAs taking advantage of in vitro transcription and 
FA-HADAMP 207 as the transcription initiator; (iii) the specific uptake of FA-siRNA by 
FR-bearing human cancer cells; (iv) FR-dependent internalization; (v) gene 
downregulation as the result of the internalized FA-siRNA via RNAi process; (vi) the 
convenient and fast assessment of RNAi efficiency by introduction of a reporter system. 
To test these hypotheses, the experiments were rationally designed and performed.  
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Scheme VI-1. Schematic illustration of the internalization of transcripted FA-siRNA 
conjugate into Gluc-KB cells through FR-dependent endocytosis.  
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Folate-HDAAMP is chemically synthesized and serves as the transcriptional initiator 
under the T7 Φ2.5 promoter.  Two single-stranded RNA are synthesized separately. FA-
HDAAMP could be added in either sense strand or antisense strand; most of time it will 
be add into the synthesis of antisense strand.  Two strands RNA will be annealed to form 
double-stranded, FA-linked siRNA.  The siRNAs specific for Gaussia luciferase, and 
GFP and a non-silencing control siRNAs used in the studies are generated by this method. 
Following internalization into the FR-bearing cells (KB cells in this case) via FR-
mediated endocytosis, the FA-siRNA is released from the endosome, processed by Dicer, 
incorporated into RISC, and eventually induces the silencing of targeted genes. 
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Result and Discussion 
Design and Synthesis of FA Conjugated siRNA 
This first step for specific siRNA delivery is to design siRNA sequences. We can 
then synthesize them by one-step in vitro transcription. Based on the experience of 
rational siRNA design accumulated in our laboratory, we chose siRNA selection 
programs 208 to design siRNA against the genes responsible for pathological disorders. 
This online tool has an option of a searching pattern which can be customized according 
to users’ purposes with different sequence length and different nucleotide at particular 
position. As a result, we set down the pattern N2AGN7UN8AN2 in consideration of 
transcription promoter requirements 188h and base preferences.70 In this 23-nt search 
sequence, N, A, G, and U strand for any nucleotide, adenosine, guanosine, and uridine 
respectively, and the number after the N means the length of the nucleotides. AG at 3 to 4 
position is for our transcription system,188h and U at 12 and A at 21 is used to meet the 
sequence preferences rules.70  
After confirmation of the search pattern, we either paste mRNA sequence or input 
the accession number (e.g., NM_001025366 for human VEGF-A) into a frame and start 
search candidate siRNAs with some established filters. Subsequently, a list of siRNA 
candidates with position in the mRNA sequence, thermodynamics, GC% content and 
other information will pop out for our reference. To minimize the off-target effects of the 
siRNA, BLAST (basic local alignment search tool) of selected siRNA sequences against 
Genbank is highly recommended afterwards to ensure that only the interested gene is 
targeted. Through this procedure, siRNAs against several genes have been designed, and 
  
importantly the significant gen
the siRNA selecting method. 
 
Figure VI-1. The formation of folate
The schematic illustration of FA conjugated dsRNA. Two dsDNA templates bearing T7 
Φ 2.5 promoters and well
ssRNAs were synthesized, and the conjugation of FA or other functional groups to RNA 
was controlled simply by adding FA
complementary sequences and formed FA
antisense RNA (lane 1 and 2), FA
Likewise, the FA-sense RNA and FA
 
 
e downregulation efficiency demonstrates the feasibility of 
 
 conjugated siRNAs by in vitro transcription
-designed siRNA sequence were chemically synthesized. Two 
-HDAAMP. The ssRNAs were annealed by 
-siRNAs. (B) PAGE analysis of sense, 
-antisense RNA (lane 3), and FA-siRNA (lane 4). 
-sense labeled siRNA could also be generated.
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After selection of siRNA sequences, their synthesis via our in vitro transcription 
is followed (Figure IV-1). Firstly, four DNA strands bearing siRNA sequence and T7 Φ 
2.5 promoter were synthesized commercially. Next complimentary DNA strands were 
annealed to form two pairs of double-stranded DNA, which were used as templates to 
transcript two single-stranded RNAs. The synthesis of FA conjugated and non-
conjugated RNA was adjusted by addition of transcriptional initiator: FA-HDAAMP 
(Scheme IV-1) which was chemically synthesized and purified by HPLC.128 After gel 
purification and UV/Vis quantification, equimolar single stranded RNAs were hybridized 
to form a FA-conjugated or unconjugated RNA as illustrated in Figure IV-1A. The 
formation of RNA duplex and FA conjugation were confirmed by PAGE analysis (Figure 
IV-1B). 
In Figure IV-1B, we can see 27-nt sense strand RNA in lane 1, 32-nt antisense 
strand RNA in lane 2. The antisense RNA with FA (MW = ~441) conjugation (in lane 3) 
is bigger in size compared to the RNA without conjugation (lane 2), and displays about 
one nucleotide shift. Besides, a small portion of unconjugated antisense strand is seen in 
lane 3 as expected. The FA-linked RNA duplex is in lane 4. The clear bands suggest the 
successful purification and hybridization of two strands.  
Comparison of FR Expression in KB and A549 Cells 
Once FA-siRNA is synthesized, its internalization into FR-expression cells is 
examined. Two human cancer cells lines, KB cells (human nasopharyngeal carcinoma) 
and A549 cells (human lung carcinoma), are used because KB cells highly express FR; 
whereas A549 has non-detectable expression. 146, 209 To test that, real-time PCR and flow 
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cytometry were utilized to analyze human FR-α (hFRα) expression in both mRNA and 
protein levels in those two cell lines (Figure IV-2).  
To compare hFRα expression in gene level, total RNA was extracted from two 
types of cells; reverse transcription was conducted; and real-time PCR was carried out. 
The representative amplification curves of hFRα in two cell lines were shown in Figure 
IV-2A. Because the amplification curves of human β-Actin gene (internal control) in KB 
and A549 are nearly overlapped; and therefore they are not displayed in Figure IV-2A. 
Statistical analysis from three repeats was presented in Figure IV-2B. The data exhibit 
~15 Ct value differences in two cell lines, indicating ~ 30,000 times variation in mRNA 
level. To confirm this result, flow cytometry was applied to quantitate the hFRα protein 
level in these two cell lines. The primary antibody against the hFRα was added into the 
medium and specific bound to the FR expressed at the plasma membrane surface. A 
FITC labeled second antibody which binds to the primary antibody was then added. Cells 
were washed and collected, followed by detection by flow cytometry. A typical result of 
FR quantification in KB was presented in Figure IV-2C.  The black, red, blue, and yellow 
lines represented the KB cells without and with antibody staining, A549 cells without and 
with antibody staining respectively. It is obvious the black and red line lines are not 
overlapped. The shifted red line indicates the expression of hFRα in KB. By contrast, the 
blue and yellow lines in A549 are almost overlapped, suggesting the non-detectable 
protein expression of hFRα in A549. The distinct expression of this protein in two cell 
lines was further confirmed in Figure IV-2D, where more than 300-fold expression 
difference was displayed. Through these analyses, the data clearly exhibit the significant 
expression difference of hFRα in KB and A549 cells. Regarding the hFRα protein is the 
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direct executor for FA or FA conjugates uptakes, approximate 300 fold difference of this 
protein might better reflect the real situation. The fold differences in real-time PCR and 
flow cytometer would partially result from post-transcriptional modification or other 
reasons. Collectively, the result has shown that KB cells highly express FR while A549 
cells have only background FR level. Therefore, KB and A549 cells can be used as FR-
positive and negative cells in our experiments. 
We propose to use GFP and luciferase system to study gene expression upon FA-
siRNA treatment because of its accuracy and sensitivity.  Among various luciferases, 
Gaussia luciferase (GLuc) is utilized because: (i) it is a secreted protein, therefore cell 
lysis step is escaped; (ii) GLuc has the 1000 fold sensitivity over Fluc. The utility of Gluc 
was first in a transient transfection system (Figure IV-3) and a stable transfection system 
where a cell line based on KB was constructed that express Gluc stably (Figure IV-4).  
  
  
Figure IV-2. Comparison of h
(A) Representative amplification plot
PCR. (B) Statistic analysis of real
expression in two cell lines. (C) Representative fluorescence b
antibody in KB and A549 cells via flow cytometer; (D) Statistic analysis of flow 
cytometer results shows the relative hFR
represents mean ± S.D. (n=3
 
Downregulation of Gluc A
As for transient system, cancer cells were transfected with plasmids (pCMV
Gluc) encoding Gluc and siRNAs against Gluc (siGLuc) by Lipofectamine consecutively. 
Six hours after transfection of plasmid, the second transfe
introduce siRNA against Gluc (siGLuc) into the cells. A siRNA control (siCon) that has 
no targeted gene in human genome is used. As expected, siCon will not cause any gene 
silencing. In contrast, the cells transfected with siGluc wil
 
uman FR-α (hFRα) expression in KB and A549 cell lines
s of hFRα in KB and A549 cells through real
-time PCR results shows the relative hFR
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α protein expression in two cell lines. Each bar 
-4).  
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76 
 
. 
-time 
α gene 
-hFRα 
-
  
expression. Luciferase will be expressed after the first transfection within a few days (at 
least 3 days), and thus provides targeted mRNA for RNAi. The medium samples were 
collected approximately every 8 hours and measured by luciferas
IV-3). The cells treated with siCon (the solid circle) serve as the mock group and show 
increasing Gluc activity along with time (
siGLuc treatment (the solid square) display lower Gluc act
downregulation from RNAi pathway. 
Figure IV-3. Downregulation of luciferase activity 
(A) KB cells were transfected 
targeting Gluc (Plasmid +
solid circle). Cellular medium 
points, and quantified through
transfected with siGLuc showed less luciferase activity; while the 
increased luciferase activity
 
The relative siGLuc efficiency was plotted in 
maximum siGLuc efficiency, 6
(HAT), and average RNAi efficiency is approximate 60%. Interestingly, the RNAi 
efficiency of 12 HAT appears to be 70%. That may not reflect the truth regarding of the 
unequal expression rates of the plasmid and the processing of RNAi. In other words, the 
plasmid is expressed in control group (plasmid + siCon); whereas RNAi effect is limited 
 
e activity assay (
Figure IV-3A). In contrast, the cells upon 
ivity, indicating gene 
 
in KB cells by transient transfection. 
with pCMV-Gluc plasmid first, then with either 
 siGLuc, solid square) or siRNA control (Plasmid + siCon
containing the secreted was collected at the different time 
 luciferase activity assay. Due to RNAi effects, the cells
control
. (B) Relative siGLuc efficiency was presented.
Figure IV-3B. The data show the 
8% of downregulation, occurs at 42 hour after transfection 
77 
Figure 
 
siRNA 
, 
 
 group showed 
 
  
in treatment group (plasmid + siGLuc). In addition, the plasmids are transfected into the 
cells prior to siRNAs. Likewise, transient transfection of siRNA first prior to plasm
has been conducted. Similar maximum siRNA efficiency (~70%) at around 48 HAT 
indicates transient transfection is sufficient for determination of the best siRNA 
efficiency.  
Overall, the data have demonstrated
can silent the Gaussia luciferase expression potently; 
conditions we studied, the max siRNA efficiency is 68% at 42 HAT; 
transfection is not an ideal system for dynamic analysis of RNAi effects.
Downregulation of Gluc A
 
Figure IV-4. The construction of Gluc
which had been transfected with KB cells. (B)
pCMV-Gluc. (C) The schem
were transected with pCMV
capable of tolerating G418 and expressing Gluc constitutively are 
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To address this issue, a stable transfection is applied, through which the Gluc 
gene is integrated into the genome of KB cells and the Gluc will express stably. The 
plasmid pCMV-Gluc vector map (Figure IV-4A), electrophoresis analysis of plasmids 
(Figure IV-4B), and the procedure for establishment of a stable cell line (Figure IV-4C) 
are presented in Figure IV-4.  
Basically there are two important genes encoded within the humanized sequence 
of pCMV-Gluc (5764 base pairs) (Figure IV-4A) Gaussia luciferase and aminoglycoside 
phosphotransferase (neo) under the strong promoters of cytomegalovirus (pCMV) and 
simian virus (pSV40), respectively. Neo is a selectable marker, conferring the transfected 
cells resistance to antibiotics Neomycin in prokaryotic cells, or genticin (G418) in 
eukaryotic cells, through which stable cell lines (usually mammalian cell lines) 
expressing reporter proteins or cloned proteins are established. To get sufficient amount 
of pCMV-Gluc for transfection purpose, the plasmid preparation was performed via 
transformation of E. coli. The extracted pCMV-Gluc was confirmed by 0.8% agarose/ 
EtBr gel electrophoresis (Figure IV-4B), the first lane is the original plasmid (100 ng, 2 
µL of 50 ng/µL), and the other 9 lanes are amplified plasmid. The procedure of the stable 
expression cell lines is illustrated in Figure IV-4C. Firstly, KB cells were transfected with 
pCMV-Gluc by DharmaFECT followed by manufacturer’s manual. One day later, the 
medium was replaced with one containing 0.5 mg/mL antibiotics G418.  Cells were first 
cultured in a 10 cm dish for 2 weeks. At this time point, the majority (> 90%) KB cells 
were killed off by G418 because of lacking the expression of neo. However, a few 
percent of KB cells that had integrated the pCMV-Gluc plasmid detoxified G418 and 
survived.  Because the resistance to the G418 only indicated the insert of neo gene into 
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the genome of KB, but necessarily meant the integrated of Gluc gene, the selection of 
Gluc activity was carried out by seeding the surviving cells at very low density (~1 
cell/0.1 mL) and plating onto 96-microplates (0.1 mL/well). The selection pressure from 
Gl418 remained for another 7 days. Positive colonies expressing Gaussia luciferase 
(Gluc) were screened by luciferase assay, transferred to a 12-well plate for propagation. 
The cells are designated as Gluc-expressing KB cells (Gluc-KB). 
Gene down-regulation studies were carried out in Gluc-KB cells with siGLuc 
(Figure IV-5) and FA-siGLuc (Figure IV-6). In Figure IV-5A we can see the continuous 
expression of Gluc in Gluc-KB cells. Without the interference of siRNA, Gluc expression 
correlates with time (mock group). The cells transfected with different concentration of 
siGLuc display downregulated expression of GLuc. The data from Figure IV-5A is 
converted to Figure IV-5B to show the siGLuc efficiency within the 72 hour after 
transfection (HAT). From the figure, the dose-dependence pattern is obvious: siRNA 
efficiency from 30 nM > 20 nM > 10 nM. At 72 HAT, 76%, 67% and 66% of Gluc 
activity has been reduced from treatments with 30 nM, 20 nM and 10 nM of siGLuc 
respectively. Due to the limitation of cell confluency (cell density in a cell culture 
container), the longer incubation time will cause error since 40% confluency is start point 
before transfection. Therefore, we have not observed the disappearance of siRNA 
efficiency here, which can map out the best RNAi efficiency of siGLuc.  
Nevertheless, the results have demonstrated: (i) after being integrated into the 
genome of KB cells, Gluc functions as an endogenous gene and is expressed by Gluc-KB 
cells constitutively; (ii) 60%-70% of Gluc activity is reduced by Lipofectamine-mediated 
transfection of siGLuc within the 36-72 HAT; (iii) dose-dependent downregulation.  
  
Figure IV-5. Downregulation of luciferase activity by siGluc in 
Gluc-KB cells were transfected by Lipofectamine 
siGLuc. (B) The relative siGLuc efficiency was 
group (mock).  
 
Based on the above results, we tested whether: 
internalized into Gluc-KB cells and silence the Gluc activity; 
FR-mediated and has the cell
Folate deficient medium all the time and seeded onto the dished with 40% confluency 
one day before the addition of FA
concentration was used afterwards) into the medium. No more additional treatment was 
performed. Every day the medium samples were collected and measured and the time 
course data was plotted into 
occurred after 5 days of incubation with ~50% downregulation. It is notable that the best 
siRNA efficiency shows up 
results of Dassie et al. who deliver PSMA aptamer
human prostate tumors and observe the best siRNA efficiency at 4 days post incubation 
121d
. This phenomenon would result from the delayed naked siRNA escape from the 
endosome, which would compromise the efficiency of siRNA.
 
Gluc-KB cells
with 10 nM, 20 nM, and 30 nM of
plotted by normalization with non
(1) FA-siGLuc would be 
(2) the delivery of siRNA is 
-specific feature.  The Gluc-KB cells are maintained in 
-siGLuc (final concentration = 20 nM, the same 
Figure IV-6 which suggested the best siRNA efficiency 
after a relatively long period of time which is similar to the 
-modified siRNA chimeras into the 
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Several groups of control (
Gluc-KB cells, including Lipofectamine/siGLuc, FA
FA-conjugated siRNA control, siGLuc without FA conjugation. The results showed 55% 
and 23% Gluc activity remained from the FA
treatment. The presence of high concentration of free FA competed the binding sites (FR) 
with FA-siGluc and blocked the internalization of FA
from this groups was unaffected.  In addition, transfection of siRN
which has no gene target in the mammalian cells showed no RNAi effects. siGLuc
without FA conjugated cannot enter Gluc
observed under this condition. Thus combination of controls demonstrated FR
siRNA delivery.  
Figure IV-6. Downregulation of luciferase activity by FA
The time course of relative Gluc expression was assessed at 3 to 6 days after transfection
(siRNA concentration = 20 nM)
(mock), FA-siGLuc plus 1 mM free folate, FA
Lipofectamine-mediated transfection of siGLuc, and siGLuc, were explored along with 
the FA-siGLuc. The concentration of siRNA 
measurement was carried out at the 5day after incubation. The data represents mean ± 
S.D (n=3-4).  
 
Figure IV-6B) were tested along with FA
-siGLuc with 1 mM 
-siGLuc and Lipofectamine
-siGLuc, thus the Gluc expression 
A control (siCon) 
-KB cells and gene downregulation was 
-siGLuc in Gluc
. (B) Several controls including cell without treatment 
-linked control siRNA (siCon), 
in the study was 20 nM, and the 
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Reduction of GFP Expression through Transient Transfection 
Besides the bioluminescence system, the possibility of utilizing GFP as a reporter 
was also exploited in our research as shown in Figure IV-7. Similarly, KB cells 
consecutively expressing humanized GFP (GFP-KB) was established by transfecting KB 
cells with plasmid pAcGFP1-MemHyg (5846 bp) and selecting with antibiotics 
Hygromycin B. The screening of GFP expression positive colonies was performed 
through typhoon scanner. Due to lack of a spectrofluorophotometer, the fluorescent 
signals cannot be quantified. Instead, confocal imaging (Figure IV-7) and real-time PCR 
(Figure IV-7B) were applied to measure the GFP expression reduction after transfection 
of siRNA against GFP. As shown in Figure IV-7, we can see the high expression level of 
GFP in GFP-KB cells, and the expression is not influenced by transfection siCon. In 
contrast, siGFPa and siGFPb (two siRNAs both target the GFP gene) can significantly 
reduce the GFP expression by 97% and 95% (Figure IV-7B). This second example 
confirms: (1) our designed and prepared siRNAs can efficiently reduce the expression of 
targeted gene; (2) the reporter-stably transfected cell is an optimal system to assess gene 
expression, especially upon RNAi.  
  
Figure IV-7. Downregulation of GFP expression in GFP
Confocal analysis of reduced fluorescence by transfection 
siGFPa and siGFPb. In contrast, the non
siRNA control (has no targets in human genome) show unaffected GFP expression. 
Real-time PCR analysis of gene expression
 
Here we synthesized FA functionalized siRNA through in vitro transcription 
system. The FA-HAD-AMP as the transcriptional initiator is the key to this conjugation. 
Subsequently, to better monitor the gene expression changes upon the siRNA treatment, 
luciferase reporter, especially 
transfection cell line based on FR
denoted Gluc-KB. Firstly, Gluc
transfection agents to test the efficiency of siGLuc; secondly, Gluc
incubated with FA-siGLuc. FA
day incubation, indicating the internalization of siRNA through FR
 
-KB cells by Lipofectamine. (A) 
of two siRNAs
-treated cells and the cells transfected with 
.  
Conclusions 
Gaussia luciferase, system was introduced. A stable 
-expressing human cancer cell KB was established and 
-KB cells were transfected with siGLuc through 
-KB cells were 
-siGLuc at 20 nM reduced Gluc activity to 50% after 5
-mediation and RNAi 
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pathway-dependent gene silencing (siRNA control group). More importantly, several 
control groups had demonstrated the FR-dependent delivery because extra free FA could 
block the gene downregulation, and the siGLuc without FA modification can not enter 
cells. Moreover, the utilization of reporter systems and the establishment of GFP-KB and 
Gluc-KB cell lines render a fast and convenient platform for monitoring gene expression 
visually and quantitatively, and assessing siRNA efficiency. 
In spite of FR-mediated siRNA delivery and gene downregulation (50%), the 
RNAi efficacy is relatively low and may not meet the needs of biomedical application. 
The key here is to increase the gene downregulation efficiency by improving delivery 
strategy. Firstly, naked siRNA would be degraded in a short period of time by 
extracellular and intracellular RNase. It has been reported the half-life of unmodified 
siRNA is ~10 min in 100% human serum. Secondly, evidence shows that monovalent 
folate conjugate (containing one attached FA) compared to its multivalent counterpart 
(with several FAs) has less efficiency in triggering pH changes in early endosome, which 
is a crucial for siRNA release into cytoplasm. Another important reason for improvement 
the strategy comes from the consideration of systemic administration. Because of small 
molecular weight (59 nt, ~20 kDa) and size (~ 3 nm) of siRNA, it will be rapidly excreted 
through urine when circulated in blood stream.86   
To address these issues, we need a system cable of protecting siRNA and 
increasing the size of siRNA (i.e., form a complex) to achieve enhanced delivery 
efficiency and RNAi efficacy. Fortunately, through collaboration, we have developed a 
series of polyvalent, FA-conjugated copolymers with advantageous solubility, protection 
and complexation functionalities, which will be discussed in the next chapter.  
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CHAPTER V 
CANCER-SPECIFIC SIRNA DELIVERY VIA FAPOL13 
Introduction 
siRNA therapeutics have to overcome several major challenges including delivery 
efficiency, target cell specificity, in vivo stability, and appropriate intracellular siRNA 
release mechanism from delivery vehicles before it enters biomedical applications.92a, 210 
To address above issues, significant efforts have been dedicated to synthesize various 
nanoparticles as siRNA carriers which have become particularly attractive because of 
their flexibility of available conjugation chemistries, and capabilities of increasing siRNA 
stability, biocompatibility.211  
Cationic (co)polymers, such as PEI, polylysine and polyarginine, have been 
broadly used because they can package siRNA, or other oligo-/polynucleotides, through 
electrostatic interactions, thus providing the bound polynucleotide protection from 
detrimental nucleases.212 Although cationic complexes can protect siRNA and remain 
aqueous soluble, the cationic surface charge leads to non-specific cellular adsorption and 
thus transfection of both healthy and unhealthy cells.213 Furthermore, cationic complexes 
can associate with anionically charged serum proteins resulting in aggregation and 
eventual phagocytic clearance.214 Utilizing hydrophilic-block-cationic copolymers for 
siRNA complexation, neutral complexes can be formed circumventing problems 
associated with cationic carriers. The cationic block still provides packaging and 
protection for siRNA, while the hydrophilic block provides biocompatibility and 
solubility for the complex. This neutral hydrophilic block also prevents unwanted 
aggregation and non-specific cellular adsorption through steric stabilization. Since neutral 
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carriers do not electrostatically adsorb to cellular surfaces, the carrier must be directed to 
or accumulated at a specific tissue or cellular site.  A promising route to direct and trigger 
cellular uptake is to incorporate cellular targeting moieties to either the copolymer 
backbone or end-groups. 
Due to progress in numerous polymerization methods, (co)polymers with 
advanced architectures and predetermined chain-end and side-chain functionalities can be 
specifically designed for targeted delivery applications. Incorporation of such 
functionalities allows facile post-polymerization conjugation of cellular targeting 
moieties. In principle, targeted delivery systems mitigate side effects, improve bio-
availability, and enhance therapeutic efficacy.  Targeting ligands applicable to cancer 
therapy include antibodies, peptides, aptamers, and folate.103, 109, 215 The overexpression 
of FR in various types of tumors, such as, uterus, brain, kidney, breast, ovary,198 makes it 
as a cancer-cell-surface receptor, and confer the use of folate as a therapeutic director for 
homing FA-conjugates to tumors. Folate has been successfully employed to deliver 
diverse drugs, siRNAs, therapeutic, diagnostic and prognostic agents,197, 199 and at least 
four FA-linked drugs are under phase I or II clinical trials.143 
Several research groups, including our own, have successfully developed 
(co)polymer systems with utility in siRNA delivery.101b, 211b, 216 Although these reports 
demonstrate gene down-regulation, cellular trafficking events (i.e., binding, uptake, and 
endosomal release) prior to gene suppression are typically overlooked or ignored. 
Furthermore, evidence shows that efficient internalization of siRNA does not necessarily 
result in favorable gene down-regulation.217 For example, trafficking or degradation 
events after uptake, such as endosomal entrapment, exocytosis or recycling, or enzymatic 
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inactivation of the siRNA, can lead to suboptimal gene suppression.  For these reasons, 
investigation of cellular trafficking processes, specifically endosomal escape, are crucial 
for gene down-regulation efficacy.217 Real-time monitoring of such events would allow 
early detection of carrier drawbacks, optimization of delivery and formulation conditions, 
dynamic visualization, and easy assessment of endosomal entrapment/release. Therefore, 
there is a need to develop imaging techniques to follow and visualize the siRNA carrier 
during various cellular trafficking events.  Herein, I describe real-time monitoring for 
siRNA delivery processes utilizing a multivalent folate-functionalized copolymer 
(FAPol13) as the carrier. Cellular trafficking events monitored via confocal fluorescence 
microscopy include (1) receptor binding, (2) polyplexes internalization, and (3) 
endosomal release. siRNA delivery to multiple cancer cell types, copolymer 
biocompatibility, and gene down-regulation are also demonstrated. In addition to the 
development of real-time imaging methods, the result also demonstrates the utility of this 
polymeric carrier in site specific gene delivery applications.   
 
Result and Discussion 
Cellular Binding and Internalization of FAPol13/siRNA Polyplexes in KB Cells 
 Previously our laboratories synthesized a series of well-defined block copolymers 
capable of delivering siRNA specifically to FR-expressing cancer cell lines.101b These 
copolymers were prepared via a controlled radical polymerization technique known as 
reversible addition-fragmentation chain transfer (RAFT) polymerization.101a, b, 101e, 172, 188a, 
218
 The RAFT-synthesized block copolymer utilized in this report consists of three 
monomer components. The first block (HPMA315-stat-APMA13; Mn = 47400 g/mol; 
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PDI=1.10) was prepared through the aqueous RAFT copolymerization of N-(2-
hydroxypropyl)methacrylamide (HPMA) and N-(3-aminopropyl)methacrylamide 
(APMA). 101b HPMA was chosen because its corresponding polymer is biocompatible 
and water soluble, while APMA was selected to introduce primary amine functionalities 
for conjugation with folate derivatives. HPMA315-stat-APMA13 macro chain transfer 
agent was then successfully chain extended with the cationic tertiary amine containing 
monomer N-[3-(dimethylamino)propyl]methacrylamide (DMAPMA) to yield (HPMA315-
stat-APMA13)-b-DMAPMA23 (Mn = 51300 g/mol; PDI = 1.14),101b thus facilitating the 
electrostatic complexation between the copolymer and siRNA. The APMA units were 
then directly conjugated to N-hydroxysuccinimide activated folate, and 11 to 13 out of 13 
possible APMA units were modified.101b Due to the presence of 13 APMA units, 
unmodified (HPMA315-stat-APMA13)-b-DMAPMA23 was given the name Pol13 and 
multivalent folate conjugated (HPMA315-stat-APMA13)-b-DMAPMA23 was named 
FAPol13. FAPol13 allows the formation of neutral (nitrogen to phosphate ratios, N/P = 1) 
complexes, thereby circumventing problems associated with charged complexes, while 
the presence of multiple folates in the aqueous stabilizing block directs this siRNA carrier 
to cancer FR-expressing cell lines.  
FAPol13 has a small molecular size (hydrodynamic diameter, Dh = 10.8 ± 0.3 
nm), and cationic change (Zeta potential = 25.4 ± 0.7 mV).101b After complexation with 
siRNA (59 nt, Dh = 2.95 ± 0.34 nm)188a, the size of FAPol13/siRNA complex is still 
nanoscale (Dh = 15.2 ± 2.4 nm). Compared to macromolecular siRNA carriers (i.e., 
antibody, aptamer), this property is advantageous in terms of tumor penetration 
potential.219 Additionally, the neutral complexes (Zeta potential = -3.88 ± 0.21 mV) 
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remain sterically stable due to the presence of the hydrophilic block, which increases the 
delivery efficiency compared with anionic complex, and enhanced targetability compared 
with cationic complex.101b Therefore, the neutral FAPol13/siRNA complex is an ideal 
model for study the delivery process (Scheme V-1), including cellular binding, entry 
(endocytosis), endosome escapes. 
After successful preparation of FAPol13 and subsequent formation of neutral 
FAPol13/siRNA polyplexes, cell binding and intracellular uptakes of these carriers were 
confirmed by confocal laser scanning microscopy. Fluorescence and thus visualization of 
the uptake process was made possible by employing either a FAM-labeled or a Cy3-
labeled siRNA. To elucidate the specificity of delivery, several control studies were first 
performed (Figure V-1). Time-lapse analyses were carried out to monitor siRNA binding 
to KB cells (Figure V-2), followed by z-axis scanning to confirm internalization of the 
siRNA/FAPol13 polyplexes (Figure V-3). Experiments were performed on 
polymer/siRNA polyplexes prior to (Pol13) and after FA (FAPol13) conjugation. 
  
Scheme V-1. Schematic depiction of siRNA delivery processes via FAPol13. 
 
FApol13 functionalized with FA carries siRNA into the FR expressing cells and release it 
once inside. FAPol13 and siRNA form a comp
the FR+ cells, b) enter the cells through FR
endosome after pH decreasing, and d) dissociate siRNA into the cytoplasm, which it will 
be processed by Dicer, incorporated i
degradation (RNAi pathway is not shown here). 
 
Control experiments were first carried out to establish the ability of FAPol13 to 
deliver FAM-labeled siRNA (FAM
naked FAM-siRNA, Pol113/FAM
or Lipofectamine/FAM-siRNA complexes. Minimal fluorescence upon treating KB cells 
with naked FAM-siRNA and Pol13/FAM
 
lex electrostatically which will a) bind to 
-dependent endocytosis, c) escape from the 
nto the RISC, and induce the homologous mRNA 
 
-siRNA) to KB cells. KB cells were treated with 
-siRNA polyplexes, FAPol13/FAM-siRNA polyplexes, 
-siRNA polyplexes was observed and attributed 
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to non-specific binding. In contrast, the fluorescence intensity from FAPol13/FAM-
siRNA polyplexes was stronger, suggesting that the conjugated FA promoted specific 
cellular associations through the FR. As a positive control FAM-siRNA was delivered via 
Lipofectamine, a commercial transfection reagent that can effectively perform 
intracellular siRNA delivery independent of the cellular receptors present.  In addition to 
standard fluorescence imaging, siRNA binding and uptake were verified by time-lapse 
and z-stack scanning analyses. For the remaining imaging experiments Cy3 labeled 
siRNA was chosen over FAM because of its resistance to photobleaching.  
Real-time monitoring of siRNA-cell binding process is important as it allows for 
dynamic visualization of the cellular receptor binding/adsorption process, determination 
of the time required for cellular binding and cellular surface saturation by the therapeutic 
carrier, as well as a rapid a straightforward analysis to prescreen the designed carrier.         
 
 
 
 
  
Figure V-1. Confocal images of specific binding of FAPol13/FAM
KB cells were treated with A) no treatment, B) FAM
FAPol13/siRNA polyplexes, and E) Lipofectamine/siRNA complexes (total [siRNA] = 
20 nM) and incubated for 40
microscopy after washing the cells with pre
each micrograph is 1.0. The panel indicated by FAM was FAM fluorescence images, 
while the DIC panel represented d
Scale bar = 100 µm. 
 
-siRNA to KB cells. 
-siRNA, C) Pol13/siRNA, D) 
 min (A-D) or 1.5 h for E. Images were taken via confocal 
-warmed PBS two times.  The 
ifferential interference contrast or bright field images. 
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 During the following real-time monitoring the temperature was maintained at 37 
°C by a heated sample holder and micrographs were taken in 10 min intervals for 80 min. 
Time-lapse images for the incubation of FAPol13/siRNA polyplexes in the KB (+FR) 
and A549 (-FR) cell lines are shown in Figure V-2. It is apparent that the cell 
fluorescence from Figure. V-2A (KB cells with FAPol13/siRNA polyplexes) was much 
stronger than Figure. V-2B (KB cells with Pol13/siRNA polyplexes), indicating siRNA-
cell binding events due to ligand-receptor interactions between the FAPol13/siRNA 
polyplexes and the FRs expressed at the cell surface. Further evidence for specific ligand-
receptor interactions is provided by comparison of Figure V-2A to Figure V-2C (A549 
cells with FAPol13/siRNA polyplexes). The absence of fluorescence in Figure 2C is 
related to negligible FR-expression in the A549 cell line.  The absence of FR expression 
precludes specific association of the FAPol13/siRNA polyplexes with from A549 cells. 
For the above three conditions, fluorescence intensities as a function of time are 
presented in Figure V-2D. Upon treatment of KB cells with FAPol13/siRNA polyplexes, 
an increase in cell-associated fluorescence was apparent after 20 min. Maximum 
fluorescence was reached near 40 min and kept for the remainder of the time-lapse. On 
the other hand, cell-associated fluorescence over the same time course was negligible for 
both treatments of KB cells with Pol13/siRNA polyplexes (Figure V-2B) and A549 cells 
with FAPol13/siRNA polyplexes (Figure V-2C).   
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Figure V-2. Time-lapse imaging of polyplexes 
with A) FAPol13/siRNA polyplexes 
polyplexes in KB cells, and C) FAPol13/siRNA polyplexes 
siRNA was labeled with Cy3 (red) ([siRNA] = 20 nM). Images were taken every 10 min 
for 80 min.  The overlaps of fluorescence image 
Scale bar = 10 µm. D) Associated fluorescence versus time for FAPol13/siRNA 
polyplexes with KB cells (
FAPol13/siRNA polyplexes with A549 cells (
calculated from 10 individual cells and background corrected. Error bars are represented 
by ± S.D (n=3). 
 
Although Figure V
cell surface of FR-expressing KB cells, subsequent intracellular uptake cannot be verified 
through time-lapse analysis. Therefore, siRNA internalization was studied separately by 
scanning cell sections vertically through the z
verify if the fluorescence signal comes from the interior or exterior of the cell, or both.  
 
20 40 60 80
FAPol13 in KB
FAPol13 in A549
Pol13 in KB
Time (Minute)
in KB and A549 cells. Cells were treated 
in KB cells (FR-positive), B) Pol13/siRNA 
in A549 cells (FR
and bright field image are shown here. 
■), Pol13/siRNA polyplexes with KB cells (●), and 
▲). The associated fluorescence is 
-2 demonstrates binding of FAPol13/siRNA polyplexes to the 
-axis via confocal microscopy, which can 
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Z-axis sectional images were taken by adjusting the focal plane from the top to the 
bottom of the cells in 3 µm increments (Figure V-3). As a negative control (Figure. V-
3A), incubation of KB cells with Cy3-labeled Pol13/siRNA complexes (-FA) resulted in 
weak but observable background fluorescence. In addition, the weak fluorescence was 
present only on the cell surface. No internalization was visible. On the contrary, 
internalization of the FAPol13/siRNA polyplexes in KB cells (Figure V-3B) was 
evidenced by the relative strong fluorescence that was not only associated with the cell 
surface but also present inside cells. The largest fluorescence difference between Figure 
3A and Figure 3B existed not on the cell surface but within cells. While Figure 3A 
displays no visible fluorescence inside cells, relative strong fluorescence can be seen in 
the intracellular volume of Figurer 3B. As a positive control (Figure V-3C), 
Lipofectamine was also used to show cellular internalization (no cell specificity) of Cy3-
labeled siRNA.  KB cells treated with Lipofectamine/siRNA complexes were incubated 
for 2 h following the manufacturer’s suggestion. As expected, incubation of cells with 
Lipofectamine-complexed Cy3-siRNA led to strong fluorescence over the whole cell  
Collectively, these results demonstrate both cell binding and intracellular uptake 
of FAPol13/siRNA polyplexes in KB cells, due to the presence of the conjugated FAs 
that promote siRNA cell binding and internalization.  In addition to cellular uptake, 
endosomal release of internalized siRNA from carrier complex would be necessary for 
efficient RNAi/gene downregulation.217a, 220 Therefore, further analysis by fluorescence 
microscopy was utilized to characterize and visualize endosomal release events during 
FAPol13-assisted siRNA delivery.    
  
Figure V-3. Z-stack scanning analysis of 
of KB cells with A) FAPol13/siRNA polyplexes (1 h), B) Pol13/siRNA polyplexes (1 h), 
and DharmaFECT/siRNA (2 h).  siRNA was labeled with Cy3 (red) with a concentration 
of 100 nM for all images.  Hoechst 33258 
before observation. The focal plane was moved from the bottom to top of the cells in 2 
µm increments. Scale bar = 20 µm.
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Endosomal Escape of FAPol13/siRNA Polyplexes 
Inefficient siRNA release from endosomal compartments is the major reason for 
subpar gene downregulation.217a, 220-221 Poor release leads to entrapment of the therapeutic 
carrier and cargo inside the endosome, potentially causing either their recycling back to 
the cell surface 217a or their degradation by lysosomal enzymes. Therefore methods to 
directly monitor endosomal escape are critical for gene downregulation assessment and 
the rational design of gene delivery vehicles. In the current system, we performed co-
localization analysis of FAPol13/Cy3-labeled siRNA polyplexes and lysotracker (a 
membrane permeable dye that only fluoresces in the endosomal or lysosomal 
compartment) during endocytotic trafficking (Figure V-4).222 Co-localization is 
determined by merging the Cy3 (red) and lysotracker (green) fluorescent images.  If 
siRNA is contained within an endosomal compartment this image overlap will produce a 
yellow signal.  Co-localization between two fluorescent probes, Cy3-siRNA and 
lysotracker, was quantified by the Pearson’s correlation coefficient (PCC) through a 
toolbox under ImageJ and JACoP (Figure 4E). PCC typically has a scale between -1 to 1, 
with -1 having no correlation whatsoever and 1 indicating a perfect overlap of fluorescent 
signals. 223   
 KB cells were first treated with FAPol13/Cy3-labeled siRNA polyplexes 
([siRNA] = 100 nM) for 1 h after which the cell medium was replaced. Prior to 
fluorescent imaging, lysotracker (100 nM) was added to the cell medium.  Cells were 
imaged at 1 h, 6 h, 24 h, and 48 h after FAPol13/siRNA polyplex treatment. Co-
localization of lysotracker and siRNA in the endosome, after 1 h treatment, is evidenced 
by the yellow and localized signals seen in Figure V-4A, indicating that most of the 
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siRNA is confined to endosomal compartments. After 6 h and 24 h treatment (Figure V-
4B and 4C), separation between the Cy3 and lysotracker signals become apparent and are 
marked by arrows in Figure 4. The loss of co-localization, or return to individual red 
(Cy3 siRNA) and green (lysotracker) signals, suggests endosomal escape of the 
FAPol13/siRNA polyplexes. After 48 h treatment (Figure V-4D), the fluorescent signal 
from siRNA has become more evenly distributed throughout the cytosol and more red 
signal (siRNA) has separated from the lysotracker signal. At the same time, less yellow 
signal is present, further indicating endosomal escape of FAPol13/siRNA polyplexes. For 
comparison, similar treatment of FR-negative A549 cells with lysotracker and 
FAPol13/siRNA polyplexes led to the observation of green signals only, without the 
presence of red signals within the cells, as expected from the results in Figure V-2.  
 In addition to visual observation of spatial distribution of Cy3-siRNA and 
lysotracker (Figure V-4), PCC is utilized to statistically and quantitatively measure the 
endosomal escape process. A PCC equal to 1 implies that the FAPol13/siRNA polyplexes 
and the endosome are completely co-localized.  In our case, the PCC from 1 h treatment 
is 0.99 indicating that the FAPol13/siRNA polyplexes were endocytosed and remained in 
the endosomal compartments. As treatment time increased, the PCC for the 6 h time point 
decreased to 0.77. This decrease suggests that a portion of the FAPol13/siRNA 
polyplexes have escaped from the endosome as visualized in Figure V-4B. The PCCs of 
the 24 h and 48 h images are 0.64 and 0.49, respectively, suggesting that the 
FAPol13/siRNA polyplexes continually escape the endosome over time. Notably, the 
decrease from 0.99 (1 h) to 0.77 (6 h) is the largest among two consecutive time points, 
suggesting that the highest escaping efficiency occurs between 1 h and 6 h.   
  
Figure V-4. Colocalization analysis of 
cells were incubated with
h, C) 24 h, and D) 48h. The endolysosome w
prior to imaging. Yellow fluorescence seen in the overlay images indicates co
localization of siRNA and lysotrac
lysotracker were held at 100 nM. Cells were washed with pre
solution three times prior to observation. Scale bar = 10 µm. Arrows mark separating or 
separated red and green signals. E
calculation is based on 3 independent images, within each containing 7
time point. Error bars are represented by ± S.D.
 
 
1h 6h 24h 48h
0.0
0.2
0.4
0.6
0.8
1.0
E
Time
Pe
ar
so
n
's
 
Co
rr
el
at
io
n
Co
ef
fic
ie
n
t (
PC
C)
 
polyplexes and endolysosome in KB cells
 FAPol13/Cy3-labeled siRNA (red) polyplexes 
as stained with lysotracker green 
ker in the endosome.  Concentrations of siRNA and 
-warmed phosphate buffer 
) The Pearson’s correlation coefficient versus time. The 
-12 cells in each 
 
100 
. The 
for A) 1 h, B) 6 
30 min 
-
101 
 
 
 
 These co-localization studies establish that FAPol13/siRNA polyplexes are 
internalized and can subsequently escape the endosome over time. Endosomal escape has 
been confirmed both visually and quantitatively by fluorescence microscopy and 
determination of PCC, respectively.  Release of siRNA from the endosome was not 
unexpected since gene down-regulation was observed in our previous report 101b. 
Although the imaging methods were developed utilizing FAPol13/siRNA polyplexes in 
KB cells, the methods may be applied to other fluorescently labeled siRNA carrier 
systems and cell lines for direct observation of endosomal escape. This direct monitoring 
can provide insight into the efficacy of endosomal escape, thereby offering some 
guidance on development of efficient siRNA carrier systems.  
 Another factor facing efficient siRNA delivery is the unpackaging of siRNA from 
the polymeric carrier. In theory, siRNA release from the carrier can be visualized through 
the development of a FRET reporter system. For example, the conjugation of quencher 
dye to the copolymer backbone would absorb the fluorescence emission from the Cy3-
labeled siRNA. Upon release, the fluorescence becomes visible allowing the researcher to 
image and determine the cellular location of release.  Such a system is currently being 
developed within our laboratories.   
Internalization of FAPol13/siRNA Polyplexes into HeLa and SKOV3 Cells 
 The above studies established both cellular uptake, via FR-mediated endocytosis, 
and endosomal release of FAPol13/siRNA polyplexes with KB cells (FR+), along with 
A549 cells (FR-) as the negative control.  Additional FR-positive cell lines, HeLa and 
SKOV3 cells, were utilized to demonstrate the capacity of this polymeric vehicle to 
  
deliver siRNA to other FR
SKOV3 cells was studied via confocal microscopy.
 Cellular internalization of FAPol13/siRNA polyp
cells can be compared by the confocal microscopy images as shown in Fig
contrast, the nuclei were stained with Hoechst (blue fluorescence). In addition, z
analysis clearly indicates internalization of FAPol13
SKOV3 cells. Furthermore, the uniformity of red fluorescence throughout the cytoplasm 
further suggests effective cellular internalization FAPol13/siRNA polyplexes. Finally, it 
is noted that the fluorescence signal decreases 
cells, which is consistent with the cellular uptake capacity of other folate conjugates in 
these cell lines.224 Quantitation of the r
levels in KB, HeLa, and SKOV3 cells, indicates FR expression level of decreasing order: 
KB > HeLa > SKOV3 (refer to Chapter VII). 
Figure V-5. Confocal analysis of cellular absorption of polyplexes with canc
KB, B) HeLa, C) SKOV3
(N/P = 1, siRNA concentration = 100 nM) for 40 min before imaging. The 
stained by Hoechst 33258
µm. 
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polyplexes bind to the HeLa and SKOV3 cells along with the time, indicating the 
interaction between the FR and FA moiety. Certain cells exhibit rapid absorbance of 
polyplexes; while some show slower uptake, probably due to different FR expression 
level and heterogeneity of the cell lines. Moreover, under the condition studied, the 
fluorescence intensity has not reached the maximum after 60 min incubation (the data not 
shown here). Secondly, the z-axis scanning (Figure V-6B and 6E) clearly indicates the 
cytoplasmic distribution of polyplexes after 6 h incubation, which is in agreement with 
the results in KB cells. More importantly, colocalization of polyplexes (red) and 
lysotracker green (Figure V-6C and V-6F) suggests the polyplexes escape from 
endolysosome after 24 h incubation. The endosomal release efficiencies indicated by 
PCC in HeLa and SKOV3 are 42% and 34% respectively, close to the 36% in KB cells.   
Taken together, these results suggest that FAPol13/siRNA polyplexes could bind 
to the FR-positive cells depending on the presence of cell surface FR; and polyplexes are 
internalized by endocytic pathway and released from endolysosome into cytoplasm after 
24 h incubation with approximate 40% efficiencies among these three FR+ cell lines. 
Furthermore, the data reveal the potential application of this useful approach to evaluate 
the trafficking process of fluorophore-labeled complexes in different cell lines or 
different drug delivery systems. 
  
  
Figure V-6. Confocal studies of polyplexes trafficking in HeLa
lapse imaging (A and D), z
F) were applied here.  The images of time
in an overlap of fluorescence (Cy3 and Hoechst) and bright field. For z
cells were incubated with polyplexes for 6 h before
Hoechst fluorescence are presented here. The 24 h incubation for colocalization imaging 
was chosen and presented here. Scale bar = 10 µm.
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Copolymer Cytotoxicity and Gene Downregulation of Luciferase  
 Prior to gene down-regulation experiments the cytotoxicity of FAPol13 was 
determined utilizing a cell viability assay with 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS).  Conversion of MTS 
to formazan by dehydrogenase enzymes can only be accomplished if cells are 
metabolically active.  Therefore, the absorbance of formazan at 490 nm is a direct 
measurement of cell viability.  As shown in Figure V-7, FAPol13 has low to negligible 
toxicity over the complete range of concentrations tested, suggesting that the copolymer 
is biocompatible and suitable for gene delivery applications.  These results are consistent 
with microscope observation (no cell death). This low toxicity and biocompatibility are 
advantageous when compared to conventional liposome-based vehicles, which have been 
shown to be cytotoxic. 225 This, in principle, allows for multiple treatments of cells with 
FAPol13/siRNA polyplexes due to the non-toxic nature of the copolymer. 
 
Figure V-7. Cell viability of KB cells at increasing concentrations of FAPol13. KB cells 
were first seeded into a 96 well plate and incubated for 24 h prior to introduction of 
FAPol13.  Five different copolymer concentrations ranging from 10 nM to 6 µM were 
tested and allowed to incubate for 48 h.  Untreated KB cells were utilized as a control.  
After incubation, a solution of MTS was added and the absorbance at 490 nm was 
measured after two hours.  All measurements were directly compared to untreated KB 
cells All experiments were performed in triplicate, and error bars represent ± S.D (n=3). 
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 To assess gene down-regulation of these polyplexes, Gluc-KB cells, which stably 
express Gaussia luciferase protein,188d were treated with neutral FAPol13/siRNA 
polyplexes ([siRNA] = 100 nM; N/P = 1) for 6 h, followed by 48 h incubation. siRNA 
targeted against Gaussia luciferase was utilized for these studies due to its convenience 
and sensitivity of the measurement. The facile manner in which luciferase protein level 
can be determined (i.e., by luminescence) makes this protein an ideal target for 
testing/optimizing gene downregulation.226 Following 48 h of incubation, the luciferase 
protein expression level was quantified and presented in Figure V-8.  
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Figure V-8. Relative Gaussia luciferase protein expression level in Gluc-KB cells.  The 
control (marked Cell) contained free siRNA and Gluc-expressing KB cells.  The 
remaining three experiments (FAPol13, Pol13, and DharmaFECT) were Gluc-expressing 
KB cells treated with FAPol13/siRNA polyplexes, Pol13/siRNA polyplexes and 
DharmaFECT/siRNA complexes. siRNA concentration was kept at 100 nM. Polyplexes 
were prepared at an N/P = 1.0. Protein expression levels were measured 48 h after 
treatment.  All experiments were repeated in triplicate and the error bars represent ± S.D. 
(n=3). 
 
The luciferase protein level was normalized to untreated Gluc-KB cells. Upon the 
treatment of FAPol13/siRNA polyplexes, the luciferase expression reduced to 32%, while 
minimal gene down-regulation for cells treated with polyplexes prior to FA conjugation 
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was observed.  This result matches the above studies in that the conjugation of FA to the 
polymeric carrier is required for cellular uptake (Figure V-1 to V-3). Treatment of Gluc-
KB cells with DharmaFECT (commercial transfection reagent, positive control) lead to 
83% down-regulation of luciferase.  The similar gene down-regulation efficiency 
between DharmaFECT and FAPol13 and the enhanced biocompatibility of the latter 
demonstrates the potential utility of FAPol13 for specifically delivering siRNA to FR-
bearing cancer cells. These results are consistent with gene down-regulation studies of 
human survivin gene by real-time PCR (Figure V-9). 101b 
 
Figure V-9. Real-time PCR analysis of downregulation of human Survivin gene upon 
treatment with FAPol13 complexed anti-survivin siRNA (siSv). The control contained 
either KB cells incubated with siSv or A549 cells incubated with siSv. The other three 
experiments (marked KB, KB/Free FA, and A549) were treated with FAPol13/siSv 
complexes in the presence (KB/Free FA) or absence (KB, A549) of 1 mM free folic acid 
(FA). All experiments were done in triplicate and error bars represent ± SD 101b. 
 
Kinetic Analysis of the Absorption of FAPol13/siRNA Polyplexes in KB Cells 
This low toxicity and biocompatibility of FAPol13 make multiple treatments of 
cells with polyplexes with minimal side-effects possible. To follow this notion, we 
conduct the kinetic analysis to determine the effective incubation time (Figure V-10).  
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KB cells were treated by DharmaFECT (positive control) and FAPol13 
complexed, Cy3-labeled siRNA in vitro, and the mean fluorescence intensity (MFI) was 
assessed by flow cytometry as a function of time. In Figure V-10, the kinetics of KB 
accumulation is quantified. KB cells appear to saturate by DharmaFECT/Cy3-siRNA in 
~10 h (half time, t1/2 = ~2.8 h), by FAPol13/Cy3-siRNA in ~13h (t1/2 = ~5.3 h). The result 
is consistent with Figure V-1 and V-3, which indicate the higher absorption efficiency of 
commercial transfection agents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure V-10. Kinetic studies of Cy3-siRNA uptake in KB cells by flow cytometry. Cy3-
siRNA (final concentration = 100 nM) were delivered by DharmaFECT (solid circles) 
and FAPol13 (solid squares). The uptake of siRNA by KB cells was monitored as a 
function of time (1h, 2h, 4h 8h, and 24h) by flow cytometry. The data represents mean ± 
SEM (n=3).  
 
Induction of Apoptosis by Transfecting KB Cells with siRNA against CASP8AP2 (siCAS)  
As discussed in Chapter I, Caspase 8 associated protein 2 (CASP8AP2) is 
involved in apoptosis. Downregulation of this gene expression through RNAi technique 
would cause cell death. 184 Therefore we choose this gene as siRNA target to enhance the 
cellular effects upon siRNA treatment. Firstly, DharmaFECT was used to deliver 
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transcription-synthesized siRNA against CASP8AP2 (siCAS) into KB cells to test the 
feasibility of this target (Figure V-11), and subsequently, FAPol13 was used to carry 
siCAS into the cells specifically (Figure V-12).  
Morphological changes, such as, cell shrinkage and DNA fragmentation (pointed 
by arrows), occur in KB upon siCAS treatment for 24 h (Figure V-11A). This indicates 
apoptotic cells and demonstrates the important role of CASP8AP2 for cell survival. 
Furthermore, cell viability (Figure V-11B) and dead cells (floating in the cell medium) 
(Figure V-11C) were measured via MTS assay and flow cytometry. From Figure V-11B, 
less than 40% KB cells after 24h-treatments are alive. By contrast, KB cells incubated 
with and without DharmaFECT are unaffected. Cell death induced by siCAS treatment 
was further validated by counting the floated cells (death cells) collected from the cell 
medium.  Several thousands of cells died after treatment, compared to a few hundreds of 
dead cells in normal situation (without any treatment) and DharmaFECT treatment. 
Overall, the data demonstrate that CASP8AP2 is a favorable target for inducing apoptosis 
through siRNA-triggered downregulation.  
 
  
Figure V-11. Transfection
Confocal (63X oil lens) studies of morphological changes between the 1h and 24h post 
transfection. The defragmented DNA is pointed by arrows. The nucleoli were stained by 
Hoechst 33258 30 min before the imaging. Scale bar = 20 µm. B) Viability studies (MTS 
assay) of the alive cells after 48 h treatment of DharmaFECT/siCAS (concentration = 100 
µM). The readout had been normalized to the non
counting of the dead cell after 48 h treatment. The medium and 2
collected and resuspended. Equal volume of the samples was detected. 
 
After confirming the crucial role of CASP8AP2 in maintaining cell survival, 
FAPol13 was applied to delivery siCAS into KB cells (
assessed by Annexin V assay. Annexin V has
phosphatidylserine which is normally located at the inner (cytoplasmic) leaflet of the 
plasma membrane. During the apoptotic process, phosphatidylserine will be translocated 
from inner to outer leaflet and detected by FI
 
 of KB cells with siRNA against CASP8AP2 (siCAS)
-treated cells. C) Flow cytometer 
-time washed PBS were 
 
Figure V-12) and apoptosis was 
 a strong and specific affinity for 
TC-labeled annexin V conjugate. Therefore 
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Annexin V assay is an easy and convenient method to evaluate and validate apoptosis by 
fluorescence microscopy or flow cytometry. Besides, co-staining apoptotic cells with 
propidium iodide (PI), a nucleic acid dye, can distinguish the cells that undergo apoptosis 
at the early stage and last stage.  
In Figure V-13A, x-axis is the fluorescence intensity from Annexin V-FITC 
staining, whereas y-axis is the fluorescence intensity from PI staining. Q1-LL stands for 
the live cells, Q1-LR and Q1-UR means early apoptotic cells and late apoptotic or 
necrotic cells respectively. The data shows 93.4%, 44.3%, and 78.5% of cells are alive 
upon non treatments, DharmaFECT/siCAS, and FAPol13/siCAS 2.5-day after treatment. 
Statistical analysis of this assay (Figure V-12B) exhibits 92.4%, 45.5%, and 76.5% 
accordingly. Intriguingly, approximate 24.5 % of KB cells have entered apoptotic 
pathways upon FAPol13/siCAS treatment. By contrast, in normal situations, only 8% of 
cells are under apoptosis. 
  
  
Figure V-12. Flow cytometric analyses of apoptosis
cells were planted into the 12
transfected with the siCAS complexed with the DharmaFECT (Positive control, 
middle panel), and FAPol13 (Right panel) according to the standard procedure (final 
siRNA concentration = 100 µM) and treated for 2.5 days. The cells were detached, 
rinsed, and stained with annexin V
iodide (PI) before flow cytometer detection. A) The representative result from the co
staining was plotted into the two
and Q1-low right (LR)) stood for collection of the apoptotic cells. B) Statistical
of the survived KB cells after treatment. Mean ± SEM. (n=3). Student 
performed by Graphpad Prism. *** (P<0.001), * (P<0.05).
 
siRNA-based therapy holds great potential to treat many types of diseases 
including cancer. Efficient and target cell
is the key for future therapeutic applications of siRNA. 
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In this chapter we have demonstrated: (1) the efficient siRNA delivery via 
FAPol13 into FR+ cells (i.e., KB, HeLa, and SKOV3); (2) the dose-dependent and FR-
dependent siRNA Delivery; (3) the significant gene down-regulation upon FAPol13 
delivered siRNA against human survivin (~60%) and Gaussia luciferase (~70%); (4) the 
non-toxicity of the FAPol13; (5) induction of KB cells into apoptosis upon FAPol13 
delivered siCAS; (6) a CLSM-based effective system to assess siRNA intracellular 
trafficking processes (cellular binding, endocytosis, and endosomal escape).   
Taken together, the non-immunogenic and biocompatible folate-conjugated 
copolymer FAPol13 may be used to construct efficient siRNA delivery systems for 
cancer therapeutic applications. 
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CHAPTER VI 
CORRELATION OF FOLATE RECEPTOR EXPRESSION LEVEL  
AND FAPOL13/SIRNA DELIVERY EFFICIENCY 
Introduction 
Folate receptor (FR), a glycosylphosphotidylinositol (GPI)-anchored glycoprotein, 
specifically binds to its ligand, folate, with high affinity. 101s FR in human has at least 
three homologous isoforms, hFR-α, hFR-β and hFR-γ with 70-80% amino acid similarity 
in sequences 227 and distinct developmental expression patterns.134 
The reduced-folate carrier (RFC) 228 is another folate transporter. RFC is a 
membrane-spanning protein 131 and transports reduced folate into cells via carrier-
mediated mechanism, distinct from receptor-mediated endocytosis of FR. Most of 
classical antifolate drugs are rapidly transferred across the plasma membrane by this 
mechanism, leading to inhibition of their target in both tumors and normal proliferating 
tissues. 229  
FR overexpresses in some epithelial tumors, such as ovary, cervical, mammary 
gland, breast colon, prostate, lung, kidney, nose, throat, and brain etc; whereas it has a 
restricted distribution in normal tissues. In addition, FR can bind with FA conjugates with 
similar binding affinity and assist their transport across the plasma membrane via 
endocytosis. These unique properties have been utilized to facilitate the delivery of a 
broad range of therapeutic agents into various cancers.  
Thus, FR-mediated system can specifically, efficiently deliver folate-drugs into FR-
positive cancer cells to correct or eliminate aberrant gene expression. The expression of 
FR on cell surface is the prerequisite to the success of therapeutics. Recently, evidence 
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shows that a subtype of macrophage cell has elevated FR expression when encountered 
stimuli, and importantly, its expression could vary upon the environment or situation 
changes accordingly.101c Other finding displays that the expression of FR is also affected 
by the surrounding FA concentration. 134 For example, the mRNA level of FR in KB and 
JEG-3 cells doubles when folate concentration reduces. 134 In addition, FR expression 
increases along with tumor progressing, 230 and FR expression patterns in tumor cell lines 
could not reflect the virtual FR expression in vivo. 134 These findings suggest that the FR 
expression level or patterns is critical for evaluating the utility potential of FR-mediated 
delivery and predicting the outcomes of FR-targeted therapeutics. 
A large body of evidence has shown high expression level of FR in KB cells and 
negligible expression level in A549 cells, 231 which explains researchers use this pair of 
cell lines as a model to illustrate the delivery of FA-conjugates. HeLa and SKOV3 are 
both FR positive cell lines. In Chapter V, we have presented data to support the FR-
mediated delivery of FRPol13/siRNA into KB, HeLa, and SKOV3 cells. The findings 
show the relatively low expression level of FR in HeLa and SKOV3 cells compared to 
that of KB cells. However, the relationship of FR expression with binding efficiency, 
uptake efficiency, and the overall RNAi efficacy remains elusive.  
To address those issues, comparative studies have been employed among KB, 
HeLa, SKOV3, and A549 cells. Firstly, FR mRNA and protein levels were quantified 
through real-time PCR and flow cytometry. Secondly, the binding (2 h incubation) and 
internalization (24 h incubation) of FAPol13/fluorophore labeled siRNAs were measured 
via microscopy and flow cytometry. Thirdly, free FA competition assay were carried out 
to “mimic” less FR availability would abolish the internalization of polyplexes. Lastly, 
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luciferase assay was utilized to demonstrate that the RNAi effects from the internalized 
siRNAs were also correlated with the FR expression in both transient and stable 
transfection systems. 
 
Result and Discussion 
Quantification of FR Expression in Human Cancer Cell Lines 
Firstly, real-time PCR was utilized to measure the human FR alpha gene (hFRα) 
expression in KB, HeLa, SKOV3, and A549 cells (Figure VI-1A). As reported in Figure 
IV-1, the A549 cells rarely express hFRα. Thus, the Ct value (the number of cycles 
required for the fluorescence signals across the threshold) of hFRα in A549 about 15 
cycles bigger than that of KB cells, indicating the nearly undetectable hFRα in this cell 
line. Compared to the expression level of a human housekeeping gene, hFRα mRNA 
level in A 549 cells is ~1.5 × 10-4 % of β-Actin mRNA level; whereas in KB cells hFRα 
is 41% (Figure VI-1A).  
Because FR protein is the direct executor for FA transportation, after determining 
the mRNA expression level of hFRα, its protein level in 4 cell lines was further assessed 
by flow cytometer (Figure VI-1B). To perform this experiment, a monoclonal antibody 
against the human FR was utilized to recognize proteins on cell membrane, then the 
secondary antibody, goat anti-mouse FITC conjugate antibody, was sequentially bind to 
the primary antibody (mouse origin). The fluorescence from the FITC was detected by 
flow cytometer. Through this procedure, the total FR protein level was obtained. To 
facilitate the comparison, the ratio of FITC-fluorescence (Signal, S) over the auto-
fluorescence (Noise, N, background) was plotted. The ratio should be correlative with the 
  
FR protein level. The S/N ratios in KB, HeLa, SKOV3 and A549 are 329.1, 166.0, 6.9, 
and 1.7 respectively.  
Figure VI-1. Comparison of h
time PCR analysis. (B) Flow cytometry
(n=4).  
 
Comparison of the expression of hFR
similarity: KB>HeLa>SKOV3>>A549. Interestingly, in protein level, there is 4
difference between SKOV3 and A549 cells. Whereas, in mRNA level, this 
difference. Assuming PCR amplification efficiency is 100%, 
fold. This discrepancy would be explained by post
translational modification mechanisms. Additionally, a group reported 
from KB cells is 4 fold of that in SKOV3 cells quantitated by PCR
there is 4.8 Ct difference (~32 fold). Regarding the heterogeneity of cells, the maintained 
cell lines, the sensitivity of the regular PCR and real
from two groups is understandable.
 
 
 
uman folate receptor expression in cancer cells.
 quantification. The data represents mean ± S
α in mRNA and protein levels shows 
nine cycles equal to 200
-transcriptional modification, or post
that hFR
. 
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Quantification of the Absorption of FAPlo13/Cy3-(FAM-) siRNA in Cell Lines 
Once we determined the different FR expression level among cell lines, 
considering the FR-dependent delivery, we propose that different binding, uptake 
efficiency of FAPol13/siRNA in cell lines would be variable accordingly. In addition, my 
previous imaging studies had shown unequal associated fluorescence intensities from 
these 4 cell lines. To confirm this hypothesis, the absorption (Figure VI-2) and 
internalization (Figure VI-3) of FAPol13/siRNA polyplexes were evaluated in 4 cell lines 
via fluorescence microscopy and flow cytometry.  
In Figure VI-2, the data show that FAPol13/Cy3-siRNA (Figure VI-2 A-D) and 
FAPol13/FAM-siRNA (Figure VI-2 E-H) bind with the FR+ positive cells after 2h 
incubation. The associated fluorescence exhibited different intensities. KB cells have the 
highest fluorescence intensity (FI), then the HeLa, and SKOV3. There is barely 
fluorescence seen in A549 cell some from the nonspecific binding, which is common and 
has been discussed in previous chapters. The associated fluorescence is then quantitated 
by ImageJ software and plotted into the Figure VI-2 I (Cy3) and Figure VI-2 J (FAM). 
All the FI has been subtracted to the background FI and normalized to the FI of A549 (FI 
of A549 = 1). In Figure VI-2I, the relative FIs on KB, HeLa, and SKOV3 cells are 4.2, 
3.4, and 1.8 respectively. Likewise, the relative FIs from FAM dyes on KB, HeLa, and 
SKOV3 cells are 3.2, 2.8, and 2.6, which displays the same trends of absorbed 
complexes: KB > HeLa > SKOV3 > A549. 
 
  
Figure VI-2. Fluorescence intensity
siRNA is either Cy3 labeled (A
SKOV3 (C, G) and A549 (D, H) cells were seeded onto glass
transfection. FAPol13/siRNA complexes (final siRNA = 100 nM) incubated the cells for 
2 hours. Cells were washed and imaged. 
were quantified by ImageJ software, and plotted. The data represents mean ± SEM (
Scale bar = 10 µm. 
 
Quantification of the Uptake of 
The absorption of the polyplexes by the cells will be followed by internalization if 
the binding is specific. In 
binding of polyplexes in 4 cells lines. The distinct uptake/internalization of polyplexes 
 
 analysis of cellular bound FAPol13/siRNA
-D) or FAM labeled (E-H). KB (A, E), HeLa (B, F), 
-bottomed wells 24h before 
(I, J)The associated fluorescence intensities (FI) 
Polyplexes in Cell Lines  
Figure VI-2 we have demonstrated the different degrees of 
119 
 
. The 
n=4). 
120 
 
 
 
follows the rationality and is examined here (Figure VI-3). Flow cytometer was applied 
to quantitate the intercellular FAPol13/FAM-siRNA after 24 h incubation.  
In Figure VI-3A, the black lines stand for the cell background (no treatment), 
whereas the red lines are the samples. If the red line is on the right of black line, that 
indicates the stronger fluorescence intensity. The internalization of polyplexes accounts 
for this augment. In addition, the degree of right-shift in KB cells is slightly bigger than 
that in HeLa cells and in SKOV3 cells. In A 549 cell, two lines are nearly overlapped, 
suggesting non-internalization of polyplexes occurs in this FR negative cells.  
The medium fluorescence intensity (MFI) from three repeats is measured and 
plotted into Figure VI-3B, displaying 2666.9, 2408.0, 1782.2, 488.4 units in KB, HeLa, 
SKOV3, and A549 cells respectively. If those numbers are normalized to A549, then the 
ratios will be 5.5, 4.9, 3.7, and 1. This number can be depicted as, for example, 5.5 fold 
polyplexes have been internalized into KB cells compared to A549 cells. 
The trend of the internalized fluorescence and the trend of the bound fluorescence 
are the same: KB> HeLa> SKOV3>A549. The difference, however, is not exactly the 
same. That would result from FR expression variation from different cell passage 
number, incubation time-associated the FR changes. Nevertheless, the trend from the 
associated siRNA and internalized siRNA are consistent with FR expression level among 
those four cell lines, indicating the correlation between the FR levels with the siRNA 
delivery.   
 
  
Figure VI-3. Quantification
HeLa, SKOV3, and A549 were plated into plates one day before transfection with ~40% 
confluency. FAPol13/FAM
treated the cells for 24h before detection. A) The
lines were exhibited. The black lines are the background signal (cellular auto
fluorescence); whereas the red lines are the signals from the samples. B) The mean 
fluorescence intensity (MFI) from repeated experimen
mean ± SEM (n=3). 
 
 
Inhibition of the Cellular 
In the previous results, we have demonstrated that the entry of FAPol13/siRNA to 
KB is FR-dependent because: 
(2) the Pol13 (the copolymer carrier without FA conjugation) cannot deliver the siRNA; 
(3) the presence of FA (1 mM) blocks gene downregulation. However, the relationship of 
FA concentration and inhibitive effe
various FR expression level.  
To examine the correlation, free FA was added into the medium 1h before 
transfection of FAPol13/FAM
 
 of the internalized polyplexes in human cancer cells
-siRNA polyplexes (final siRNA concentration = 100 nM) 
 representative histogram plots of 4 cell 
ts was plotted. The data represents 
Internalization of Polyplexes by Free Folic Acid
(1) the polyplexes cannot enter the FR deficient A549 cells
cts are not clear, especially in different cells with 
 
-siRNA polyplexes (siRNA concentration = 100 nM) to 
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make the final concentration of 1 mM, 0.2 mM, and 0.04 mM along with the control (no 
treatment). After 24 h incubation, the cells were trypsinized and the internalized 
complexes were evaluated by flow cytometer (Figure IV-4). As expected, the presence of 
free FA greatly reduced the uptake of the polyplexes in the FR+ cells. In contrast, it 
showed non-detectable effects in A549 cells. It is noted that a higher concentration of 
free FA led to stronger inhibitive effects on the internalization. 
KB HeLa SKOV3 A549
0
2000
4000
6000 1mM
0.2mM
0.04mM
0mM
M
FI
 
Figure VI-4. Free folate inhibition assay. KB, HeLa, SKOV3, and A549 were seeded in 
plates 24 h before transfection with ~40% confluency.  One hour prior to the transfection, 
free FA were added into the medium to make the final concentration 1 mM, 0.2 mM, and 
0.04 mM. FAPol13/FAM-siRNA polyplexes treated and incubated the cells for 24h 
before flow cytometry detection.  
 
A calculation was performed based on the assumption that 1 mM of FA could 
invariably block >99% of binding/uptake of FA conjugate 232. The results show that 95.7% 
and 90.1% internalization of polyplexes in KB cells, 91.5% and 81.9% internalization of 
polyplexes in HeLa cells; 85.6% and 54.7% internalization of polyplexes in SKOV3 are 
blocked by incubation of 0.2 mM and 0.04 mM FA respectively. As for the expression 
levels (Figure VI-1), a correlation is indicated that a higher expression of FR (e.g., in KB) 
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is correlated with more activated FR-mediated uptake, and therefore stronger inhibition 
effects from the competitor—FA. In other words, cancer cells with higher FR expression 
are susceptible to the competition from free FA.  
Studies of Gene Downregulation Efficiency in Cell Lines 
Previous data indicate that the binding/update of polyplexes (Figure VI-2 and VI-
3) is correlative with the FR expression level (Figure VI-1), and the inhibition effect 
from free FA is also relative to the FR expression level (Figure VI-4). RNAi effects from 
the internalized siRNA should also follow this rule. To test it, both transient (Figure VI-
5) and stable (Figure VI-6) transfection have been implemented. The Gaussia luciferase 
reporter system is utilized here because of its accurate, rapid, and sensitive measurement.  
The principle and utility of transient transfection system have been discussed and 
detailed in Chapter VI. In this case, four cell lines were transfected with the plasmid 
pCMV-Gluc that encodes the Gaussia luciferase by conventional transfection agent — 
DharmaFECT. The cells were rinsed 6 h later and waiting for second transfection. The 
polyplexes (FAPol13/siGLuc) were added into the medium and incubated with cells for a 
period of time (1 to 4 days) before the luciferase detection.  
124 
 
 
 
KBHe
La
SK
OV
3
A5
49 KBHe
La
SK
OV
3
A5
49 KBHe
La
SK
OV
3
A5
49 KBHe
La
SK
OV
3
A5
49
0.0
0.5
1.0
1 day
2 day
3d
4d
 *
Re
la
tiv
eG
lu
c 
Ac
tiv
ity
 
(%
)
 
Figure VI-5. Transient transfection of pCMV-Gluc and siGLuc in human cancer cells. 
KB, HeLa, SKOV3, and A549 were seeded on the plates one day before the transfection 
with ~40% confluency. The cells were first transfected with DharmaFECT/pCMV-Gluc 
(1 µg) for 6 h. The medium was replaced and the cells were rinsed and incubated for 2 h. 
FAPol13/siGLuc polyplexes (siRNA concentration = 100 nM) were prepared and added 
into the medium. The Gluc activity was assessed at 1, 2, 3, and 4 day. The Relative Gluc 
activity was normalized to non-siGLuc treated (plasmid transfected) control. The data 
represents mean ± SEM (n=3). 
 
As shown in Figure VI-5, the relative Gluc activity in A549 is barely affected 
upon the siGLuc treatment in 4 days because FA-linked polyplexes cannot enter into FR 
negative cells. In contrast, in all three FR positive cell lines, the relative Glu activities 
have been reduced. In addition, along with time processes, RNAi effects increase. For 
instance, in KB cells, 76%, 64%, 54%, 49% of Gluc activity remains after 1, 2, 3, and 4 
day treatment. Importantly, at each time point, RNAi effect is correlated with the FR 
expression level. For example, after 3-day incubation, Gluc activity has been reduced to 
59%, 65%, 74%, and 91% in KB, HeLa, SKOV3 and A549 cells respectively. This 
correlation between the RNAi effects and FR expression level suggests: (1) the FR-
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mediated siRNA uptake; (2) the FR expression level determines the therapeutic efficacy 
of the delivered drugs.  
To confirm the correlation between RNAi effects and FR expression, a new stable 
cell line, SKOV3 cells that constitutively expresses Gluc, is established and denoted as 
Gluc-SKOV3. Therefore, experiments were conducted in Gluc-KB and Gluc-SKOV3, 
which have different expression level of FR. If the FR expression level is the key factor 
for determining the downstream RNAi effects, the degrees of gene downregulation from 
transfection of polyplexes should be distinct, and KB-Gluc should have better RNAi 
efficacy.  
To test this hypothesis, FAPol13/siGLuc (siRNA concentration = 100 nM) 
polyplexes were transfected into Gluc-SKOV3 and Gluc-KB and the relative Gluc 
activity was determined at 1 day and 2 days. As shown in Figure VI-6, after 2d 
incubation of polyplexes, 35% and 65% Gluc activities remained in Gluc-KB and Gluc-
SKOV3 respectively. Approximately, 60% and 80% Gluc activity remains in Gluc-KB 
and Gluc-SKOV3 cells at 1d incubation.  The findings shows better RNAi efficacy in 
Gluc-KB cells compared to Gluc-SKOV3, suggesting a good correlation of FR 
expression level with RNAi effects from FR-mediated siRNA delivery.  
126 
 
 
 
Glu
c-
KB
Glu
c-
SK
OV
3
Glu
c-
KB
Glu
c-
SK
OV
3
0.0
0.2
0.4
0.6
0.8
1.0
1 day
2 day
Re
la
tiv
e
G
lu
c
 
Ac
tiv
ity
 
(%
)
 
Figure VI-6. Comparative studies of gene downregulation upon FAPol13/siGLuc 
treatments in Gluc-KB and Gluc-SKOV3 cells. Cells were plated in plates one day before 
transfection with ~40% confluency. Cells were transfected with polyplexes (siRNA 
concentration = 100 nM) and incubated for two days. The Gluc activity was detected 
after one and two day incubation by Gluc assay. The relative Gluc activity was calculated 
by normalization of non-transfected controls. The data represents mean ± SEM (n=3). 
 
Conclusions 
Increasing lines of evidence show that FR expression on cell surfaces would vary 
upon condition changes. High expression level of FR might be a key factor for successful 
delivery of therapeutic drugs in tumors through FR-mediated strategies. To demonstrate 
this concept, we take advantage of four human cancer cell lines: KB, HeLa, SKOV3 and 
A549, which have different FR expression level, to study binding, internalization of 
FAPol13-assisted siRNA delivery. Utilizing fluorescence microscopy and flow 
cytometry, we have demonstrated a correlation between FR expression and efficiency of 
binding and internalization of polyplexes in different cells. Subsequently, transient and 
stable transfection systems combined with luciferase reporter were employed to study the 
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gene downregulation of Gluc activity upon transfection with siRNA. The findings 
confirmed the previous conclusion and strongly indicate that high FR expression level is 
crucial for significant RNAi effects in FR-dependent siRNA delivery systems. The 
competition studies suggest that low FR expression level or less available FR on the cell 
surface will compromise the delivery efficiency. 
Taking FAPol13 as a model, our results reveal a correlation between FR 
expression and absorption/internalization of FA-functionalized therapeutic agents; 
highlighting the importance of clarification of FR expression level when performing FR-
dependence drug delivery strategies.  The finding suggests that we can increase delivery 
efficiency and thereby enhance therapeutic effects through inducing FR expression (e.g., 
stimulation, folic acid starvation).   
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CHAPTER VII 
DELIVERY OF AU NANOPARTICLE-SIRNA IN CANCER CELLS 
Introduction 
The nonviral siRNA delivery system, 92b, 233 such as liposome, dendrimers, 
polycations (i.e., PEI), copolymers, and Au nanoparticles (AuNPs), harbors the several 
advantages over the viral system, such as bio-safety, non-immunogenicity. 97a, 234 
Typically, the nonviral siRNA carriers are cationic for the purpose of complexing with 
anionic nucleic acid and increasing the transfection efficiency. Although the cationic 
carrier/siRNA complexes (N/P > 1) have the higher delivery efficiency by the nature of 
plasma membrane, their interactions with membrane and serum proteins that are required 
for cell maintenance would result in non-specific binding or internalization, which 
compromise the targetability of delivery. While the neutral complex (N/P = 1) hold the 
equilibrium between the transfection efficiency and specificity: having higher delivery 
efficiency than anionic complex, and higher specificity than cationic complex. 
Over the past decades, AuNPs have been widely employed in chemistry, biology, 
engineering, and medicine 235 by virtue of controllable size, shape, facile surface 
modification, and unique optical properties. 235b Therefore, they have been applied to 
imaging, optical and electrochemical sensing, diagnostics, and diseases therapy (e.g., 
cancer, Alzheimer, AIDS, hepatitis, arthritis, diabetes). 236 Recently, a few lines of 
evidence display its great potential in delivering siRNA for cancer treatment. For 
instance, Mirkin group synthesized and characterized a polyvalent AuNPs that are 
modified with thiolated RNA duplexes and capable of inducing the RNAi pathway. 237 
These highly anionic particles can enter into cells through absorbing of serum proteins 
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(opsonization), rather the transfection reagent, which confers the cellular uptake and 
sequential gene downregulation in HeLa cells. 237 Nagasaki group generated a type of 
AuNP with poly(ethylene glycol)-block-poly(2-(N,N-dimethylamino)ethyl methacrylate) 
copolymer (PEG-PAMA), which was further functionalized by immobilization of siRNA 
bearing a thiol group. 238 The RNAi activity from the uptake of this AuNP-siRNA was 
demonstrated in HuH-7 cells. 238  
One main advantage of AuNPs as a scaffold for siRNA delivery is its high 
loading capacity. For example, in case of FAPol13 (refer to Chapter V), there are 2-3 
copolymer molecules per one 59-nt siRNA. However, an AuNP with ~13 nm gold core 
can easily load up to dozens of siRNA cargoes. Through this, we can achieve much 
higher intracellular siRNA concentration if the equal amounts of siRNA complexes have 
been internalized. 
Although promising, AuNPs have some drawbacks in synthesizing their 
stabilizing ligands, which have the poorly-defined molecular weight (MW) control of 
polymerization. Nevertheless, reversible addition-fragmentation chain transfer 
polymerization, a controlled polymerization technique, has the abilities to control MW, 
synthesize complex architectures (i.e., blocks, stars, grafts), and maintain a narrow 
polydispersity. 188d, 239 A polymer stabilized AuNP had been rationally designed and 
synthesized by this technique in our collaborative laboratory. 188d   
In this AuNP, a copolymer poly(N-2-hydroxypropyl methacrylamide70-block-N-
[3-(dimethylamino)propyl] meth- acrylamide24) (P(HPMA70-b-DMAPMA24)) (Mn = 
15000, PDI = 1.08) 188a is utilized as a AuNP stabilizing ligand. 188d  P(HPMA) block is 
chosen because: (1) its hydrophilicity prevents AuNP aggregation; (2) its stability confers 
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the steric protection of siRNAs against the enzymatic degradation; (3) its neutral property 
diminishes opsonization. On the other hand, the cationic DMAPMA block renders the 
sites for the electrostatic complexation of anionic siRNA. These advantages of copolymer 
have been elaborated in Chapter V when we discuss the properties of FAPol13. 
As a result, this AuNP can encapsulate the therapeutic potential siRNAs 
electrostatically and form neutral a soluble polyplexes, AuNP/siRNA. The AuNP/siRNAs 
display significant stability in biological medium because the enzymatic tests 
demonstrate approximately 100 times increased protection effects compared with free 
siRNAs. 188d Additionally, AuNP/siRNAs readily enter a series of human cancer cells 
without assistance from transfection agents, and knowdown Gluc expression in Gluc-KB 
cells. 188d   
 
Result and Discussion 
The Characterization of AuNP 
The surface charge and relevant hydrodynamic diameter (Dh) of the P(HPMA70-b-
DMAPMA24) and AuNP were measured by zeta potential and dynamic light scattering 
(DLS) respectively.  The zeta potential of P(HPMA70-b-DMAPMA24) and AuNP are 19 
mV and -1.1 mV. As expected, P(HPMA70-b-DMAPMA24) has a positive surface change 
due to the presence of cationic DMAPMA block. In contrast, P(HPMA70-b-DMAPMA24) 
stabilized gold nanoparticle exhibits near-neutral zeta potential, indicating the DMAPMA 
repeats are segregated close to the Au and hidden inside AuNPs as depicted in Scheme 
VII-1. On the other side, the Dh of AuNP is 29 nm, significantly larger than the Dh of 
P(HPMA70-b-DMAPMA24) which is 3.8 nm, further confirming the formation of 
  
complexed architecture as illustrated in 
presumably because after DMAPMA block interacts with the Au co
chains become extended due to steric repulsion
(DAu) determined by transmission electron microscopy (TEM) and small
scattering is 6.5 nm and 7.8 nm respectively 
 
Scheme VII-1. Schematic depiction 
 
Complexation of AuNP and siRNA
To test whether this AuNP has the ability of a gene delivery carrier, the 
complexation with siRNAs was first explored. Due to the cationic property of t
DMAPMA, the siRNA will bind to this block and be close to the gold core as illustrated 
in the Scheme VII-1. Because a fraction of the DMAPMA groups has been used to 
reduce and activate Au, the preparation of 
based on the calculated charge of AuNP. In another words, the actual 
complexes should be greater than 1. 
To determine the neutral point, a series of AuNP/siRNA polyplexes were 
complexed and analyzed by gel electrophoresis with ethidium bromide (E
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data show that the N/P ratio for neutral complexes is between 1.8 and 1.9 where siRNA is 
restricted in the wells, suggesting approximate 46% of DMAPMA repeats have been 
utilized for Au reduction, and 54% is available for siRNA complexation
 Once the neutral point is determined, the available cationic change of DMAPAM 
would be figured out and applied to future neutralization. Besides its ability of 
complexing siRNAs, AuNP could also form a complex with plasmid DNAs as shown in
Figure VII-1. Two plasmids, pCMV
which are used for stable cell line establishment discussed in Chapter IV are utilized to 
exemplify it.  
Figure VII-1. Agarose/EtBr electrophoresis analysis of AuNP
plasmids, pCMV-Gluc (left) and pAcGFP1
AuNP to form neutral complexes according to the
complexes were analyzed along with the uncomplexed plasmid.  Each lane contains 33 
pmol siRNA. Each lane contains approximate 166 ng plasmid DNA.
 
After complexation with the AuNP, siRNA acquires the capability to resist
RNase, which is confirmed by degradation studies
complexed siRNA were exposed to a
 
.
-Gluc (5764 bp) and pAcGFP1-MemHyg (5846 bp) 
 
/plasmid complexes. Twp 
-MemHyg (right), were complexed with 
 cationic change of AuNP
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then assessed by UV/Vis spectroscopy monitored at 260 nm wavelength. If the 
nucleotides are degraded, the absorbance increases. The results demonstrate that AuNP 
confer ~100 fold long half-life time than that of the free siRNAs.188d 
Uptake of AuNP/siRNA Complexes by Human Cancer Cells 
The internalization of AuNP/siRNA complexes in several human cancer cells was 
evaluated by fluorescence microscopy (Figure VII-2). The cell lines include KB, HeLa, 
SKOV3 and A549 (refer to Chapters V and VI). The neutral complexes were prepared by 
mixing AuNP and Cy3-labeled siRNA against human Survivin gene and added into 
medium for 40 min. Following incubation, cells were rinsed thoroughly with pre-warmed 
PBS for three times to remove free complexes and fixed by polyformaldehyde and 
stained with DAPI. As seen in Figure VII-2 A-D, all cell lines treated with siRNA/AuNP 
complexes exhibited red fluorescence, indicating internalization of siRNA. Since lacking 
of FA conjugation, the complexes cannot distinguish the folate receptor positive cells 
(KB, HeLa, SKOV3) and FR negative cell (A549), which is a principal difference 
between this AuNP/siRNA and aforementioned FAPol13/siRNA. By contrast, the KB 
cells treated with uncomplexed Cy3-siRNA display negligible fluorescence (Figure VII-
2E), suggesting the prerequisite of AuNP in siRNA delivery. Generally, some nonspecific 
binding signals from the free fluorophore-labeled siRNA incubation will be observed 
from such control panel. Here, such background has been normalized by adjusting the 
contrast settings to all the images.   
  
Figure VII-2. Imaging analysis of the cellular
cells, (B) HeLa cells, (C) SKOV3 cells, and (D) A549 cells
complexes. (E) KB cells incubated with uncomplexed Cy3
The cells were plated onto the glass
neutral complexes (N/P = 1.85) were added to the cell media to give 
concentration of cy3-labeled siRNA. After 40 min incubation, the cells were washed, 
fixed with 4% paraformaldehyde, mounted, and stained with DAPI. The imaging was 
conduct through Zeiss LSM 510 confocal with 40X/1.3 oil lens. Scale bars 
 
 
 uptake of AuNP/Cy3-siRNA
 were incubated with 
-siRNA serves as a control. 
-bottom wells 24 h before transfection. Then the 
100 nM 
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Our data also show, surprisingly, serum proteins are dispensable for the uptake of 
AuNP/siRNA complexes from the studies of fluorescence microscope and gene 
downregulation (Figure VII-3). In contrast to the serum-dependent AuNP reported by 
Mirkin group, 237  the difference presumably stems from the distinct surface properties of 
complexes. In their work, thiolated siRNA is covalently conjugated to AuNPs which is 
further coated with oligoethylene glycol-thiol (OEG-thiol) for stabilization; 237 while in 
our system, siRNA electrostatically bind to cationic DMAPAM at Au core, and therefore 
is physically excluded from serum proteins by extended, neutral, hydrophilic HPMA 
blocks. In terms of that, our AuNP/siRNA is more stable and has less possibility to cause 
non-specific uptake. Nevertheless, the mechanism for AuNP/siRNA internalization is not 
well understood here and need to be further exploited.  
Gene Downregulation by AuNP/siRNA Treatments in Gluc-KB Cells 
Gene downregulation of a Gluc gene was performed to determine whether siRNA 
could be released from the AuNP carrier once internalized.  The reasons we choose this 
reporter system has been elaborated in previous chapter. As well, a KB cell line stably 
expressing Gaussia luciferase (Gluc-KB) was utilized here.  
Complexes of the AuNP and siGLuc were prepared according to the results from 
electrophoresis studies and incubated the Gluc-KB cells ([siGLuc] = 100 nM) for 6 h 
before changing the cell medium. To test the potential opsonization effect from serum 
proteins, cells were treated with complexes in the presence and absence of serum. The 
luciferase assay was conducted with the medium samples by the virtue of the secretion of 
the Gaussia luciferase after one-day incubation.  
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In addition to the AuNP/siGLuc treatment, the cells have been tested with positive 
and negative controls which contain Gluc-KB cells, siGLuc only, DharmaFECT 
complexed control siRNA (has no siRNA target in mammalian cells), and DharmaFECT 
complexed siGLuc.  All the results have been normalized to the untreated Gluc-KB cells. 
As shown in Figure VII-3, the Gluc activity has been reduced to 53% and 52% after 
AuNP/siGLuc treatment with and without serum protein presence, confirming the update 
of the complexes and the release of siRNAs from the complexes after internalization. As 
expected, incubation of Gluc-KB with DharmaFECT/siCon and siGLuc only does not 
induce the gene downregulation as a result of lacking of siRNA target and internalization 
respectively. Additionally, siGLuc delivered via transfection agent DharmaFECT reduce 
the Gluc activity to 48% of non-treatment control after one-day incubation, and to ~25% 
after two-day incubation 101b, demonstrating the well-designed siRNA. 
The moderate RNAi effects could presumably result from: (i) relative low 
efficiency of uptake of complexes by cancer cells, which is indicated by low associated 
fluorescence intensity (would be evaluated by flow cytometry and microscopy); (ii) 
inadequate release of complexes from the compartments, which would be assessed by 
colocalization analysis and quantified by PCC; (iii) insufficient dissociation of siRNA 
from the complexes because of the steric hindrance from the polymer chains (i.e., 
HPMA). On the other hand, the similar gene downregulation efficiency from serum-
absence treatment suggests that the delivery of AuNP/siRNA in our case is serum-
independent as discussed before.  
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Figure VII-3. Relative Gaussia luciferase (Gluc) protein expression level in Gluc-KB.  
The Gluc-KB cells were seeded in 96-well plate with ~40% confluency 24 h before the 
transfection. The preformed complexes or siRNA were then added into the cell medium 
to make the siRNA concentration of 100 nM. The cell medium was changes 6 h later and 
the cells were kept culturing for 18 h before luciferase activity assay conducted. The 
experimental controls included non-treated, DharmaFECT/siCon, free siGLuc, and 
DharmaFECT/siGLuc treated cells (from left to right). The neutral AuNPs/siGLuc 
complexes (N/P = 1.85) treated the cells at the absence and present of 10% FCS.  Protein 
expression levels were measured 24 h after treatment.  All experiments were repeated in 
triplicate and the error bars represent ± S.D. (n=5). 
 
Time course study shows the best gene downregulation efficiency from 
AuNP/siGLuc occurs after one day, which is different from the two-day optimum of 
FAPol13. This discrepancy suggests the distinct internalization mechanism and 
trafficking processes between these two siRNA delivery strategies.  
Nontoxic AuNP as a siRNA Carrier 
After gene downregulation experiments, the cytotoxicity of AuNP were assessed 
using a CellTitr 96 Aqueous one solution cell proliferation (MTS) assay, which is a 
colorimetric method for determining the number of viable cells in cytotoxicity or 
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proliferation.  The principle of method has been discussed in Chapter IV. Basically, the 
dehydrogenase in the viable cells can convert the MTS substrate to blue/brown formazan 
which is detectable with a plate reader via monitoring absorbance at 490 nm (Ab490); 
while the dying or dead cells cannot reduce the MTS and change the color. Importantly, 
the quantity of product as measure by the amount of Ab490 is proportional to the number 
of living cells.  
 
Figure VII-4. Cytotoxicity studies of Au nanoparticles (AuNPs). KB cells were first 
seeded into a 96-well plate 24 h prior to treatment.  Six different AuNP concentrations 
ranging from 0.5 µM to 100 µM were tested and allowed to incubate for 48 h. A small 
amount (20 µL) of the CellTiter 96 AQueous One Solution Reagent was added directly to 
wells (100 µL) and incubated for 2 hours before recording Ab490 with Synergy 2 multi-
mode microplate reader (BioTeck, Winooski, VT). The relative cell viability has been 
normalized to the non-treated cells. All experiments were performed in triplicate, and 
error bars represent ± S.D. The concentration of DMAPMA utilized in gene delivery 
studies is 1 µM.  
 
As shown in Figure VII-4, AuNP has negligible toxicity over the concentration 
from 0.5 µM to 100 µM regarding the concentration of DMAPMA in the experiments is 
1 µM (to make complexes with N/P=1.85, [siRNA] = 100 nM), suggesting that the AuNP 
0
0.2
0.4
0.6
0.8
1
1.2
0 0.5 µM 1 µM 5 µM 10 µM 50 µM 100 µM
S
u
rv
iv
a
l 
(%
)
[DMAPMA] (µM)
139 
 
 
 
is cyto-friendly and suitable for gene delivery applications. These results are also in 
agreement with morphological observations through microscopy. The biocompatibility of 
AuNP is of fundamental importance for its potential therapeutic, and diagnostic 
applications 236.  
 
Conclusions 
A rational design Au nanoparticle (P(HPMA70-b-DMAPMA24)) is reported here. 
This copolymer is synthesized through aqueous RAFT polymerization and has a narrow 
polydispersity (PDI=1.08), controlled MW (Mn = 15,000), dual-functionalized blocks 
(HPMA for solubility, DMAPMA for polycation), and small size. This copolymer is 
employed as stabilizing ligands of neutral Au nanoparticles (zeta potential = -1.1mV), 
which have a high loading capability for oligonucleotides (siRNA duplexes and plasmid 
DNA) through electrostatic effects. Additionally, the ability of the AuNPs as a siRNA 
delivery vehicle has been intensively investigated and characterized by demonstrating 
cellular uptake of complexes in a variety of human cancer cells without the aid of 
transfection agents, and the downregulation of luciferase activity in Gluc-KB cells. Taken 
together, these findings shred lights on the potential biomedical applications of this 
AuNP. 
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CHAPTER VIII 
FUTURE RESEARCH 
Although major aims of my research have been achieved, there are still some 
aspects of investigations that deserve further exploitation, which are likely to lead to 
other projects. Some remaining questions include: which mechanism of endocytosis 
underlies the delivery of FApol13/siRNA and AuNP/siRNA, how to improve the efficacy 
of endosomal release of FAPol13/siRNA complexes, when and where does the 
dissociation of FApol13/siRNA occur, how to improve of inhibition effects of 
FApol13/siCAS in cell level.   
 
Exploration of Cell Entry Pathways 
Essentially, there are at least five different routes for the entry of macromolecules 
via endocytosis pathway: macropinocytosis, phagocytosis, clathrin-dependent 
endocytosis, caveolae-dependent endocytosis, and clathrin/caveolae-independent 
endocytosis.  Among them, the clathrin-mediated and caveolae-mediated deliveries are 
the major routes for the uptake of polyplexes and lipoplexes.  
In recent years, numerous innovative drug/gene delivery strategies have emerged 
and exhibited great potential in biomedical applications. In many systems, the mechanism 
for the cellular internalization of complexes is mainly elusive. For example, in the cases 
of peptide transduction domain (PTD)/dsRNA binding domain (DRBD)/siRNA delivery 
system from Dowdy group, the serum protein-dependent AuNP from Mirkin group, and 
serum protein-independent AuNP from our group, the membrane penetration machinery 
is not well understood.  
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To this issue, the specific inhibitors to certain enzymes that play roles in special 
entry pathways are valuable and commonly utilized.240 Besides, the energy- or 
temperature-dependence are usually characterized. Combining our expertise in 
fluorescence imaging and colocalization analysis, we might gain plenty of valuable data 
from conducting it. 
 
Spatiotemporal Analysis of the Dissociation of FAPol13/siRNA 
Our data have demonstrated that FAPol13/siRNA polyplexes can release from 
endosome compartment through PCC-equipped colocalization analysis. However, when 
and where dissociation of FAPol13/siRNA occurs in a cell is ambiguous. It is one of the 
important steps for siRNA intracellular trafficking.  
We have an opportunity to clarify it by utilizing a NHS-activated black hole 
quencher (BHQ). BHQ is a dye with absorption range of 550-650 nm and an absorption 
max at 579 nm. BHQ can be facilely conjugated to the backbone of a copolymer (i.e., 
FAPol13). Via complexation with Cy3-siRNA electrostatically, BHQ will quench the 
fluorescence from Cy3 because of their overlapped emission spectrums. Furthermore, this 
BHQ-conjugated FAPol13 can facilitate fluorescence resonance energy transfer (FRET) 
analysis (Cy3: donor, BHQ: acceptor). When the Cy3-siRNA is encapsulated with BHQ-
FAPol13, the fluorescence from Cy3 is invisible; upon release, fluorescence is restored. 
According to this change, the dynamic process of dissociation of polyplex could be 
calculated by FRET. In addition to the colocalization of endolysosome, we can determine 
the cellular distribution of siRNAs or polyplexes. Taken together, the special and 
temporal dissociation of polyplexes within a cell will be evaluated. 
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Improvement of the Endosomal Escape of FAPol13/siRNA 
Complex release in the endosome is the result of interplays between the complex, 
siRNAs, carriers, and compartmental environment, and it is an efficiency-limiting step in 
many nonviral delivery systems. Additionally, endosomal release plays a pivotal role in 
connecting siRNA uptake and RNAi pathway, and insufficient release might be the major 
reason for the fact that efficient binding and uptake of siRNA yield suboptimal siRNA 
effects. 221, 241 To address this issue, efforts have been dedicated to conjugate pH-
stimulable, 242 temperature-sensible, 243 light-tiggerable, 244 fusogenic245 compounds with 
nanocarriers for spatiotemporally controllable, enhanced releasing of therapeutic 
cargoes.233  
The PCC quantification (PCC48h = 0.51) of endosomal escape of FAPol13/siRNA 
in KB indicates the possible insufficiency. Thus, the conjugation of some fusogenic 
peptides with FAPol13 is recommended.  
 
 
143 
 
 
 
REFERENCES 
 
1. Hanahan, D.; Weinberg, R. A., The hallmarks of cancer. Cell 2000, 100 (1), 57-
70. 
2. (a) Jemal, A.; Siegel, R.; Ward, E.; Hao, Y. P.; Xu, J. Q.; Thun, M. J., Cancer 
Statistics, 2009. Ca-a Cancer Journal for Clinicians 2009, 59 (4), 225-249; (b) Ho, 
Q. T.; Kuo, C. J., Vascular endothelial growth factor: biology and therapeutic 
applications. Int J Biochem Cell Biol 2007, 39 (7-8), 1349-57. 
3. Fitch, M. I.; Turner, F., Ovarian cancer. Can Nurse 2006, 102 (1), 16-20. 
4. Yamamoto, H.; Ngan, C. Y.; Monden, M., Cancer cells survive with survivin. 
Cancer Sci 2008, 99 (9), 1709-14. 
5. Kerbel, R. S., Molecular origins of cancer: Tumor angiogenesis. New England 
Journal of Medicine 2008, 358 (19), 2039-49. 
6. (a) Song, S.; Liu, D.; Peng, J.; Sun, Y.; Li, Z.; Gu, J. R.; Xu, Y., Peptide ligand-
mediated liposome distribution and targeting to EGFR expressing tumor in vivo. 
Int J Pharm 2008, 363 (1-2), 155-61; (b) Kim, B.; Tang, Q.; Biswas, P. S.; Xu, J.; 
Schiffelers, R. M.; Xie, F. Y.; Ansari, A. M.; Scaria, P. V.; Woodle, M. C.; Lu, P.; 
Rouse, B. T., Inhibition of ocular angiogenesis by siRNA targeting vascular 
endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal 
keratitis. Am J Pathol 2004, 165 (6), 2177-85. 
7. (a) Antony, A. C., Folate receptors. Annu Rev Nutr 1996, 16, 501-21; (b) Kalli, 
K. R.; Oberg, A. L.; Keeney, G. L.; Christianson, T. J.; Low, P. S.; Knutson, K. 
L.; Hartmann, L. C., Folate receptor alpha as a tumor target in epithelial ovarian 
cancer. Gynecol Oncol 2008, 108 (3), 619-26. 
8. (a) Scholtka, B.; Schneider, M.; Melcher, R.; Katzenberger, T.; Friedrich, D.; 
Berghof-Jager, K.; Scheppach, W.; Steinberg, P., A gene marker panel covering 
the Wnt and the Ras-Raf-MEK-MAPK signalling pathways allows to detect gene 
mutations in 80% of early (UICC I) colon cancer stages in humans. Cancer 
Epidemiol 2009, 33 (2), 123-9; (b) Salh, B.; Marotta, A.; Matthewson, C.; 
Ahluwalia, M.; Flint, J.; Owen, D.; Pelech, S., Investigation of the Mek-MAP 
kinase-Rsk pathway in human breast cancer. Anticancer Res 1999, 19 (1B), 731-
40. 
9. Thornberry, N. A., Caspases: key mediators of apoptosis. Chem Biol 1998, 5 (5), 
R97-103. 
10. Shi, Y. G., Mechanisms of caspase activation and inhibition during apoptosis. 
Molecular Cell 2002, 9 (3), 459-70. 
11. Johnstone, R. W.; Ruefli, A. A.; Lowe, S. W., Apoptosis: a link between cancer 
genetics and chemotherapy. Cell 2002, 108 (2), 153-64. 
12. Fukuda, S.; Pelus, L. M., Survivin, a cancer target with an emerging role in 
normal adult tissues. Mol Cancer Ther 2006, 5 (5), 1087-98. 
13. Sporn, M. B., The war on cancer. Lancet 1996, 347 (9012), 1377-81. 
14. (a) Kinsella, A. R.; Green, B.; Lepts, G. C.; Hill, C. L.; Bowie, G.; Taylor, B. A., 
The role of the cell-cell adhesion molecule E-cadherin in large bowel tumour cell 
invasion and metastasis. Br J Cancer 1993, 67 (5), 904-9; (b) Behrens, J., The role 
of cell adhesion molecules in cancer invasion and metastasis. Breast Cancer Res 
Treat 1993, 24 (3), 175-84. 
144 
 
 
 
15. Balakin, K. V.; Ivanenkov, Y. A.; Tkachenko, S. E.; Kiselyov, A. S.; 
Ivachtchenko, A. V., Regulators of chemokine receptor activity as promising 
anticancer therapeutics. Curr Cancer Drug Targets 2008, 8 (4), 299-340. 
16. Qian, F.; Vaux, D. L.; Weissman, I. L., Expression of the integrin alpha 4 beta 1 
on melanoma cells can inhibit the invasive stage of metastasis formation. Cell 
1994, 77 (3), 335-47. 
17. Burger, J. A.; Kipps, T. J., CXCR4: a key receptor in the crosstalk between tumor 
cells and their microenvironment. Blood 2006, 107 (5), 1761-7. 
18. Torchilin, V. P., Passive and active drug targeting: drug delivery to tumors as an 
example. Handb Exp Pharmacol 2010,  (197), 3-53. 
19. Matsumura, Y.; Maeda, H., A new concept for macromolecular therapeutics in 
cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and 
the antitumor agent smancs. Cancer Res 1986, 46 (12 Pt 1), 6387-92. 
20. (a) Ferrara, N.; Gerber, H. P.; LeCouter, J., The biology of VEGF and its 
receptors. Nat Med 2003, 9 (6), 669-76; (b) Ferrara, N., VEGF and the quest for 
tumour angiogenesis factors. Nat Rev Cancer 2002, 2 (10), 795-803. 
21. Tassi, E.; Wellstein, A., Tumor angiogenesis: initiation and targeting - therapeutic 
targeting of an FGF-binding protein, an angiogenic switch molecule, and indicator 
of early stages of gastrointestinal adenocarcinomas. Cancer Res Treat 2006, 38 
(4), 189-97. 
22. Evan, G. I.; Vousden, K. H., Proliferation, cell cycle and apoptosis in cancer. 
Nature 2001, 411 (6835), 342-8. 
23. Taylor, A.; Powell, M. E., Intensity-modulated radiotherapy--what is it? Cancer 
Imaging 2004, 4 (2), 68-73. 
24. Sirikantaramas, S.; Asano, T.; Sudo, H.; Yamazaki, M.; Saito, K., Camptothecin: 
therapeutic potential and biotechnology. Curr Pharm Biotechnol 2007, 8 (4), 196-
202. 
25. Basili, S.; Moro, S., Novel camptothecin derivatives as topoisomerase I inhibitors. 
Expert Opin Ther Pat 2009, 19 (5), 555-74. 
26. Mayani, D. D., Proton therapy for cancer treatment. J Oncol Pharm Pract 2010. 
27. Rochlitz, C. F., Gene therapy of cancer. Swiss Medical Weekly 2001, 131 (1-2), 
4-9. 
28. Blaese, R. M., Steps toward gene therapy: 1. The initial trials. Hosp Pract 
(Minneap) 1995, 30 (11), 33-40. 
29. El-Aneed, A., Current strategies in cancer gene therapy. Eur J Pharmacol 2004, 
498 (1-3), 1-8. 
30. Celli, J. P.; Spring, B. Q.; Rizvi, I.; Evans, C. L.; Samkoe, K. S.; Verma, S.; 
Pogue, B. W.; Hasan, T., Imaging and photodynamic therapy: mechanisms, 
monitoring, and optimization. Chem Rev 2010, 110 (5), 2795-838. 
31. Bedognetti, D.; Wang, E.; Sertoli, M. R.; Marincola, F. M., Gene-expression 
profiling in vaccine therapy and immunotherapy for cancer. Expert Rev Vaccines 
2010, 9 (6), 555-65. 
32. Sone, S.; Kuramoto, T.; Sato, S.; Mitsuhashi, A.; Kakiuchi, S.; Goto, H.; Tada, 
H.; Nishioka, Y., [Molecular targeted therapy for cancer]. Nippon Rinsho 2010, 
68 (6), 997-1006. 
145 
 
 
 
33. Christensen, C. L.; Zandi, R.; Gjetting, T.; Cramer, F.; Poulsen, H. S., 
Specifically targeted gene therapy for small-cell lung cancer. Expert Rev 
Anticancer Ther 2009, 9 (4), 437-52. 
34. Cohnheim, J., Congenitales, quergestreiftes Muskelsarkom der Nieren. Virchows 
Archiv 1875, 65 (1), 64-69. 
35. (a) Park, C. H.; Bergsagel, D. E.; McCulloch, E. A., Mouse myeloma tumor stem 
cells: a primary cell culture assay. J. Natl. Cancer Inst. 1971, 46, 411-22; (b) 
Makino, S., Further evidence favoring the concept of the stem cell in ascites 
tumors of rats. Ann. NY Acad. Sci. 1956, 63, 818-30; (c) Bruce, W. R.; Van Der 
Gaag, H., A Quantitative assay for the number of murine lymphoma cells capable 
of proliferation in vivo. Nature 1963, 199, 79-80; (d) Kleinsmith, L. J.; Pierce, G. 
B., Multipotentiality of single embryonal carcinoma cells. Cancer Res. 1964, 24, 
1544-51. 
36. (a) Reya, T.; Morrison, S. J.; Clarke, M. F.; Weissman, I. L., Stem cells, cancer, 
and cancer stem cells. Nature 2001, 414 (6859), 105-11; (b) Al-Hajj, M.; Clarke, 
M. F., Self-renewal and solid tumor stem cells. Oncogene 2004, 23 (43), 7274-82. 
37. (a) Shimono, Y.; Zabala, M.; Cho, R. W.; Lobo, N.; Dalerba, P.; Qian, D.; Diehn, 
M.; Liu, H.; Panula, S. P.; Chiao, E.; Dirbas, F. M.; Somlo, G.; Pera, R. A.; Lao, 
K.; Clarke, M. F., Downregulation of miRNA-200c links breast cancer stem cells 
with normal stem cells. Cell 2009, 138 (3), 592-603; (b) He, S.; Nakada, D.; 
Morrison, S. J., Mechanisms of stem cell self-renewal. Annu Rev Cell Dev Biol 
2009, 25, 377-406; (c) Lobo, N. A.; Shimono, Y.; Qian, D.; Clarke, M. F., The 
biology of cancer stem cells. Annu Rev Cell Dev Biol 2007, 23, 675-99. 
38. Polyak, K.; Hahn, W. C., Roots and stems: stem cells in cancer. Nat Med 2006, 
12 (3), 296-300. 
39. Blick, T.; Hugo, H.; Widodo, E.; Waltham, M.; Pinto, C.; Mani, S. A.; Weinberg, 
R. A.; Neve, R. M.; Lenburg, M. E.; Thompson, E. W., Epithelial mesenchymal 
transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-
) stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia 
2010, 15 (2), 235-52. 
40. (a) Glinsky, G. V., Stem cell origin of death-from-cancer phenotypes of human 
prostate and breast cancers. Stem Cell Rev 2007, 3 (1), 79-93; (b) Stingl, J.; 
Caldas, C., Molecular heterogeneity of breast carcinomas and the cancer stem cell 
hypothesis. Nat Rev Cancer 2007, 7 (10), 791-9; (c) Croce, C. M.; Calin, G. A., 
miRNAs, cancer, and stem cell division. Cell 2005, 122 (1), 6-7. 
41. (a) Ebben, J. D.; Treisman, D. M.; Zorniak, M.; Kutty, R. G.; Clark, P. A.; Kuo, J. 
S., The cancer stem cell paradigm: a new understanding of tumor development 
and treatment. Expert Opin Ther Targets 2010, 14 (6), 621-32; (b) Donnenberg, 
V. S.; Donnenberg, A. D., Multiple drug resistance in cancer revisited: the cancer 
stem cell hypothesis. J Clin Pharmacol 2005, 45 (8), 872-7. 
42. (a) Lagos-Quintana, M.; Rauhut, R.; Lendeckel, W.; Tuschl, T., Identification of 
novel genes coding for small expressed RNAs. Science 2001, 294 (5543), 853-8; 
(b) Ambros, V., microRNAs: tiny regulators with great potential. Cell 2001, 107 
(7), 823-6. 
43. Friedman, R. C.; Farh, K. K.; Burge, C. B.; Bartel, D. P., Most mammalian 
mRNAs are conserved targets of microRNAs. Genome Res 2009, 19 (1), 92-105. 
146 
 
 
 
44. Filipowicz, W.; Bhattacharyya, S. N.; Sonenberg, N., Mechanisms of post-
transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 
2008, 9 (2), 102-14. 
45. Berezikov, E.; van Tetering, G.; Verheul, M.; van de Belt, J.; van Laake, L.; Vos, 
J.; Verloop, R.; van de Wetering, M.; Guryev, V.; Takada, S.; van Zonneveld, A. 
J.; Mano, H.; Plasterk, R.; Cuppen, E., Many novel mammalian microRNA 
candidates identified by extensive cloning and RAKE analysis. Genome Res 
2006, 16 (10), 1289-98. 
46. Riedmann, L. T.; Schwentner, R., miRNA, siRNA, piRNA and argonautes: news 
in small matters. RNA Biol 2010, 7 (2), 133-9. 
47. Valencia-Sanchez, M. A.; Liu, J.; Hannon, G. J.; Parker, R., Control of translation 
and mRNA degradation by miRNAs and siRNAs. Genes Dev 2006, 20 (5), 515-
24. 
48. Moss, E. G., MicroRNAs: hidden in the genome. Curr Biol 2002, 12 (4), R138-
40. 
49. (a) He, L.; He, X.; Lim, L. P.; de Stanchina, E.; Xuan, Z.; Liang, Y.; Xue, W.; 
Zender, L.; Magnus, J.; Ridzon, D.; Jackson, A. L.; Linsley, P. S.; Chen, C.; 
Lowe, S. W.; Cleary, M. A.; Hannon, G. J., A microRNA component of the p53 
tumour suppressor network. Nature 2007, 447 (7148), 1130-4; (b) Martello, G.; 
Rosato, A.; Ferrari, F.; Manfrin, A.; Cordenonsi, M.; Dupont, S.; Enzo, E.; 
Guzzardo, V.; Rondina, M.; Spruce, T.; Parenti, A. R.; Daidone, M. G.; Bicciato, 
S.; Piccolo, S., A MicroRNA targeting dicer for metastasis control. Cell 2010, 141 
(7), 1195-207; (c) Vidic, S.; Markelc, B.; Sersa, G.; Coer, A.; Kamensek, U.; 
Tevz, G.; Kranjc, S.; Cemazar, M., MicroRNAs targeting mutant K-ras by 
electrotransfer inhibit human colorectal adenocarcinoma cell growth in vitro and 
in vivo. Cancer Gene Ther 2010, 17 (6), 409-19; (d) Yu, F.; Yao, H.; Zhu, P.; 
Zhang, X.; Pan, Q.; Gong, C.; Huang, Y.; Hu, X.; Su, F.; Lieberman, J.; Song, E., 
let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 
131 (6), 1109-23. 
50. Tong, A. W.; Nemunaitis, J., Modulation of miRNA activity in human cancer: a 
new paradigm for cancer gene therapy? Cancer Gene Ther 2008, 15 (6), 341-55. 
51. (a) Mishra, P. J.; Merlino, G., MicroRNA reexpression as differentiation therapy 
in cancer. J Clin Invest 2009, 119 (8), 2119-23; (b) Olive, V.; Bennett, M. J.; 
Walker, J. C.; Ma, C.; Jiang, I.; Cordon-Cardo, C.; Li, Q. J.; Lowe, S. W.; 
Hannon, G. J.; He, L., miR-19 is a key oncogenic component of mir-17-92. Genes 
Dev 2009, 23 (24), 2839-49. 
52. Zhang, B.; Pan, X.; Cobb, G. P.; Anderson, T. A., microRNAs as oncogenes and 
tumor suppressors. Dev Biol 2007, 302 (1), 1-12. 
53. Fire, A.; Xu, S.; Montgomery, M.; Kostas, S.; Driver, S.; Mello, C., Potent and 
specific genetic interference by double-stranded RNA in Caenorhabditis elegans. 
Nature 1998, 391, 806-11. 
54. Kim, D.; Rossi, J., Strategies for silencing human disease using RNA 
interference. Nat Rev Genet 2007, 8, 173-84. 
55. Mittal, V., Improving the efficiency of RNA interference in mammals. Nat Rev 
Genet 2004, 5 (5), 355-65. 
147 
 
 
 
56. Napoli, C.; Lemieux, C.; Jorgensen, R., Introduction of a Chimeric Chalcone 
Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous 
Genes in trans. Plant Cell 1990, 2 (4), 279-89. 
57. van der Krol, A. R.; Mur, L. A.; Beld, M.; Mol, J. N.; Stuitje, A. R., Flavonoid 
genes in petunia: addition of a limited number of gene copies may lead to a 
suppression of gene expression. Plant Cell 1990, 2 (4), 291-9. 
58. Sharp, P. A., RNAi and double-strand RNA. Genes Dev 1999, 13 (2), 139-41. 
59. Stark, G. R.; Kerr, I. M.; Williams, B. R.; Silverman, R. H.; Schreiber, R. D., 
How cells respond to interferons. Annu Rev Biochem 1998, 67, 227-64. 
60. Elbashir, S. M.; Harborth, J.; Lendeckel, W.; Yalcin, A.; Weber, K.; Tuschl, T., 
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured 
mammalian cells. Nature 2001, 411 (6836), 494-8. 
61. Kennerdell, J. R.; Carthew, R. W., Use of dsRNA-mediated genetic interference 
to demonstrate that frizzled and frizzled 2 act in the wingless pathway. Cell 1998, 
95 (7), 1017-26. 
62. Ngo, H.; Tschudi, C.; Gull, K.; Ullu, E., Double-stranded RNA induces mRNA 
degradation in Trypanosoma brucei. Proc Natl Acad Sci U S A 1998, 95 (25), 
14687-92. 
63. (a) Yang, S.; Tutton, S.; Pierce, E.; Yoon, K., Specific double-stranded RNA 
interference in undifferentiated mouse embryonic stem cells. Mol Cell Biol 2001, 
21 (22), 7807-16; (b) Elbashir, S. M.; Harborth, J.; Weber, K.; Tuschl, T., 
Analysis of gene function in somatic mammalian cells using small interfering 
RNAs. Methods 2002, 26 (2), 199-213. 
64. Bernstein, E.; Caudy, A. A.; Hammond, S. M.; Hannon, G. J., Role for a bidentate 
ribonuclease in the initiation step of RNA interference. Nature 2001, 409 (6818), 
363-6. 
65. Hammond, S. M.; Bernstein, E.; Beach, D.; Hannon, G. J., An RNA-directed 
nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 
2000, 404 (6775), 293-6. 
66. Martinez, J.; Patkaniowska, A.; Urlaub, H.; Luhrmann, R.; Tuschl, T., Single-
stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 2002, 110 
(5), 563-74. 
67. Meister, G.; Tuschl, T., Mechanisms of gene silencing by double-stranded RNA. 
Nature 2004, 431 (7006), 343-9. 
68. Aravin, A.; Gaidatzis, D.; Pfeffer, S.; Lagos-Quintana, M.; Landgraf, P.; Iovino, 
N.; Morris, P.; Brownstein, M. J.; Kuramochi-Miyagawa, S.; Nakano, T.; Chien, 
M.; Russo, J. J.; Ju, J.; Sheridan, R.; Sander, C.; Zavolan, M.; Tuschl, T., A novel 
class of small RNAs bind to MILI protein in mouse testes. Nature 2006, 442 
(7099), 203-7. 
69. (a) Eddy, S. R., Non-coding RNA genes and the modern RNA world. Nat Rev 
Genet 2001, 2 (12), 919-29; (b) Hall, P. A.; Russell, S. H., New perspectives on 
neoplasia and the RNA world. Hematol Oncol 2005, 23 (2), 49-53. 
70. Pei, Y.; Tuschl, T., On the art of identifying effective and specific siRNAs. Nat 
Methods 2006, 3 (9), 670-6. 
71. Reynolds, A.; Anderson, E. M.; Vermeulen, A.; Fedorov, Y.; Robinson, K.; 
Leake, D.; Karpilow, J.; Marshall, W. S.; Khvorova, A., Induction of the 
148 
 
 
 
interferon response by siRNA is cell type- and duplex length-dependent. RNA 
2006, 12 (6), 988-93. 
72. Holen, T.; Amarzguioui, M.; Wiiger, M. T.; Babaie, E.; Prydz, H., Positional 
effects of short interfering RNAs targeting the human coagulation trigger Tissue 
Factor. Nucleic Acids Res 2002, 30 (8), 1757-66. 
73. Huesken, D.; Lange, J.; Mickanin, C.; Weiler, J.; Asselbergs, F.; Warner, J.; 
Meloon, B.; Engel, S.; Rosenberg, A.; Cohen, D.; Labow, M.; Reinhardt, M.; 
Natt, F.; Hall, J., Design of a genome-wide siRNA library using an artificial 
neural network. Nat Biotechnol 2005, 23 (8), 995-1001. 
74. (a) Saetrom, P.; Snove, O., Jr., A comparison of siRNA efficacy predictors. 
Biochem Biophys Res Commun 2004, 321 (1), 247-53; (b) Zhao, H. F.; L'Abbe, 
D.; Jolicoeur, N.; Wu, M.; Li, Z.; Yu, Z.; Shen, S. H., High-throughput screening 
of effective siRNAs from RNAi libraries delivered via bacterial invasion. Nat 
Methods 2005, 2 (12), 967-73. 
75. (a) Chalk, A. M.; Warfinge, R. E.; Georgii-Hemming, P.; Sonnhammer, E. L., 
siRNAdb: a database of siRNA sequences. Nucleic Acids Res 2005, 33 (Database 
issue), D131-4; (b) Truss, M.; Swat, M.; Kielbasa, S. M.; Schafer, R.; Herzel, H.; 
Hagemeier, C., HuSiDa--the human siRNA database: an open-access database for 
published functional siRNA sequences and technical details of efficient transfer 
into recipient cells. Nucleic Acids Res 2005, 33 (Database issue), D108-11. 
76. Reynolds, A.; Leake, D.; Boese, Q.; Scaringe, S.; Marshall, W. S.; Khvorova, A., 
Rational siRNA design for RNA interference. Nat Biotechnol 2004, 22 (3), 326-
30. 
77. Zamore, P. D.; Tuschl, T.; Sharp, P. A.; Bartel, D. P., RNAi: double-stranded 
RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide 
intervals. Cell 2000, 101 (1), 25-33. 
78. Lum, L.; Yao, S.; Mozer, B.; Rovescalli, A.; Von Kessler, D.; Nirenberg, M.; 
Beachy, P. A., Identification of Hedgehog pathway components by RNAi in 
Drosophila cultured cells. Science 2003, 299 (5615), 2039-45. 
79. Carpenter, A. E.; Sabatini, D. M., Systematic genome-wide screens of gene 
function. Nat Rev Genet 2004, 5 (1), 11-22. 
80. Sioud, M., Therapeutic siRNAs. Trends Pharmacol Sci 2004, 25 (1), 22-8. 
81. Zhang, L.; Yang, N.; Mohamed-Hadley, A.; Rubin, S. C.; Coukos, G., Vector-
based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-
angiogenesis gene therapy of cancer. Biochem Biophys Res Commun 2003, 303 
(4), 1169-78. 
82. Takei, Y.; Kadomatsu, K.; Yuzawa, Y.; Matsuo, S.; Muramatsu, T., A small 
interfering RNA targeting vascular endothelial growth factor as cancer 
therapeutics. Cancer Res 2004, 64 (10), 3365-70. 
83. Hughes, M. D.; Hussain, M.; Nawaz, Q.; Sayyed, P.; Akhtar, S., The cellular 
delivery of antisense oligonucleotides and ribozymes. Drug Discov Today 2001, 6 
(6), 303-15. 
84. Dorsett, Y.; Tuschl, T., siRNAs: applications in functional genomics and potential 
as therapeutics. Nat Rev Drug Discov 2004, 3 (4), 318-29. 
85. Behlke, M. A., Progress towards in vivo use of siRNAs. Mol Ther 2006, 13 (4), 
644-70. 
149 
 
 
 
86. Xie, F. Y.; Woodle, M. C.; Lu, P. Y., Harnessing in vivo siRNA delivery for drug 
discovery and therapeutic development. Drug Discov Today 2006, 11 (1-2), 67-
73. 
87. Kim, V. N., Small RNAs: classification, biogenesis, and function. Mol Cells 
2005, 19 (1), 1-15. 
88. (a) Lotze, M. T.; Kost, T. A., Viruses as gene delivery vectors: application to gene 
function, target validation, and assay development. Cancer Gene Ther 2002, 9 (8), 
692-9; (b) Ni, Y. H., In vivo hepatic gene therapy. Acta Paediatr Taiwan 2001, 42 
(4), 191-200. 
89. Ekblad, M.; Hallden, G., Adenovirus-based therapy for prostate cancer. Curr Opin 
Mol Ther 2010, 12 (4), 421-31. 
90. Brunetti-Pierri, N.; Ng, P., Progress and prospects: gene therapy for genetic 
diseases with helper-dependent adenoviral vectors. Gene Ther 2008, 15 (8), 553-
60. 
91. D'Costa, J.; Mansfield, S. G.; Humeau, L. M., Lentiviral vectors in clinical trials: 
Current status. Curr Opin Mol Ther 2009, 11 (5), 554-64. 
92. (a) Gao, K.; Huang, L., Nonviral methods for siRNA delivery. Mol Pharm 2009, 6 
(3), 651-8; (b) Medina-Kauwe, L. K.; Xie, J.; Hamm-Alvarez, S., Intracellular 
trafficking of nonviral vectors. Gene Ther 2005, 12 (24), 1734-51; (c) Pun, S.; 
Davis, M., Development of a nonviral gene delivery vehicle for systemic 
application. Bioconjug Chem 2002, 13, 630-39. 
93. Smyth Templeton, N., Cationic liposomes as in vivo delivery vehicles. Curr Med 
Chem 2003, 10 (14), 1279-87. 
94. Boussif, O.; Lezoualc'h, F.; Zanta, M. A.; Mergny, M. D.; Scherman, D.; 
Demeneix, B.; Behr, J. P., A versatile vector for gene and oligonucleotide transfer 
into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A 
1995, 92 (16), 7297-301. 
95. Urban-Klein, B.; Werth, S.; Abuharbeid, S.; Czubayko, F.; Aigner, A., RNAi-
mediated gene-targeting through systemic application of polyethylenimine (PEI)-
complexed siRNA in vivo. Gene Ther 2005, 12, 461-66. 
96. Thomas, M.; Lu, J. J.; Ge, Q.; Zhang, C.; Chen, J.; Klibanov, A. M., Full 
deacylation of polyethylenimine dramatically boosts its gene delivery efficiency 
and specificity to mouse lung. Proc Natl Acad Sci U S A 2005, 102 (16), 5679-84. 
97. (a) York, A. W.; Kirkland, S. E.; McCormick, C. L., Advances in the synthesis of 
amphiphilic block copolymers via RAFT polymerization: Stimuli-responsive drug 
and gene delivery. Advanced Drug Delivery Reviews 2008, 60, 1018-1036; (b) 
Park, T. G.; Jeong, J. H.; Kim, S. W., Current status of polymeric gene delivery 
systems. Advanced Drug Delivery Reviews 2006, 58 (4), 467-486; (c) Pack, D. 
W.; Hoffman, A. S.; Pun, S.; Stayton, P. S., Design and development of polymers 
for gene delivery. Nature Reviews Drug Discovery 2005, 4 (7), 581-593; (d) 
Kabanov, A. V.; Kabanov, V. A., Interpolyelectrolyte and block ionomer 
complexes for gene delivery: physico-chemical aspects. Advanced Drug Delivery 
Reviews 1998, 30, 49-60. 
98. (a) Xia, C. F.; Boado, R. J.; Pardridge, W. M., Antibody-mediated targeting of 
siRNA via the human insulin receptor using avidin-biotin technology. Mol Pharm 
2009, 6 (3), 747-751; (b) Wen, W. H.; Liu, J. Y.; Qin, W. J.; Zhao, J.; Wang, T.; 
150 
 
 
 
Jia, L. T.; Meng, Y. L.; Gao, H.; Xue, C. F.; Jin, B. Q.; Yao, L. B.; Chen, S. Y.; 
Yang, A. G., Targeted inhibition of HBV gene expression by single-chain 
antibody mediated small interfering RNA delivery. Hepatology 2007, 46 (1), 84-
94; (c) Vornlocher, H. P., Antibody-directed cell-type-specific delivery of siRNA. 
Trends Mol Med 2006, 12 (1), 1-3; (d) Song, E.; Zhu, P.; Lee, S. K.; Chowdhury, 
D.; Kussman, S.; Dykxhoorn, D. M.; Feng, Y.; Palliser, D.; Weiner, D. B.; 
Shankar, P.; Marasco, W. A.; Lieberman, J., Antibody mediated in vivo delivery 
of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005, 23 (6), 
709-17; (e) Liu, H.; Rajasekaran, A.; Moy, P.; Xia, Y.; Kim, S.; Navarro, V.; 
Rahmati, R.; Bander, N., Constitutive and antibody-induced internalization of 
prostate-specific membrane antigen. Cancer Res 1998, 58, 4055-60; (f) De Potter, 
C. R.; Schelfhout, A. M.; De Smet, F. H.; Van Damme, S.; de Ridder, L.; Dhont, 
E.; van Emmelo, J., A monoclonal antibody directed against a human cell 
membrane antigen prevents cell substrate adhesion and tumor invasion. Am J 
Pathol 1994, 144 (1), 95-103; (g) Courtete, J.; Sibler, A. P.; Zeder-Lutz, G.; 
Dalkara, D.; Oulad-Abdelghani, M.; Zuber, G.; Weiss, E., Suppression of cervical 
carcinoma cell growth by intracytoplasmic codelivery of anti-oncoprotein E6 
antibody and small interfering RNA. Mol Cancer Ther 2007, 6 (6), 1728-35. 
99. (a) Pangburn, T. O.; Petersen, M. A.; Waybrant, B.; Adil, M. M.; Kokkoli, E., 
Peptide- and aptamer-functionalized nanovectors for targeted delivery of 
therapeutics. J Biomech Eng 2009, 131 (7), 074005; (b) Pandey, K. N., Ligand-
mediated endocytosis and intracellular sequestration of guanylyl 
cyclase/natriuretic peptide receptors: role of GDAY motif. Mol Cell Biochem 
2009; (c) Liu, S., Radiolabeled multimeric cyclic RGD peptides as integrin 
alphavbeta3 targeted radiotracers for tumor imaging. Mol Pharm 2006, 3 (5), 472-
87; (d) Blackburn, W. H.; Dickerson, E. B.; Smith, M. H.; McDonald, J. F.; Lyon, 
L. A., Peptide-Functionalized Nanogels for Targeted siRNA Delivery. Bioconjug 
Chem 2009, 20 (5), 960-8. 
100. (a) Ng, E. W.; Shima, D. T.; Calias, P.; Cunningham, E. T., Jr.; Guyer, D. R.; 
Adamis, A. P., Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular 
disease. Nat Rev Drug Discov 2006, 5 (2), 123-32; (b) McNamara, J.; Andrechek, 
E.; Wang, Y.; Viles, K.; Rempel, R.; Gilboa, E.; Sullenger, B.; Giangrande, P., 
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat 
Biotechnol 2006, 24, 1005-15; (c) Levy-Nissenbaum, E.; Radovic-Moreno, A.; 
Wang, A.; Langer, R.; Farokhzad, O., Nanotechnology and aptamers: applications 
in drug delivery. Trends Biotechnol 2008, 26, 442-9; (d) Hicke, B.; Stephens, A.; 
Gould, T.; Chang, Y.; Lynott, C.; Heil, J.; Borkowski, S.; Hilger, C.; Cook, G.; 
Warren, S.; Schmidt, P., Tumor targeting by an aptamer. J Nucl Med 2006, 47, 
668-78; (e) Ferreira, C.; Cheung, M.; Missailidis, S.; Bisland, S.; Gariepy, J., 
Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic 
Acids Res 2009, 37, 866-76; (f) Barbas, A. S.; Mi, J.; Clary, B. M.; White, R. R., 
Aptamer applications for targeted cancer therapy. Future Oncol 2010, 6 (7), 1117-
26; (g) Bagalkot, V.; Farokhzad, O.; Langer, R.; Jon, S., An aptamer-doxorubicin 
physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int 
Ed Engl 2006, 45, 8149-152. 
151 
 
 
 
101. (a) York, A. W.; Huang, F.; McCormick, C. L., Rational Design of Targeted 
Cancer Therapeutics through the Multiconjugation of Folate and Cleavable 
siRNA to RAFT-Synthesized (HPMA-s-APMA) Copolymers. 
Biomacromolecules 2010, 11 (2) 505-14; (b) York, A. W.; Zhang, Y.; Holley, A. 
C.; Guo, Y.; Huang, F.; McCormick, C. L., Facile synthesis of multivalent folate-
block copolymer conjugates via aqueous RAFT polymerization: targeted delivery 
of siRNA and subsequent gene suppression. Biomacromolecules 2009, 10 (4), 
936-43; (c) Xia, W.; Hilgenbrink, A. R.; Matteson, E. L.; Lockwood, M. B.; 
Cheng, J. X.; Low, P. S., A functional folate receptor is induced during 
macrophage activation and can be used to target drugs to activated macrophages. 
Blood 2009, 113 (2), 438-46; (d) Low, P. S.; Kularatne, S. A., Folate-targeted 
therapeutic and imaging agents for cancer. Curr Opin Chem Biol 2009, 13 (3), 
256-62; (e) Yoshizawa, T.; Hattori, Y.; Hakoshima, M.; Koga, K.; Maitani, Y., 
Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor 
xenografts. European Journal of Pharmaceutics and Biopharmaceutics 2008, 70 
(3), 718-25; (f) Sega, E. I.; Low, P. S., Tumor detection using folate receptor-
targeted imaging agents. Cancer Metastasis Rev 2008, 27 (4), 655-64; (g) Lu, Y.; 
You, F.; Vlahov, I.; Westrick, E.; Fan, M.; Low, P. S.; Leamon, C. P., Folate-
targeted dinitrophenyl hapten immunotherapy: effect of linker chemistry on 
antitumor activity and allergic potential. Mol Pharm 2007, 4 (5), 695-706; (h) 
Hwa Kim, S.; Hoon Jeong, J.; Chul Cho, K.; Wan Kim, S.; Gwan Park, T., 
Target-specific gene silencing by siRNA plasmid DNA complexed with folate-
modified poly(ethylenimine). J Control Release 2005, 104 (1), 223-32; (i) Low, P. 
S.; Antony, A. C., Folate receptor-targeted drugs for cancer and inflammatory 
diseases. Adv Drug Deliv Rev 2004, 56 (8), 1055-8; (j) Leamon, C. P.; Reddy, J. 
A., Folate-targeted chemotherapy. Adv Drug Deliv Rev 2004, 56 (8), 1127-41; (k) 
Reddy, J. A.; Low, P. S., Enhanced folate receptor mediated gene therapy using a 
novel pH-sensitive lipid formulation. J Control Release 2000, 64 (1-3), 27-37; (l) 
Lee, R. J.; Low, P. S., Delivery of liposomes into cultured KB cells via folate 
receptor-mediated endocytosis. J Biol Chem 1994, 269 (5), 3198-204; (m) 
Leamon, C. P.; Low, P. S., Selective targeting of malignant cells with cytotoxin-
folate conjugates. J Drug Target 1994, 2 (2), 101-12; (n) Turek, J. J.; Leamon, C. 
P.; Low, P. S., Endocytosis of folate-protein conjugates: ultrastructural 
localization in KB cells. J Cell Sci 1993, 106 ( Pt 1), 423-30; (o) Leamon, C. P.; 
Pastan, I.; Low, P. S., Cytotoxicity of folate-Pseudomonas exotoxin conjugates 
toward tumor cells. Contribution of translocation domain. J Biol Chem 1993, 268 
(33), 24847-54; (p) Leamon, C. P.; Low, P. S., Membrane folate-binding proteins 
are responsible for folate-protein conjugate endocytosis into cultured cells. 
Biochem J 1993, 291 ( Pt 3), 855-60; (q) Leamon, C. P.; Low, P. S., Cytotoxicity 
of momordin-folate conjugates in cultured human cells. J Biol Chem 1992, 267 
(35), 24966-71; (r) Leamon, C. P.; Low, P. S., Delivery of macromolecules into 
living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad 
Sci U S A 1991, 88 (13), 5572-6; (s) Campbell, I. G.; Jones, T. A.; Foulkes, W. 
D.; Trowsdale, J., Folate-binding protein is a marker for ovarian cancer. Cancer 
Res 1991, 51 (19), 5329-38. 
152 
 
 
 
102. Daugherty, A. L.; Mrsny, R. J., Formulation and delivery issues for monoclonal 
antibody therapeutics. Adv Drug Deliv Rev 2006, 58 (5-6), 686-706. 
103. Yu, B.; Zhao, X.; Lee, L. J.; Lee, R. J., Targeted delivery systems for 
oligonucleotide therapeutics. AAPS J 2009, 11 (1), 195-203. 
104. Baker, M., Upping the ante on antibodies. Nat Biotechnol 2005, 23 (9), 1065-72. 
105. (a) Venisnik, K. M.; Olafsen, T.; Gambhir, S. S.; Wu, A. M., Fusion of Gaussia 
luciferase to an engineered anti-carcinoembryonic antigen (CEA) antibody for in 
vivo optical imaging. Mol Imaging Biol 2007, 9 (5), 267-77; (b) Kwong, P.; 
Wyatt, R.; Robinson, J.; Sweet, R.; Sodroski, J.; Hendrickson, W., Structure of an 
HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a 
neutralizing human antibody. Nature 1998, 393, 648-59. 
106. Abes, S.; Moulton, H.; Turner, J.; Clair, P.; Richard, J. P.; Iversen, P.; Gait, M. J.; 
Lebleu, B., Peptide-based delivery of nucleic acids: design, mechanism of uptake 
and applications to splice-correcting oligonucleotides. Biochem Soc Trans 2007, 
35 (Pt 1), 53-5. 
107. Midoux, P.; Pichon, C.; Yaouanc, J. J.; Jaffres, P. A., Chemical vectors for gene 
delivery: a current review on polymers, peptides and lipids containing histidine or 
imidazole as nucleic acids carriers. Br J Pharmacol 2009, 157 (2), 166-78. 
108. (a) Wu, X.; Yan, Q.; Huang, Y.; Huang, H.; Su, Z.; Xiao, J.; Zeng, Y.; Wang, Y.; 
Nie, C.; Yang, Y.; Li, X., Isolation of a novel basic FGF-binding peptide with 
potent antiangiogenetic activity. J Cell Mol Med 2010, 14 (1-2), 351-6; (b) Abes, 
S.; Ivanova, G. D.; Abes, R.; Arzumanov, A. A.; Williams, D.; Owen, D.; Lebleu, 
B.; Gait, M. J., Peptide-based delivery of steric-block PNA oligonucleotides. 
Methods Mol Biol 2009, 480, 85-99; (c) Meade, B. R.; Dowdy, S. F., Exogenous 
siRNA delivery using peptide transduction domains/cell penetrating peptides. 
Adv Drug Deliv Rev 2007, 59 (2-3), 134-40; (d) Abes, R.; Arzumanov, A. A.; 
Moulton, H. M.; Abes, S.; Ivanova, G. D.; Iversen, P. L.; Gait, M. J.; Lebleu, B., 
Cell-penetrating-peptide-based delivery of oligonucleotides: an overview. 
Biochem Soc Trans 2007, 35 (Pt 4), 775-9. 
109. Ikeda, Y.; Taira, K., Ligand-targeted delivery of therapeutic siRNA. Pharm Res 
2006, 23 (8), 1631-40. 
110. (a) Eble, J. A., Collagen-binding integrins as pharmaceutical targets. Curr Pharm 
Des 2005, 11 (7), 867-80; (b) Vanderslice, P.; Woodside, D. G., Integrin 
antagonists as therapeutics for inflammatory diseases. Expert Opin Investig Drugs 
2006, 15 (10), 1235-55. 
111. Schiffelers, R. M.; Ansari, A.; Xu, J.; Zhou, Q.; Tang, Q.; Storm, G.; Molema, G.; 
Lu, P. Y.; Scaria, P. V.; Woodle, M. C., Cancer siRNA therapy by tumor selective 
delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 
2004, 32 (19), e149. 
112. Schwarze, S. R.; Ho, A.; Vocero-Akbani, A.; Dowdy, S. F., In vivo protein 
transduction: delivery of a biologically active protein into the mouse. Science 
1999, 285 (5433), 1569-72. 
113. Chiu, Y. L.; Ali, A.; Chu, C. Y.; Cao, H.; Rana, T. M., Visualizing a correlation 
between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol 
2004, 11 (8), 1165-75. 
153 
 
 
 
114. Rudolph, C.; Plank, C.; Lausier, J.; Schillinger, U.; Muller, R. H.; Rosenecker, J., 
Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of 
transferring plasmid DNA into cells. J Biol Chem 2003, 278 (13), 11411-8. 
115. Juliano, R. L., Intracellular delivery of oligonucleotide conjugates and dendrimer 
complexes. Ann N Y Acad Sci 2006, 1082, 18-26. 
116. Kang, H.; DeLong, R.; Fisher, M. H.; Juliano, R. L., Tat-conjugated PAMAM 
dendrimers as delivery agents for antisense and siRNA oligonucleotides. Pharm 
Res 2005, 22 (12), 2099-106. 
117. Kumar, P.; Wu, H.; McBride, J. L.; Jung, K. E.; Kim, M. H.; Davidson, B. L.; 
Lee, S. K.; Shankar, P.; Manjunath, N., Transvascular delivery of small 
interfering RNA to the central nervous system. Nature 2007, 448 (7149), 39-43. 
118. Zhou, J.; Rossi, J., Aptamer-targeted cell-specific RNA interference. Silence 
2010, 1 (1), 4. 
119. Tuerk, C.; Gold, L., Systematic evolution of ligands by exponential enrichment: 
RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249 (4968), 
505-10. 
120. (a) Zhang, Y.; Chen, Y.; Han, D.; Ocsoy, I.; Tan, W., Aptamers selected by cell-
SELEX for application in cancer studies. Bioanalysis 2010, 2 (5), 907-918; (b) 
Sefah, K.; Shangguan, D.; Xiong, X.; O'Donoghue, M. B.; Tan, W., Development 
of DNA aptamers using Cell-SELEX. Nat Protoc 2010, 5 (6), 1169-85; (c) Fang, 
X.; Tan, W., Aptamers generated from cell-SELEX for molecular medicine: a 
chemical biology approach. Acc Chem Res 2010, 43 (1), 48-57. 
121. (a) Zhou, J.; Swiderski, P.; Li, H.; Zhang, J.; Neff, C.; Akkina, R.; Rossi, J., 
Selection, characterization and application of new RNA HIV gp 120 aptamers for 
facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids 
Res 2009, 37, 3094-109; (b) Zhou, J.; Li, H.; Li, S.; Zaia, J.; Rossi, J., Novel dual 
inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther 
2008, 16, 1481-9; (c) Wullner, U.; Neef, I.; Eller, A.; Kleines, M.; Tur, M.; Barth, 
S., Cell-specific induction of apoptosis by rationally designed bivalent aptamer-
siRNA transcripts silencing eukaryotic elongation factor 2. Curr Cancer Drug 
Targets 2008, 8, 554-65; (d) Dassie, J.; Liu, X.; Thomas, G.; Whitaker, R.; Thiel, 
K.; Stockdale, K.; Meyerholz, D.; McCaffrey, A.; McNamara, J.; Giangrande, P., 
Systemic administration of optimized aptamer-siRNA chimeras promotes 
regression of PSMA-expressing tumors. Nat Biotechnol 2009, 27, 839-49. 
122. Chen, C. H.; Dellamaggiore, K. R.; Ouellette, C. P.; Sedano, C. D.; Lizadjohry, 
M.; Chernis, G. A.; Gonzales, M.; Baltasar, F. E.; Fan, A. L.; Myerowitz, R.; 
Neufeld, E. F., Aptamer-based endocytosis of a lysosomal enzyme. Proc Natl 
Acad Sci U S A 2008, 105 (41), 15908-13. 
123. Tong, G.; Hsiao, S.; Carrico, Z.; Francis, M., Viral capsid DNA aptamer 
conjugates as multivalent cell-targeting vehicles. J Am Chem Soc 2009, 131, 
11174-8. 
124. Chu, T.; Marks, J.; Lavery, L.; Faulkner, S.; Rosenblum, M.; Ellington, A.; Levy, 
M., Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer 
Res 2006, 66, 5989-92. 
125. Mi, J.; Zhang, X.; Rabbani, Z. N.; Liu, Y.; Reddy, S. K.; Su, Z.; Salahuddin, F. 
K.; Viles, K.; Giangrande, P. H.; Dewhirst, M. W.; Sullenger, B. A.; Kontos, C. 
154 
 
 
 
D.; Clary, B. M., RNA aptamer-targeted inhibition of NF-kappa B suppresses 
non-small cell lung cancer resistance to doxorubicin. Mol Ther 2008, 16 (1), 66-
73. 
126. Lupold, S.; Hicke, B.; Lin, Y.; Coffey, D., Identification and characterization of 
nuclease-stabilized RNA molecules that bind human prostate cancer cells via the 
prostate-specific membrane antigen. Cancer Res 2002, 62, 4029-33. 
127. Clifford, A. J.; Arjomand, A.; Dueker, S. R.; Schneider, P. D.; Buchholz, B. A.; 
Vogel, J. S., The dynamics of folic acid metabolism in an adult given a small 
tracer dose of 14C-folic acid. Adv Exp Med Biol 1998, 445, 239-51. 
128. de Crecy-Lagard, V.; El Yacoubi, B.; de la Garza, R. D.; Noiriel, A.; Hanson, A. 
D., Comparative genomics of bacterial and plant folate synthesis and salvage: 
predictions and validations. BMC Genomics 2007, 8, 245. 
129. Jackman, A. L.; Theti, D. S.; Gibbs, D. D., Antifolates targeted specifically to the 
folate receptor. Adv Drug Deliv Rev 2004, 56 (8), 1111-25. 
130. Toffoli, G.; Cernigoi, C.; Russo, A.; Gallo, A.; Bagnoli, M.; Boiocchi, M., 
Overexpression of folate binding protein in ovarian cancers. Int J Cancer 1997, 74 
(2), 193-8. 
131. Kamen, B. A.; Capdevila, A., Receptor-mediated folate accumulation is regulated 
by the cellular folate content. Proc Natl Acad Sci U S A 1986, 83 (16), 5983-7. 
132. Shen, F.; Ross, J. F.; Wang, X.; Ratnam, M., Identification of a novel folate 
receptor, a truncated receptor, and receptor type beta in hematopoietic cells: 
cDNA cloning, expression, immunoreactivity, and tissue specificity. 
Biochemistry 1994, 33 (5), 1209-15. 
133. Reddy, J. A.; Haneline, L. S.; Srour, E. F.; Antony, A. C.; Clapp, D. W.; Low, P. 
S., Expression and functional characterization of the beta-isoform of the folate 
receptor on CD34(+) cells. Blood 1999, 93 (11), 3940-8. 
134. Lee, R. J.; Wang, S.; Low, P. S., Measurement of endosome pH following folate 
receptor-mediated endocytosis. Biochim Biophys Acta 1996, 1312 (3), 237-42. 
135. Low, P. S.; Henne, W. A.; Doorneweerd, D. D., Discovery and Development of 
Folic-Acid-Based Receptor Targeting for Imaging and Therapy of Cancer and 
Inflammatory Diseases. Acc Chem Res 2008, 41 (1), 120-9. 
136. (a) Rijnboutt, S.; Jansen, G.; Posthuma, G.; Hynes, J. B.; Schornagel, J. H.; 
Strous, G. J., Endocytosis of GPI-linked membrane folate receptor-alpha. J Cell 
Biol 1996, 132 (1-2), 35-47; (b) Smart, E. J.; Mineo, C.; Anderson, R. G., 
Clustered folate receptors deliver 5-methyltetrahydrofolate to cytoplasm of 
MA104 cells. J Cell Biol 1996, 134 (5), 1169-77. 
137. Lu, Y.; Low, P. S., Folate-mediated delivery of macromolecular anticancer 
therapeutic agents. Adv Drug Deliv Rev 2002, 54 (5), 675-93. 
138. Bueno, R.; Appasani, K.; Mercer, H.; Lester, S.; Sugarbaker, D., The alpha folate 
receptor is highly activated in malignant pleural mesothelioma. J Thorac 
Cardiovasc Surg 2001, 121 (2), 225-33. 
139. Leamon, C. P.; DePrince, R. B.; Hendren, R. W., Folate-mediated drug delivery: 
effect of alternative conjugation chemistry. J Drug Target 1999, 7 (3), 157-69. 
140. Ebel, W.; Routhier, E. L.; Foley, B.; Jacob, S.; McDonough, J. M.; Patel, R. K.; 
Turchin, H. A.; Chao, Q.; Kline, J. B.; Old, L. J.; Phillips, M. D.; Nicolaides, N. 
C.; Sass, P. M.; Grasso, L., Preclinical evaluation of MORAb-003, a humanized 
155 
 
 
 
monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun 2007, 7, 
6. 
141. Low, P. S.; Henne, W. A.; Doorneweerd, D. D., Discovery and development of 
folic-acid-based receptor targeting for imaging and therapy of cancer and 
inflammatory diseases. Acc Chem Res 2008, 41 (1), 120-9. 
142. Reddy, J. A.; Dorton, R.; Dawson, A.; Vetzel, M.; Parker, N.; Nicoson, J. S.; 
Westrick, E.; Klein, P. J.; Wang, Y.; Vlahov, I. R.; Leamon, C. P., In Vivo 
Structural Activity and Optimization Studies of Folate-Tubulysin Conjugates. 
Molecular Pharmaceutics 2009, 6 (5), 1518-25. 
143. Leamon, C. P.; Reddy, J. A.; Vetzel, M.; Dorton, R.; Westrick, E.; Parker, N.; 
Wang, Y.; Vlahov, I., Folate targeting enables durable and specific antitumor 
responses from a therapeutically null tubulysin B analogue. Cancer Res 2008, 68 
(23), 9839-44. 
144. Reddy, J. A.; Westrick, E.; Santhapuram, H. K.; Howard, S. J.; Miller, M. L.; 
Vetzel, M.; Vlahov, I.; Chari, R. V.; Goldmacher, V. S.; Leamon, C. P., Folate 
receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate. 
Cancer Res 2007, 67 (13), 6376-82. 
145. (a) Vlahov, I. R.; Santhapuram, H. K.; You, F.; Wang, Y.; Kleindl, P. J.; Hahn, S. 
J.; Vaughn, J. F.; Reno, D. S.; Leamon, C. P., Carbohydrate-based synthetic 
approach to control toxicity profiles of folate-drug conjugates. J Org Chem 2010, 
75 (11), 3685-91; (b) Reddy, J. A.; Dorton, R.; Westrick, E.; Dawson, A.; Smith, 
T.; Xu, L. C.; Vetzel, M.; Kleindl, P.; Vlahov, I. R.; Leamon, C. P., Preclinical 
evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res 2007, 67 (9), 
4434-2; (c) Li, J.; Sausville, E. A.; Klein, P. J.; Morgenstern, D.; Leamon, C. P.; 
Messmann, R. A.; LoRusso, P., Clinical pharmacokinetics and exposure-toxicity 
relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients. J Clin 
Pharmacol 2009, 49 (12), 1467-76; (d) Leamon, C. P.; Reddy, J. A.; Vlahov, I. R.; 
Westrick, E.; Parker, N.; Nicoson, J. S.; Vetzel, M., Comparative preclinical 
activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145. Int J 
Cancer 2007, 121 (7), 1585-92. 
146. Reddy, J. A.; Low, P. S., Folate-mediated targeting of therapeutic and imaging 
agents to cancers. Crit Rev Ther Drug Carrier Syst 1998, 15 (6), 587-627. 
147. Lee, R. J.; Low, P. S., Folate-mediated tumor cell targeting of liposome-entrapped 
doxorubicin in vitro. Biochim Biophys Acta 1995, 1233 (2), 134-44. 
148. Paulos, C. M.; Turk, M. J.; Breur, G. J.; Low, P. S., Folate receptor-mediated 
targeting of therapeutic and imaging agents to activated macrophages in 
rheumatoid arthritis. Adv Drug Deliv Rev 2004, 56 (8), 1205-17. 
149. Oh, Y. K.; Park, T. G., siRNA delivery systems for cancer treatment. Adv Drug 
Deliv Rev 2009, 61 (10), 850-62. 
150. Ashihara, E.; Kawata, E.; Maekawa, T., Future prospect of RNA interference for 
cancer therapies. Curr Drug Targets 2010, 11 (3), 345-60. 
151. Pradeep, C. R.; Sunila, E. S.; Kuttan, G., Expression of vascular endothelial 
growth factor (VEGF) and VEGF receptors in tumor angiogenesis and 
malignancies. Integr Cancer Ther 2005, 4 (4), 315-21. 
156 
 
 
 
152. Yancopoulos, G. D.; Davis, S.; Gale, N. W.; Rudge, J. S.; Wiegand, S. J.; Holash, 
J., Vascular-specific growth factors and blood vessel formation. Nature 2000, 407 
(6801), 242-8. 
153. Sumpio, B. E.; Riley, J. T.; Dardik, A., Cells in focus: endothelial cell. Int J 
Biochem Cell Biol 2002, 34 (12), 1508-12. 
154. Carmeliet, P., Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000, 6 
(4), 389-95. 
155. Muller, Y. A.; Li, B.; Christinger, H. W.; Wells, J. A.; Cunningham, B. C.; de 
Vos, A. M., Vascular endothelial growth factor: crystal structure and functional 
mapping of the kinase domain receptor binding site. Proc Natl Acad Sci U S A 
1997, 94 (14), 7192-7. 
156. Tischer, E.; Mitchell, R.; Hartman, T.; Silva, M.; Gospodarowicz, D.; Fiddes, J. 
C.; Abraham, J. A., The human gene for vascular endothelial growth factor. 
Multiple protein forms are encoded through alternative exon splicing. J Biol 
Chem 1991, 266 (18), 11947-54. 
157. Karkkainen, M. J.; Makinen, T.; Alitalo, K., Lymphatic endothelium: a new 
frontier of metastasis research. Nat Cell Biol 2002, 4 (1), E2-5. 
158. Olsson, A. K.; Dimberg, A.; Kreuger, J.; Claesson-Welsh, L., VEGF receptor 
signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006, 7 (5), 
359-71. 
159. Carmeliet, P.; Moons, L.; Luttun, A.; Vincenti, V.; Compernolle, V.; De Mol, M.; 
Wu, Y.; Bono, F.; Devy, L.; Beck, H.; Scholz, D.; Acker, T.; DiPalma, T.; 
Dewerchin, M.; Noel, A.; Stalmans, I.; Barra, A.; Blacher, S.; Vandendriessche, 
T.; Ponten, A.; Eriksson, U.; Plate, K. H.; Foidart, J. M.; Schaper, W.; Charnock-
Jones, D. S.; Hicklin, D. J.; Herbert, J. M.; Collen, D.; Persico, M. G., Synergism 
between vascular endothelial growth factor and placental growth factor 
contributes to angiogenesis and plasma extravasation in pathological conditions. 
Nat Med 2001, 7 (5), 575-83. 
160. Perona, R., Cell signalling: growth factors and tyrosine kinase receptors. Clin 
Transl Oncol 2006, 8 (2), 77-82. 
161. Aiello, L. P.; Pierce, E. A.; Foley, E. D.; Takagi, H.; Chen, H.; Riddle, L.; 
Ferrara, N.; King, G. L.; Smith, L. E., Suppression of retinal neovascularization in 
vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble 
VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 1995, 92 (23), 
10457-61. 
162. Shen, J.; Samul, R.; Silva, R. L.; Akiyama, H.; Liu, H.; Saishin, Y.; Hackett, S. 
F.; Zinnen, S.; Kossen, K.; Fosnaugh, K.; Vargeese, C.; Gomez, A.; Bouhana, K.; 
Aitchison, R.; Pavco, P.; Campochiaro, P. A., Suppression of ocular 
neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 2006, 13 
(3), 225-34. 
163. Kim, D. H.; Longo, M.; Han, Y.; Lundberg, P.; Cantin, E.; Rossi, J. J., Interferon 
induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat 
Biotechnol 2004, 22 (3), 321-5. 
164. Ambrosini, G.; Adida, C.; Altieri, D. C., A novel anti-apoptosis gene, survivin, 
expressed in cancer and lymphoma. Nat Med 1997, 3 (8), 917-21. 
157 
 
 
 
165. (a) Wheatley, S. P.; McNeish, I. A., Survivin: a protein with dual roles in mitosis 
and apoptosis. Int Rev Cytol 2005, 247, 35-88; (b) Mita, A. C.; Mita, M. M.; 
Nawrocki, S. T.; Giles, F. J., Survivin: key regulator of mitosis and apoptosis and 
novel target for cancer therapeutics. Clin Cancer Res 2008, 14 (16), 5000-5. 
166. Altieri, D. C., Survivin, cancer networks and pathway-directed drug discovery. 
Nat Rev Cancer 2008, 8 (1), 61-70. 
167. Duffy, M. J.; O'Donovan, N.; Brennan, D. J.; Gallagher, W. M.; Ryan, B. M., 
Survivin: a promising tumor biomarker. Cancer Lett 2007, 249 (1), 49-60. 
168. Minematsu, T.; Iwai, M.; Umehara, K.; Usui, T.; Kamimura, H., Characterization 
of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-
mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-
ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 
monobromide), a novel small molecule survivin suppressant. Drug Metab Dispos 
2010, 38 (1), 1-4. 
169. Pennati, M.; Folini, M.; Zaffaroni, N., Targeting survivin in cancer therapy: 
fulfilled promises and open questions. Carcinogenesis 2007, 28 (6), 1133-9. 
170. Nakahara, T.; Takeuchi, M.; Kinoyama, I.; Minematsu, T.; Shirasuna, K.; 
Matsuhisa, A.; Kita, A.; Tominaga, F.; Yamanaka, K.; Kudoh, M.; Sasamata, M., 
YM155, a novel small-molecule survivin suppressant, induces regression of 
established human hormone-refractory prostate tumor xenografts. Cancer Res 
2007, 67 (17), 8014-21. 
171. Tolcher, A. W.; Mita, A.; Lewis, L. D.; Garrett, C. R.; Till, E.; Daud, A. I.; 
Patnaik, A.; Papadopoulos, K.; Takimoto, C.; Bartels, P.; Keating, A.; Antonia, 
S., Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of 
survivin. J Clin Oncol 2008, 26 (32), 5198-203. 
172. (a) Sato, A.; Ito, K.; Asano, T.; Sumitomo, M.; Hayakawa, M., Topotecan and 
small interfering RNA suppress survivin expression synergistically in Caki-1 
renal cancer cells: Direct suppression of survivin and enhancement of transfection 
efficiency by topotecan. Int J Oncol 2008, 32 (1), 171-6; (b) Sato, A.; Ito, K.; 
Asano, T.; Sumitomo, M.; Hayakawa, M., Synergistic effect of survivin-specific 
small interfering RNA and topotecan in renal cancer cells: topotecan enhances 
liposome-mediated transfection by increasing cellular uptake. Int J Oncol 2007, 
30 (3), 695-700. 
173. Li, B.; Fan, J.; Liu, X.; Qi, R.; Bo, L.; Gu, J.; Qian, C., Suppression of colorectal 
tumor growth by regulated survivin targeting. J Mol Med 2006, 84 (12), 1077-86. 
174. Vogel, C.; Hager, C.; Bastians, H., Mechanisms of mitotic cell death induced by 
chemotherapy-mediated G2 checkpoint abrogation. Cancer Res 2007, 67 (1), 339-
45. 
175. Knauer, S. K.; Mann, W.; Stauber, R. H., Survivin's dual role: an export's view. 
Cell Cycle 2007, 6 (5), 518-21. 
176. Wang, Z.; Sampath, J.; Fukuda, S.; Pelus, L. M., Disruption of the inhibitor of 
apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced 
apoptosis. Cancer Res 2005, 65 (18), 8224-32. 
177. Wolanin, K.; Magalska, A.; Mosieniak, G.; Klinger, R.; McKenna, S.; Vejda, S.; 
Sikora, E.; Piwocka, K., Curcumin affects components of the chromosomal 
158 
 
 
 
passenger complex and induces mitotic catastrophe in apoptosis-resistant Bcr-
Abl-expressing cells. Mol Cancer Res 2006, 4 (7), 457-69. 
178. Imai, Y.; Kimura, T.; Murakami, A.; Yajima, N.; Sakamaki, K.; Yonehara, S., 
The CED-4-homologous protein FLASH is involved in Fas-mediated activation 
of caspase-8 during apoptosis. Nature 1999, 398 (6730), 777-85. 
179. Krieghoff, E.; Milovic-Holm, K.; Hofmann, T. G., FLASH meets nuclear bodies: 
CD95 receptor signals via a nuclear pathway. Cell Cycle 2007, 6 (7), 771-5. 
180. Barcaroli, D.; Bongiorno-Borbone, L.; Terrinoni, A.; Hofmann, T. G.; Rossi, M.; 
Knight, R. A.; Matera, A. G.; Melino, G.; De Laurenzi, V., FLASH is required for 
histone transcription and S-phase progression. Proc Natl Acad Sci U S A 2006, 
103 (40), 14808-12. 
181. Shi, Y., Mechanical aspects of apoptosome assembly. Current Opinion in Cell 
Biology 2006, 18 (6), 677-84. 
182. Kittler, R.; Putz, G.; Pelletier, L.; Poser, I.; Heninger, A. K.; Drechsel, D.; 
Fischer, S.; Konstantinova, I.; Habermann, B.; Grabner, H.; Yaspo, M. L.; 
Himmelbauer, H.; Korn, B.; Neugebauer, K.; Pisabarro, M. T.; Buchholz, F., An 
endoribonuclease-prepared siRNA screen in human cells identifies genes essential 
for cell division. Nature 2004, 432 (7020), 1036-40. 
183. Flotho, C.; Coustan-Smith, E.; Pei, D.; Iwamoto, S.; Song, G.; Cheng, C.; Pui, C. 
H.; Downing, J. R.; Campana, D., Genes contributing to minimal residual disease 
in childhood acute lymphoblastic leukemia: prognostic significance of 
CASP8AP2. Blood 2006, 108 (3), 1050-7. 
184. Yang, Y. L.; Lin, S. R.; Chen, J. S.; Lin, S. W.; Yu, S. L.; Chen, H. Y.; Yen, C. 
T.; Lin, C. Y.; Lin, J. F.; Lin, K. H.; Jou, S. T.; Hu, C. Y.; Chang, S. K.; Lu, M. 
Y.; Chang, H. H.; Chang, W. H.; Lin, K. S.; Lin, D. T., Expression and prognostic 
significance of the apoptotic genes BCL2L13, Livin, and CASP8AP2 in 
childhood acute lymphoblastic leukemia. Leuk Res 2010, 34 (1), 18-23. 
185. (a) Kino, T.; Chrousos, G. P., Tumor necrosis factor alpha receptor- and Fas-
associated FLASH inhibit transcriptional activity of the glucocorticoid receptor 
by binding to and interfering with its interaction with p160 type nuclear receptor 
coactivators. J Biol Chem 2003, 278 (5), 3023-9; (b) Barcaroli, D.; Dinsdale, D.; 
Neale, M. H.; Bongiorno-Borbone, L.; Ranalli, M.; Munarriz, E.; Sayan, A. E.; 
McWilliam, J. M.; Smith, T. M.; Fava, E.; Knight, R. A.; Melino, G.; De 
Laurenzi, V., FLASH is an essential component of Cajal bodies. Proc Natl Acad 
Sci U S A 2006, 103 (40), 14802-7; (c) Milovic-Holm, K.; Krieghoff, E.; Jensen, 
K.; Will, H.; Hofmann, T. G., FLASH links the CD95 signaling pathway to the 
cell nucleus and nuclear bodies. EMBO J 2007, 26 (2), 391-401; (d) Alm-
Kristiansen, A. H.; Saether, T.; Matre, V.; Gilfillan, S.; Dahle, O.; Gabrielsen, O. 
S., FLASH acts as a co-activator of the transcription factor c-Myb and localizes to 
active RNA polymerase II foci. Oncogene 2008, 27 (34), 4644-56; (e) Yang, X. 
C.; Burch, B. D.; Yan, Y.; Marzluff, W. F.; Dominski, Z., FLASH, a proapoptotic 
protein involved in activation of caspase-8, is essential for 3' end processing of 
histone pre-mRNAs. Mol Cell 2009, 36 (2), 267-78. 
186. (a) Scales, C. W.; Huang, F.; Li, N.; Vasilieva, Y. A.; Ray, J.; Convertine, A. J.; 
McCormick, C. L., Corona-Stabilized Interpolyelectrolyte Complexes of SiRNA 
with Nonimmunogenic, Hydrophilic/Cationic Block Copolymers Prepared by 
159 
 
 
 
Aqueous RAFT Polymerization. Macromolecules 2006, 39 (20), 6881; (b) Li, N.; 
Yu, C.; Huang, F., Novel cyanine-AMP conjugates for efficient 5' RNA 
fluorescent labeling by one-step transcription and replacement of [gamma-
32P]ATP in RNA structural investigation. Nucleic Acids Res 2005, 33 (4), e37; 
(c) Li, N.; Huang, F., Ribozyme-catalyzed aminoacylation from CoA thioesters. 
Biochemistry 2005, 44 (11), 4582-90; (d) Kirkland-York, S.; Zhang, Y.; Smith, 
A. E.; York, A. W.; Huang, F.; McCormick, C. L., Tailored Design of Au 
Nanoparticle-siRNA Carriers Utilizing Reversible Addition-Fragmentation Chain 
Transfer Polymers. Biomacromolecules 2010, 11 (4), 1052-9; (e) Huang, F.; 
Wang, G.; Coleman, T.; Li, N., Synthesis of adenosine derivatives as transcription 
initiators and preparation of 5' fluorescein- and biotin-labeled RNA through one-
step in vitro transcription. RNA 2003, 9 (12), 1562-70; (f) Huang, F.; He, J.; 
Zhang, Y.; Guo, Y., Synthesis of biotin-AMP conjugate for 5' biotin labeling of 
RNA through one-step in vitro transcription. Nat Protoc 2008, 3 (12), 1848-61; 
(g) Huang, F.; Bugg, C. W.; Yarus, M., RNA-Catalyzed CoA, NAD, and FAD 
synthesis from phosphopantetheine, NMN, and FMN. Biochemistry 2000, 39 
(50), 15548-55; (h) Huang, F., Efficient incorporation of CoA, NAD and FAD 
into RNA by in vitro transcription. Nucleic Acids Res 2003, 31 (3), e8; (i) Guo, 
S.; Huang, F.; Guo, P., Construction of folate-conjugated pRNA of bacteriophage 
phi29 DNA packaging motor for delivery of chimeric siRNA to nasopharyngeal 
carcinoma cells. Gene Ther 2006, 13 (10), 814-20; (j) Coleman, T. M.; Wang, G.; 
Huang, F., Superior 5' homogeneity of RNA from ATP-initiated transcription 
under the T7 phi 2.5 promoter. Nucleic Acids Res 2004, 32 (1), e14; (k) Coleman, 
T. M.; Li, N.; Huang, F., A simple and efficient method to prepare thioesters in 
aqueous solutions. Tetrahedron Letters 2005, 46 (25), 4310; (l) Coleman, T. M.; 
Huang, F., Optimal random libraries for the isolation of catalytic RNA. RNA Biol 
2005, 2 (4), 129-36; (m) Coleman, T. M.; Huang, F., RNA-catalyzed thioester 
synthesis. Chem Biol 2002, 9 (11), 1227-36. 
187. Donze, O.; Picard, D., RNA interference in mammalian cells using siRNAs 
synthesized with T7 RNA polymerase. Nucleic Acids Res 2002, 30 (10), e46. 
188. Li, L.; Liu, J.; Diao, Z.; Shu, D.; Guo, P.; Shen, G., Evaluation of specific 
delivery of chimeric phi29 pRNA/siRNA nanoparticles to multiple tumor cells. 
Mol Biosyst 2009, 5, 1361-8. 
189. Collins, T. J., ImageJ for microscopy. Biotechniques 2007, 43 (1 Suppl), 25-30. 
190. Russ, V.; Wagner, E., Cell and tissue targeting of nucleic acids for cancer gene 
therapy. Pharm Res 2007, 24 (6), 1047-57. 
191. (a) Moore, A.; Medarova, Z., Imaging of siRNA delivery and silencing. Methods 
Mol. Biol. 2009, 487, 93-110; (b) Cerchia, L.; Giangrande, P. H.; McNamara, J. 
O.; de Franciscis, V., Cell-specific aptamers for targeted therapies. Methods Mol. 
Biol. 2009, 535, 59-78. 
192. Endoh, T.; Ohtsuki, T., Cellular siRNA delivery using cell-penetrating peptides 
modified for endosomal escape. Adv Drug Deliv Rev 2009, 61 (9), 704-9. 
193. Han, S. E.; Kang, H.; Shim, G. Y.; Suh, M. S.; Kim, S. J.; Kim, J. S.; Oh, Y. K., 
Novel cationic cholesterol derivative-based liposomes for serum-enhanced 
delivery of siRNA. Int J Pharm 2008, 353 (1-2), 260-9. 
160 
 
 
 
194. Nishina, K.; Unno, T.; Uno, Y.; Kubodera, T.; Kanouchi, T.; Mizusawa, H.; 
Yokota, T., Efficient in vivo delivery of siRNA to the liver by conjugation of 
alpha-tocopherol. Mol Ther 2008, 16, 734-40. 
195. Zhang, K.; Wang, Q.; Xie, Y.; Mor, G.; Sega, E.; Low, P. S.; Huang, Y., 
Receptor-mediated delivery of siRNAs by tethered nucleic acid base-paired 
interactions. RNA 2008, 14 (3), 577-83. 
196. Sega, E. I.; Low, P. S., Tumor detection using folate receptor-targeted imaging 
agents. Cancer Metastasis Rev. 2008, 27 (4), 655-64. 
197. Thomas, M.; Kularatne, S. A.; Qi, L.; Kleindl, P.; Leamon, C. P.; Hansen, M. J.; 
Low, P. S., Ligand-targeted delivery of small interfering RNAs to malignant cells 
and tissues. Ann. N. Y. Acad. Sci. 2009, 1175, 32-9. 
198. Gross, S.; Piwnica-Worms, D., Spying on cancer: Molecular imaging in vivo with 
genetically encoded reporters. Cancer Cell2005, 7 (1), 5-15. 
199. (a) Contag, C. H.; Bachmann, M. H., Advances in in vivo bioluminescence 
imaging of gene expression. Annu Rev Biomed Eng 2002, 4, 235-60; (b) Wilson, 
T.; Hastings, J. W., Bioluminescence. Annu Rev Cell Dev Biol 1998, 14, 197-
230. 
200. (a) Malik, I.; Garrido, M.; Bahr, M.; Kugler, S.; Michel, U., Comparison of test 
systems for RNAinterference. Biochem Biophys Res Commun 2006, 341 (1), 
245-53; (b) Rousseau, J.; Escriou, V.; Perrot, P.; Picarda, G.; Charrier, C.; 
Scherman, D.; Heymann, D.; Redini, F.; Trichet, V., Advantages of 
bioluminescence imaging to follow siRNA or chemotherapeutic treatments in 
osteosarcoma preclinical models. Cancer Gene Ther 2010, 17 (6), 387-97. 
201. McElroy, W. D.; Seliger, H. H.; White, E. H., Mechanism of bioluminescence, 
chemiluminescence and enzyme function in the oxidation of firefly luciferin. 
Photochem Photobiol 1969, 10 (3), 153-70. 
202. (a) Widder, E. A., Bioluminescence in the ocean: origins of biological, chemical, 
and ecological diversity. Science 2010, 328 (5979), 704-8; (b) Greer, L. F., 3rd; 
Szalay, A. A., Imaging of light emission from the expression of luciferases in 
living cells and organisms: a review. Luminescence 2002, 17 (1), 43-74. 
203. Tannous, B. A., Gaussia luciferase reporter assay for monitoring biological 
processes in culture and in vivo. Nat Protoc 2009, 4 (4), 582-91. 
204. (a) Verhaegent, M.; Christopoulos, T. K., Recombinant Gaussia luciferase. 
Overexpression, purification, and analytical application of a bioluminescent 
reporter for DNA hybridization. Anal Chem 2002, 74 (17), 4378-85; (b) Tannous, 
B. A.; Kim, D. E.; Fernandez, J. L.; Weissleder, R.; Breakefield, X. O., Codon-
optimized Gaussia luciferase cDNA for mammalian gene expression in culture 
and in vivo. Mol Ther 2005, 11 (3), 435-43. 
205. Guo, S.; Tschammer, N.; Mohammed, S.; Guo, P., Specific delivery of 
therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor 
pRNA. Hum Gene Ther 2005, 16, 1097-109. 
206. Yuan, B.; Latek, R.; Hossbach, M.; Tuschl, T.; Lewitter, F., siRNA Selection 
Server: an automated siRNA oligonucleotide prediction server. Nucleic Acids Res 
2004, 32 (Web Server issue), W130-4. 
161 
 
 
 
207. Lu, J. Y.; Lowe, D. A.; Kennedy, M. D.; Low, P. S., Folate-targeted enzyme 
prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug. 
J Drug Target 1999, 7 (1), 43-53. 
208. Nguyen, T.; Menocal, E. M.; Harborth, J.; Fruehauf, J. H., RNAi therapeutics: an 
update on delivery. Curr Opin Mol Ther 2008, 10 (2), 158-67. 
209. (a) Pack, D. W.; Hoffman, A. S.; Pun, S.; Stayton, P. S., Design and development 
of polymers for gene delivery. Nat. Rev. Drug Discov. 2005, 4 (7), 581-93; (b) 
Jeong, J. H.; Mok, H.; Oh, Y. K.; Park, T. G., siRNA conjugate delivery systems. 
Bioconjug. Chem. 2009, 20 (1), 5-14. 
210. (a) Kabanov, V. A.; Kabanov, A. V., Interpolyelectrolyte and block ionomer 
complexes for gene delivery: physico-chemical aspects. Adv. Drug Deliv. Rev. 
1998, 30 (1-3), 49-60; (b) Lam, J. K.; Ma, Y.; Armes, S. P.; Lewis, A. L.; 
Baldwin, T.; Stolnik, S., Phosphorylcholine-polycation diblock copolymers as 
synthetic vectors for gene delivery. J. Control. Release 2004, 100 (2), 293-312. 
211. (a) Merdan, T.; Kunath, K.; Fischer, D.; Kopecek, J.; Kissel, T., Intracellular 
processing of poly(ethylene imine)/ribozyme complexes can be observed in living 
cells by using confocal laser scanning microscopy and inhibitor experiments. 
Pharm. Res. 2002, 19 (2), 140-6; (b) Leonetti, J. P.; Degols, G.; Lebleu, B., 
Biological activity of oligonucleotide-poly(L-lysine) conjugates: mechanism of 
cell uptake. Bioconjug. Chem. 1990, 1 (2), 149-53; (c) Deshpande, M. C.; Davies, 
M. C.; Garnett, M. C.; Williams, P. M.; Armitage, D.; Bailey, L.; Vamvakaki, M.; 
Armes, S. P.; Stolnik, S., The effect of poly(ethylene glycol) molecular 
architecture on cellular interaction and uptake of DNA complexes. J. Control. 
Release 2004, 97 (1), 143-56. 
212. (a) Zou, S. M.; Erbacher, P.; Remy, J. S.; Behr, J. P., Systemic linear 
polyethylenimine (L-PEI)-mediated gene delivery in the mouse. J. Gene Med. 
2000, 2 (2), 128-34; (b) Dash, P. R.; Read, M. L.; Barrett, L. B.; Wolfert, M. A.; 
Seymour, L. W., Factors affecting blood clearance and in vivo distribution of 
polyelectrolyte complexes for gene delivery. Gene Ther. 1999, 6 (4), 643-50. 
213. (a) Wagner, E., Advances in cancer gene therapy: tumor-targeted delivery of 
therapeutic pDNA, siRNA, and dsRNA nucleic acids. J BUON 2007, 12 Suppl 1, 
S77-82; (b) Yan, A.; Levy, M., Aptamers and aptamer targeted delivery. RNA 
Biol 2009, 6, 316-20. 
214. (a) Hobel, S.; Aigner, A., Polyethylenimine (PEI)/siRNA-mediated gene 
knockdown in vitro and in vivo. Methods Mol. Biol. 2010, 623 (623), 283-97; (b) 
Biswal, B. K.; Debata, N. B.; Verma, R. S., Development of a targeted siRNA 
delivery system using FOL-PEG-PEI conjugate. Mol. Biol. Rep. 2010, 37 (6), 
2919-26 (c) Merkel, O. M.; Beyerle, A.; Librizzi, D.; Pfestroff, A.; Behr, T. M.; 
Sproat, B.; Barth, P. J.; Kissel, T., Nonviral siRNA delivery to the lung: 
investigation of PEG-PEI polyplexes and their in vivo performance. Mol. Pharm. 
2009, 6 (4), 1246-1260; (d) Patil, Y.; Panyam, J., Polymeric nanoparticles for 
siRNA delivery and gene silencing. Int. J. Pharm. 2009, 367 (1-2), 195-203; (e) 
Heredia, K. L.; Nguyen, T. H.; Chang, C. W.; Bulmus, V.; Davis, T. P.; Maynard, 
H. D., Reversible siRNA-polymer conjugates by RAFT polymerization. Chem. 
Commun. 2008, (28), 3245-7; (f) Boyer, C.; Bulmus, V.; Davis, T. P.; Ladmiral, 
V.; Liu, J.; Perrier, S., Bioapplications of RAFT polymerization. Chem Rev 2009, 
162 
 
 
 
109 (11), 5402-36; (g) Convertine, A. J.; Benoit, D. S.; Duvall, C. L.; Hoffman, 
A. S.; Stayton, P. S., Development of a novel endosomolytic diblock copolymer 
for siRNA delivery. J. Control. Release 2009, 133 (3), 221-9; (h) Lee, S. H.; Kim, 
S. H.; Park, T. G., Intracellular siRNA delivery system using polyelectrolyte 
complex micelles prepared from VEGF siRNA-PEG conjugate and cationic 
fusogenic peptide. Biochem. Biophys. Res. Commun. 2007, 357 (2), 511-6; (i) 
Lee, S. H.; Bae, K. H.; Kim, S. H.; Lee, K. R.; Park, T. G., Amine-functionalized 
gold nanoparticles as non-cytotoxic and efficient intracellular siRNA delivery 
carriers. Int J Pharm 2008, 364 (1), 94-101; (j) Oishi, M.; Nagasaki, Y.; Itaka, K.; 
Nishiyama, N.; Kataoka, K., Lactosylated poly(ethylene glycol)-siRNA conjugate 
through acid-labile beta-thiopropionate linkage to construct pH-sensitive polyion 
complex micelles achieving enhanced gene silencing in hepatoma cells. J. Am. 
Chem. Soc. 2005, 127 (6), 1624-5; (k) Oishi, M.; Nagasaki, Y.; Nishiyama, N.; 
Itaka, K.; Takagi, M.; Shimamoto, A.; Furuichi, Y.; Kataoka, K., Enhanced 
growth inhibition of hepatic multicellular tumor spheroids by lactosylated 
poly(ethylene glycol)-siRNA conjugate formulated in PEGylated polyplexes. 
ChemMedChem 2007, 2 (9), 1290-7; (l) York, A. W.; Huang, F.; McCormick, C. 
L., Rational Design of Targeted Cancer Therapeutics through the 
Multiconjugation of Folate and Cleavable siRNA to RAFT-Synthesized (HPMA-
s-APMA) Copolymers. Biomacromolecules 2010, 11, 505-14; (m) Scales, C. W.; 
Huang, F.; Li, N.; Vasilieva, Y. A.; Ray, J.; Convertine, A. J.; McCormick, C. L., 
Corona-Stabilized Interpolyelectrolyte Complexes of SiRNA with 
Nonimmunogenic, Hydrophilic/Cationic Block Copolymers Prepared by Aqueous 
RAFT Polymerization. Macromolecules 2006, 39 (20), 6871-81. 
215. (a) Medina-Kauwe, L. K.; Xie, J.; Hamm-Alvarez, S., Intracellular trafficking of 
nonviral vectors. Gene Ther. 2005, 12 (24), 1734-51; (b) Christie, R. J.; 
Nishiyama, N.; Kataoka, K., Minireview: Delivering the Code: Polyplex Carriers 
for Deoxyribonucleic Acid and Ribonucleic Acid Interference Therapies. 
Endocrinology 2009, 151, 466-73; (c) Tseng, Y. C.; Mozumdar, S.; Huang, L., 
Lipid-based systemic delivery of siRNA. Adv. Drug Deliv. Rev. 2009, 61 (9), 
721-31. 
216. (a) Mathias, C. J.; Wang, S.; Low, P. S.; Waters, D. J.; Green, M. A., Receptor-
mediated targeting of 67Ga-deferoxamine-folate to folate-receptor-positive 
human KB tumor xenografts. Nucl Med Biol 1999, 26 (1), 23-5; (b) Pal, A.; 
Ahmad, A.; Khan, S.; Sakabe, I.; Zhang, C.; Kasid, U.; Ahmad, I., Systemic 
delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 
expression and inhibits tumor growth in xenograft model of human prostate 
cancer. Int J Oncol 2005, 26, 1087-91. 
217. Dreher, M. R.; Liu, W.; Michelich, C. R.; Dewhirst, M. W.; Yuan, F.; Chilkoti, 
A., Tumor vascular permeability, accumulation, and penetration of 
macromolecular drug carriers. J Natl Cancer Inst 2006, 98 (5), 335-44. 
218. Low, P. S.; Henne, W. A.; Doorneweerd, D. D., Discovery and development of 
folic-acid-based receptor targeting for imaging and therapy of cancer and 
inflammatory diseases. Acc. Chem. Res. 2008, 41 (1), 120-9. 
163 
 
 
 
219. Magzoub, M.; Pramanik, A.; Graslund, A., Modeling the endosomal escape of 
cell-penetrating peptides: transmembrane pH gradient driven translocation across 
phospholipid bilayers. Biochemistry 2005, 44 (45), 14890-7. 
220. Bolte, S.; Cordelieres, F. P., A guided tour into subcellular colocalization analysis 
in light microscopy. J. Microsc. 2006, 224 (Pt 3), 213-32. 
221. (a) Manders, E. M.; Stap, J.; Brakenhoff, G. J.; van Driel, R.; Aten, J. A., 
Dynamics of three-dimensional replication patterns during the S-phase, analysed 
by double labelling of DNA and confocal microscopy. J. Cell Sci. 1992, 103 ( Pt 
3), 857-62; (b) Manders, E. M. M.; VERBEEK, F. J.; ATEN, J. A., Measurement 
of co-localization of objects in dual-colour confocal images. J. Microsc. 1993, 
169 (3), 375-82. 
222. Leamon, C. P.; Pastan, I.; Low, P. S., Cytotoxicity of folate-Pseudomonas 
exotoxin conjugates toward tumor cells. Contribution of translocation domain. J. 
Biol. Chem. 1993, 268 (33), 24847-54. 
223. Filion, M. C.; Phillips, N. C., Toxicity and immunomodulatory activity of 
liposomal vectors formulated with cationic lipids toward immune effector cells. 
Biochimica et Biophysica Acta (BBA) - Biomembranes 1997, 1329 (2), 345-56. 
224. (a) Tannous, B. A.; Kim, D. E.; Fernandez, J. L.; Weissleder, R.; Breakefield, X. 
O., Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in 
culture and in vivo. Mol. Ther. 2005, 11 (3), 435-43; (b) Tannous, B. A., Gaussia 
luciferase reporter assay for monitoring biological processes in culture and in 
vivo. Nat. Protoc. 2009, 4 (4), 582-91; (c) Chung, E.; Yamashita, H.; Au, P.; 
Tannous, B. A.; Fukumura, D.; Jain, R. K., Secreted gaussia luciferase as a 
biomarker for monitoring tumor progression and treatment response of systemic 
metastases. PLoS One 2009, 4 (12), e8316. 
225. Prasad, P. D.; Ramamoorthy, S.; Moe, A. J.; Smith, C. H.; Leibach, F. H.; 
Ganapathy, V., Selective expression of the high-affinity isoform of the folate 
receptor (FR-alpha) in the human placental syncytiotrophoblast and 
choriocarcinoma cells. Biochim Biophys Acta 1994, 1223 (1), 71-5. 
226. (a) Chello, P. L.; Sirotnak, F. M.; Wong, E.; Kisliuk, R. L.; Gaumont, Y.; 
Combepine, G., Further studies stereospecificity at carbon 6 for membrane 
transport of tetrahydrofolates. Diastereoisomers of 5-methyltetrahydrofolates as 
competitive inhibitors of transport of methotrexate in L1210 cells. Biochem 
Pharmacol 1982, 31 (8), 1527-30; (b) Fry, D. W.; Besserer, J. A.; Boritzki, T. J., 
Transport of the antitumor antibiotic Cl-920 into L1210 leukemia cells by the 
reduced folate carrier system. Cancer Res 1984, 44 (8), 3366-70. 
227. (a) Gorlick, R.; Cole, P.; Banerjee, D.; Longo, G.; Li, W. W.; Hochhauser, D.; 
Bertino, J. R., Mechanisms of methotrexate resistance in acute leukemia. 
Decreased transport and polyglutamylation. Adv Exp Med Biol 1999, 457, 543-
50; (b) Guo, W.; Healey, J. H.; Meyers, P. A.; Ladanyi, M.; Huvos, A. G.; 
Bertino, J. R.; Gorlick, R., Mechanisms of methotrexate resistance in 
osteosarcoma. Clin Cancer Res 1999, 5 (3), 621-7. 
228. Lu, Y.; Low, P. S., Folate targeting of haptens to cancer cell surfaces mediates 
immunotherapy of syngeneic murine tumors. Cancer Immunol Immunother 2002, 
51 (3), 153-62. 
164 
 
 
 
229. Ross, J. F.; Chaudhuri, P. K.; Ratnam, M., Differential regulation of folate 
receptor isoforms in normal and malignant tissues in vivo and in established cell 
lines. Physiologic and clinical implications. Cancer 1994, 73 (9), 2432-43. 
230. Paulos, C. M.; Reddy, J. A.; Leamon, C. P.; Turk, M. J.; Low, P. S., Ligand 
binding and kinetics of folate receptor recycling in vivo: impact on receptor-
mediated drug delivery. Mol Pharmacol 2004, 66 (6), 1406-14. 
231. Dincer, S.; Turk, M.; Piskin, E., Intelligent polymers as nonviral vectors. Gene 
Ther 2005, 12 Suppl 1, S139-45. 
232. (a) Gilmore, I. R.; Fox, S. P.; Hollins, A. J.; Sohail, M.; Akhtar, S., The design 
and exogenous delivery startegies of siRNA for post-transcriptional gene 
silencing. Journal of Drug Targeting 2004, 12, 315-40; (b) Gilmore, I. R.; Fox, S. 
P.; Hollins, A. J.; Akhtar, S., Delivery strategies for siRNA-mediated gene 
silencing. Current Drug Delivery 2006, 3, 147-55; (c) Aigner, A., Delivery 
systems for the direct application of siRNAs to induce RNA interference (RNAi) 
in vivo. Journal of Biomedicine and Biotechnology 2006, 71659. 
233. (a) Giljohann, D. A.; Seferos, D. S.; Daniel, W. L.; Massich, M. D.; Patel, P. C.; 
Mirkin, C. A., Gold nanoparticles for biology and medicine. Angew Chem Int Ed 
Engl 2010, 49 (19), 3280-94; (b) Jennings, T.; Strouse, G., Past, present, and 
future of gold nanoparticles. Adv Exp Med Biol 2007, 620, 34-47. 
234. Boisselier, E.; Astruc, D., Gold nanoparticles in nanomedicine: preparations, 
imaging, diagnostics, therapies and toxicity. Chem Soc Rev 2009, 38 (6), 1759-
82. 
235. Giljohann, D. A.; Seferos, D. S.; Prigodich, A. E.; Patel, P. C.; Mirkin, C. A., 
Gene regulation with polyvalent siRNA-nanoparticle conjugates. J Am Chem Soc 
2009, 131 (6), 2072-3. 
236. Oishi, M.; Nakaogami, J.; Ishii, T.; Nagasaki, Y., Smart PEGylated Gold 
Nanoparticles for the Cytoplasmic Delivery of siRNA to Induce Enhanced Gene 
Silencing. Chemistry Letters 2006, 35 (9), 1046-7. 
237. (a) Chiefari, J.; Chong, Y. K.; Ercole, F.; Krstina, J.; Jeffery, J.; Le, T. P. T.; 
Mayadunne, R. T. A.; Meijs, G. F.; Moad, C. L.; Moad, G.; Rizzardo, E.; Thang, 
S. H., Living free-radical polymerization by reversible addition-fragmentation 
chain transfer: the RAFT process. Macromolecules 1998, 31, 5559-62; (b) Lowe, 
A. B.; McCormick, C. L., Reversible addition-fragmentation chain transfer 
(RAFT) radical polymerization and the synthesis of water-soluble (co)polymers 
under homogeneous conditions in organic and aqueous media. Prog. Polym. Sci. 
2007, 32 (3), 283-351; (c) McCormick, C. L.; Lowe, A. B., Aqueous RAFT 
polymerization: Recent developments in synthesis of functional water-soluble 
(co)polymers with controlled structures. Acc. Chem. Res. 2004, 37 (5), 312-25; 
(d) Moad, G.; Rizzardo, E.; Thang, S. H., Living radical polymerization by the 
RAFT process. Aust. J. Chem. 2005, 58, 379-410; (e) Moad, G.; Rizzardo, E.; 
Thang, S. H., Living radical polymerization by the RAFT process—A first 
update. Aust. J. Chem. 2006, 59, 669-92. 
238. Khalil, I. A., Uptake Pathways and Subsequent Intracellular Trafficking in 
Nonviral Gene Delivery. Pharmacological Reviews 2006, 58 (1), 32-45. 
239. Akita, H.; Kogure, K.; Moriguchi, R.; Nakamura, Y.; Higashi, T.; Nakamura, T.; 
Serada, S.; Fujimoto, M.; Naka, T.; Futaki, S.; Harashima, H., Nanoparticles for 
165 
 
 
 
ex vivo siRNA delivery to dendritic cells for cancer vaccines: Programmed 
endosomal escape and dissociation. J. Control. Release 2010, 143, 311-7. 
240. (a) Dehousse, V.; Garbacki, N.; Colige, A.; Evrard, B., Development of pH-
responsive nanocarriers using trimethylchitosans and methacrylic acid copolymer 
for siRNA delivery. Biomaterials 2010, 31 (7), 1839-49; (b) Wang, X. L.; Xu, R.; 
Lu, Z. R., A peptide-targeted delivery system with pH-sensitive amphiphilic cell 
membrane disruption for efficient receptor-mediated siRNA delivery. J Control 
Release 2009, 134 (3), 207-13; (c) Hatakeyama, H.; Ito, E.; Akita, H.; Oishi, M.; 
Nagasaki, Y.; Futaki, S.; Harashima, H., A pH-sensitive fusogenic peptide 
facilitates endosomal escape and greatly enhances the gene silencing of siRNA-
containing nanoparticles in vitro and in vivo. J Control Release 2009, 139 (2), 
127-32. 
241. Lee, S. H.; Choi, S. H.; Kim, S. H.; Park, T. G., Thermally sensitive cationic 
polymer nanocapsules for specific cytosolic delivery and efficient gene silencing 
of siRNA: swelling induced physical disruption of endosome by cold shock. J 
Control Release 2008, 125 (1), 25-32. 
242. (a) Febvay, S.; Marini, D. M.; Belcher, A. M.; Clapham, D. E., Targeted cytosolic 
delivery of cell-impermeable compounds by nanoparticle-mediated, light-
triggered endosome disruption. Nano Lett 2010, 10 (6), 2211-9; (b) Fretz, M. M.; 
Hogset, A.; Koning, G. A.; Jiskoot, W.; Storm, G., Cytosolic delivery of 
liposomally targeted proteins induced by photochemical internalization. Pharm 
Res 2007, 24 (11), 2040-7; (c) Oliveira, S.; Fretz, M. M.; Hogset, A.; Storm, G.; 
Schiffelers, R. M., Photochemical internalization enhances silencing of epidermal 
growth factor receptor through improved endosomal escape of siRNA. Biochim 
Biophys Acta 2007, 1768 (5), 1211-7. 
243. (a) Moore, N. M.; Sheppard, C. L.; Barbour, T. R.; Sakiyama-Elbert, S. E., The 
effect of endosomal escape peptides on in vitro gene delivery of polyethylene 
glycol-based vehicles. J Gene Med 2008, 10 (10), 1134-49; (b) Oliveira, S.; van 
Rooy, I.; Kranenburg, O.; Storm, G.; Schiffelers, R. M., Fusogenic peptides 
enhance endosomal escape improving siRNA-induced silencing of oncogenes. Int 
J Pharm 2007, 331 (2), 211-4. 
 
 
